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Summary
The potential inducing ability of azole antifungal drugs on cytochrome 
P450 isozymes, in particular the P4504A subfamily, have been investigated in vivo 
and in vitro. In rat liver, bifonazole (1-(P, a-diphenylbenzyl) imidazole), but not 
the structurally related clotrimazole, was found to induce the cytochrome P4504A 
subfamily (similar to clofibrate), based on their relative abilities to induce lauric acid 
co-hydroxylase activity, immunochemical reactivity with an antibody raised against 
P4504A1, and Northern blotting with a cytochrome P4504A1 cDNA probe. 
Additionally, bifonazole was subsequently shown to be a peroxisome proliferator, 
inducing peroxisomal palmitoyl-CoA oxidation, trifunctional protein, and 
associated hepatomegaly. Furthermore, immunoblotting data demonstrated that 
bifonazole also induces P4501A1 and 2B1/2 proteins, and the P4503A subfamily. 
By contrast, clotrimazole did not induce the cytochrome P4504A subfamily, but did 
induce P4502B1/2 proteins and the P4503A subfamily, and to a lesser extent 
P4501A1.
In rat kidney, based on the ability to induce lauric acid 0)-hydroxylase 
activity, cytochrome P4504A1 apoprotein, and cytochrome P4504A1 mRNA, 
bifonazole, but not clotrimazole, was found to be a weak inducer of the cytochrome 
P4504A subfamily. In addition, bifonazole at the high dose level was able to cause 
only slight increases in kidney cytochromes P4501A1 and P4502B1/2 proteins, and 
the P4503A subfamily, as judged by EROD, PROD, and immunoblotting assays. 
Bifonazole was also able to induce the trifunctional protein (similar to clofibrate), 
but did not induce peroxisomal palmitoyl-CoA activity.
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In vitro, using rat hepatocyte primary cultures, clofibrate and all of the 
other azole antimycotic agents studied (except itraconazole), namely bifonazole, 
clotrimazole, geniconazole, miconazole, and UK-47265, maintained levels of total 
cytochrome P450 over the 70 hours culture period as compared to the freshly 
isolated cells. However, only bifonazole and clofibrate were able to induce lauric 
acid 11- and 12-hydroxylase activities, and cytochrome P4504A1 apoprotein. The 
apparent EC50  values for bifonazole and clofibrate for the induction of the 11- and 
12-hydroxylation of lauric acid, demonstrated that bifonazole is 160 and 44 times 
more potent than clofibrate, respectively.
In order to explain the inductive effect observed by bifonazole, 
molecular modelling of the interaction of the test compounds with the putative 
binding site of the recently isolated receptor, PPAR, were investigated. The results 
showed a more facile docking of bifonazole and clofibric acid with the PPAR than 
the other imidazole agents, as reflected in more favourable AG values.
Taken collectively, results of the present study further substantiate the 
close relationship between induction of P4504A1 and peroxisome proliferation, in 
vivo and in vitro. In addition, the result of molecular modelling studies is not 
inconsistent with the involvement of the PPAR in P4504A1 induction and 
peroxisome proliferation.
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CHAPTER 1
General Introduction
General Introduction
The incidence of systemic mycoses is continuously increasing not 
only due to improved recognition and diagnosis of fungal infections, but also to 
the greater chance of survival for patients with defective defence mechanisms, 
including patients with neoplastic disease, organ transplant recipients, diabetics, 
and patient with AIDS (acquired immune deficiency syndrome). There has been 
considerable progress in the treatment of systemic fungal infections by the better 
application of established antifungal agents and also by the development of new 
agents (Lyman and Walsh, 1992).
The azole derivatives are synthetic compounds which have proven to 
be potent inhibitors of fungal growth. They are active agents against many 
different fungi, displaying less toxicity than amphotericin B (the first 
commercially available systemic antifungal drug), and showing excellent 
pharmacokinetic properties. The azole agents contain one or more five-membered 
rings, with either two (imidazole) or three (triazole) nitrogen atoms in each 
heterocyclic ring. The imidazoles are extensively used in clinical therapy as H2 - 
receptor antagonists (4,5-disubstituted) such as cimetidine, and in the treatment of 
topical and systemic mycoses (N-substituted) with agents such as clotrimazole, 
miconazole and ketoconazole. The substitution of the imidazole ring by triazole 
has led to the introduction of a new group of antifungals with greater polarity, less 
nucleophilicity, and increased specificity for fungal enzyme systems and, 
apparently increased potency (Grant and Clissold, 1990; and Richardson et al., 
1990).
The mode of action of azole antifungals involves inhibition of the 
microsomal cytochrome P450-dependent 14a-demethylation of lanosterol in the 
biosynthetic pathway of ergosterol. The presence of 14a-methylsterol leads to 
membrane disruption and subsequent inhibition of cell growth (Henry and Sisler, 
1984; and Vanden Bossche, 1985). However, this inhibitory potency is not 
restricted to fungi, as a number of clinically used imidazole antifungal drugs, 
including clotrimazole, miconazole, and ketoconazole, have been reported to 
inhibit monooxygenase activity in a number of mammalian tissues (Mason et ah, 
1985; and Meredith et al., 1985). Almost all monooxygenase inhibitors display a 
biphasic effect, in which the inhibitory phase is followed by an induction phase. 
Accordingly, clotrimazole, miconazole, and ketoconazole can act as both 
inhibitors and inducers of the cytochrome P450-dependent mixed function 
oxidase system, depending on the time course of exposure to the xenobiotic 
(Rodrigues et al., 1988). It has been shown that a brief course of treatment with 
clotrimazole causes the induction of liver microsomal enzymes, which can destroy 
its antifungal activity because of the increased metabolism of the drug. 
Consequently, clotrimazole is currently used as a topical agent (Lyman and 
Walsh, 1992). As P450s play a central role in the metabolism of this class of 
antifungal drugs, it is important to consider some of the characteristics of this 
enzyme system.
The cytochromes P450 actively contribute to drug metabolism which, 
in general, is divided into two phases; namely phase I (or functionalisation 
reactions) and phase II (or conjugative reactions). It is thought that the phase I 
reactions act to prepare the drug for phase II reactions, which enhance excretion 
of the chemical (Gibson and Skett, 1994). Cytochrome P450 is the terminal
oxidase component of an electron transfer system catalysing the monooxygenase 
(phase I) reaction. The P450 catalysed reactions of exogenous substrates generally 
result in one of two possible outcomes: (i) metabolising the chemical to a suitable 
intermediate for phase II reaction/conjugation leading to excretion, or 
alternatively, (ii) formation of reactive metabolites which can bind covalently to a 
cellular constituent, resulting in toxicity (Gasser and Philpot, 1989). The principal 
role of cytochrome P450 in the metabolism of foreign compounds, however, is to 
introduce a polar oxygen-containing group into the exogenous molecule. This 
provides a ‘handle’ for the phase II reactions, that mostly generate toxicologically 
inactive products which are then readily excreted.
Mammalian cytochromes P450 can be divided into two general 
groups based on their means of obtaining reducing equivalents from NADPH and, 
additionally, in eukaryotes, their intracellular location (Gonzalez, 1991). On the 
one hand, cytochromes P450 that are found exclusively in the inner mitochondrial 
membranes (initially isolated from the adrenal cortex) such as cholesterol side 
chain cleavage P450 (P450ssc or P45011A1), and steroid 116-hydroxylase P450 
(P450116 or P45011B1). These cytochromes P450, that are involved in the 
metabolism of steroids and related physiological substrates, do not have 
significant capacity to metabolise exogenous compounds, and receive electrons 
from NADPH via NADPH-adrenodoxin reductase and adrenodoxin. The second 
group of P450s are found primarily in the endoplasmic reticulum (bound to 
microsomal membranes) and receive their electrons via NADPH-cytochrome 
P450 reductase, a flavoprotein containing a single molecule each of flavin adenine 
dinucleotide and flavin mononucleotide (Gonzalez, 1993).
1.1. Cytochrome P450 Gene Superfamily; 
Nomenclature and Multiplicity.
Cytochrome P450 is a general term for a group of haemoproteins 
which are probably the most numerous of all drug-metabolising enzymes, with a 
broad range of substrate specificity. This superfamily comprises many enzymes 
which are important in the oxidative, peroxidative, and reductive metabolism of 
various endogenous compounds such as steroids, fatty acids, prostaglandins and 
eicosanoids (Hall, 1986; and Hardwick et al., 1987). Additionally, many of these 
enzymes are capable of metabolising a wide range of exogenous compounds 
(xenobiotics) including drugs, carcinogens, environmental pollutants, and other 
chemicals (Hardwick et a l, 1987; and Nelson et al., 1993). Cytochrome P450 is 
classified as a superfamily of b-type haemoproteins with an invariant haem (the 
prosthetic group) binding domain and similar catalytic mechanism, but different 
apoprotein primary structures responsible for their various substrate specificities.
The cytochrome P450 monooxygenases have been detected in 
essentially all animals, plants, fungi, and bacteria studied (Black and Coon 1987; 
Gonzalez, 1989; and Porter and Coon, 1991). Initial characterisation of most of 
these P450s was achieved by protein purification studies, although these 
investigations showed that individual cytochrome P450 isoenzymes may have 
different but overlapping substrate specificities. In order to avoid confusion 
between individual P450 isoenzymes, several investigators have proposed a 
universal systematic nomenclature (Nebert et al., 1991; and Nelson et al., 1993). 
This nomenclature system is based on the percentage sequence relatedness which 
defines cytochrome P450 families and subfamilies. However, the limits defining 
families and subfamilies may change slightly following publication of a new
updated listing, since these values may become modified as more P450s are 
isolated and characterised.
The ability of P450s to metabolise endogenous and foreign 
compounds is probably the reason for the remarkably large number of cytochrome 
P450 isoenzymes, where their evolution is believed to have begun 2-3 billion 
years ago (Nelson et al., 1993). The extent of this multiplicity of forms has been 
demonstrated by the current listing of 221 P450 genes and twelve putative 
pseudogenes that have been described in 31 eukaryotes (including eleven 
mammalian and three plant species) and in eleven prokaryotes. To date, at least 36 
gene families have been described, 12 of which exist in all mammals comprising 
22 subfamilies, or clusters of genes, of which 17 have been mapped on the human 
gene (Nelson et al., 1993).
According to this nomenclature system, cytochrome P450 genes or 
cDNAs are now named with the italicised root symbol ‘C 7P’ (‘Cj/?’ for the 
mouse gene) derived from cytochrome P450, gene families are designated by 
Arabic numbers, subfamilies are represented by letters when more than one 
subfamily are known to exist within that family, followed by another Arabic 
numeral designating the individual gene. For the corresponding gene product, 
mRNA and protein in all species including mouse, application of the same 
nomenclature but nonitalicised ‘CYP’ has been proposed. All members of a 
single gene family are defined as usually having more than 40% nucleotide/amino 
acid sequence similarity, and those mammalian sequences with greater than 55% 
identity are included in the same subfamily. These P450 gene families have 
diverged from an ancestral P450 gene about 1000 million years ago and the 
naming of genes has been carried out in order of their discovery.
1.2. Cytochrome P450 Structure, Function and 
Catalysis.
Cytochrome P450 is a haem-containing enzyme with a ferric 
protoporphyrin IX (prosthetic group) linked to a cysteine thiol group of the 
apoprotein at the fifth haem co-ordination site. Cytochrome P450 catalyses the 
hydroxylation of thousands of structurally diverse drugs and chemicals, with the 
only common feature amongst these substrates being some degree of lipophilicity.
The microsomal monooxygenase reaction has the following 
stoichiometry
SH + O2 + NADPH + H+ ------------^  SOH + H2O + NADP +
where SH represents as oxidisable drug substrate and SOH the hydroxylated 
metabolite, with the enzyme cytochrome P450 being the active catalyst in this 
process. During monooxygenase reactions, cytochrome P450 mediates the 
incorporation of a single atom of molecular oxygen into the substrate, with the 
concomitant reduction of the other atom of oxygen to water (Schenkman, 1993).
Cytochrome P450 serves as both the substrate- and oxygen-binding 
locus for the monooxygenase reaction (Gibson and Skett, 1994). The ability of the 
haem iron to undergo cyclic oxidation/reduction reactions is the central feature of 
the cytochrome P450 catalytic cycle, in conjugation with substrate binding and 
oxygen activation. A sketch of the cytochrome P450 cycle is outlined in Figure 
1.1 The haem iron in the ferric state exists as an equilibrium mixture of low 
(hexa-coordinated with in-plane iron) and high (penta-coordinated with out-of- 
plane iron) spin states. The high spin configuration appears to be more readily
SH
3+Fe (SH)
SOH
© (SH)
© j r 02
e
Fe'+
O2
Figure 1.1. Catalytic cycle of cytochrome P450. Fe^+ represents 
oxidised cytochrome P450; SH, the drug substrate; and SOH, the corresponding 
hydroxylated metabolite. Adapted from Rein and Jung, 1993; and Schenkman, 
1993.
reducible for enzymatic reduction than the low-spin, but this correlation is not an 
absolute one (Schenkman, 1993).
Following substrate binding to P450, however, a modulation in the 
haem iron spin equilibrium from a predominantly low spin to high spin 
configuration occurs, due to displacement of a water molecule (Lewis, 1992; and 
Schenkman, 1993). This change forces the iron atom out of the haem plane and is 
associated with a shift in the mid-point redox potential of the haemoprotein to a 
more positive value (Lewis, 1992; Schenkman, 1993; and Gibson and Skett, 
1994). This enables the more favourable input of the first electron from the 
flavoprotein NADPH cytochrome P450 reductase to reduce substrate-bound ferric 
(Fe^+) cytochrome P450 to the ferrous (Fe^+) form of the haemoprotein. As 
cytochrome P450 is a one electron acceptor, oxygen activation occurs in two steps 
(Figure 1.1., steps 3 & 4). In step 3, oxygen is bound to the one-electron reduced 
haemoprotein to form an intermediate, Fe^+(02"), with the substrate still attached. 
Subsequent reduction of P450 occurs following introduction of the second 
electron (Figure 1.1., step 4) derived from NADPH-cytochrome P450 reductase 
with the possible involvement of cytochrome bs as an additional electron donor 
(Schenkman et al., 1976). The precise role of cytochrome bs in the cytochrome 
P450 oxidative reaction remains a subject of debate. However, Schenkman and 
co-workers, 1987, suggested that cytochrome P450 becomes a 2 electron acceptor, 
with cytochrome bg bound to it, which is the basis of the cytochrome bs influence 
on the reaction.
The next step following insertion of the second electron is not fully 
understood where insertion of oxygen into the carbon substrate occurs resulting in 
product formation (SOH). However, the prevalent reaction appears to be involved
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in two steps, a hydrogen atom abstraction from the substrate followed by oxygen 
rebound as follows:
(FeO^'^ + SH --------- ► (FeOH)^* S' ______ ► Fe^+ + SOH
Dissociation of the product (SOH) then completes the cycle, which restores the 
cytochrome P450 to the initial ferric state.
1.3. Cytochrome P4504 Family.
Many of the cytochromes P450 are present at low levels in untreated 
animals but are capable of induction by a variety of xenobiotics. However, a 
group of the cytochromes P450 are present in measurable levels in livers, kidneys 
and lungs of untreated animals, known as constitutive enzymes. They are believed 
to be involved in specific metabolic pathways, in that they have high catalytic 
activities toward endogenous chemicals (Hall, 1986).
Cytochromes P450 catalysing ©-hydroxylation of fatty acids are 
constitutively expressed enzymes that participate in the metabolism of 
endogenous substrates. Medium chain-length fatty acid oxidation occurs by either 
of two microsomal pathways, co- or ©-1 oxidation. The capacity of some 
cytochrome P450 forms to preferentially oxidise primary carbon-hydrogen bonds 
(rather than secondary or tertiary) is an unusual aspect. This is particularly evident 
for fatty acid substrates (such as lauric acid, arachidonic acid and the eicosanoids) 
where the hydroxylation of the terminal carbon is referred to as ©-hydroxylation 
(Hardwick et al., 1987).
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For normal straight-chain fatty acids, ©-hydroxylation is usually a 
minor metabolic pathway compared to 6-oxidation, but in ketotic states such as 
starvation or diabetes, or in pregnancy, ©-hydroxylation is stimulated (Hardwick 
et al., 1987). The ©-hydroxylation of fatty acids produces primary alcohols, which 
are subsequently oxidised further to dicarboxylic acids by alcohol and aldehyde 
dehydrogenase.
It is clear from the available evidence that the cytochrome P450 
enzymes involved in the ©-hydroxylation reactions, comprise a distinct family of 
haemoproteins belonging to the cytochrome P4504 family (CaJacob et al., 1988; 
Gibson and Lake, 1991; and Nelson et al., 1993). The complementary DNAs of 
this family of proteins have been isolated from cDNA libraries from liver, kidney, 
lung, intestine, and prostate of various species including the rat, mouse, rabbit, 
guinea pig, insects, and man (Gibson and Lake, 1991; and Nelson et al., 1993). 
Cytochrome P4504 family consists of 22 genes arranged in seven subfamilies, in 
which all of them have been sequenced and their amino acid sequences predicted 
(Nelson et al., 1993).
The cytochrome P4504A subfamily consists of at least 13 genes 
encoding enzymes, in which eleven are cDNAs and only two (P4504A1 and 
P4504A2) are derived from genomic libraries (Table 1.1.) As such, these latter 
two contain introns and 5’ upstream flanking regions, the latter containing putative 
regulatory sites that may interact with its inducer. ©-Hydroxylation activity 
appears to be the most important characteristic of the cytochrome P4504A 
subfamily, although several members of other cytochrome P450 families 
additionally hydroxylate their lipid substrates at various positions in the alkyl 
chain (Gibson and Lake, 1991).
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Table 1.1. The cytochrome P4504A gene subfamily.*
Gene symbol Trivial name (s) Species Tissue Representative
substrates
CYP4A1 LAcû, P452 Rat Liver, kidney Fatty acids
CYP4A2 IVA2, k-5, K-2 Rat Liver, kidney Probably 
fatty acids
CYP4A3 IVA3, DM-2 Rat Liver, kidney Fatty acids
CYP4A4 p-2, LPGco Rabbit Lung, kidney, 
liver, uterus, 
placenta
Fatty acids 
and
prostaglandins
CYP4A5 KDB3,kd Rabbit Kidney, liver, 
small intestine
Fatty acids
CYP4A6 ka-1, KDA6, 
LPGAco-1
Rabbit Kidney
liver
Fatty acids
CYP4A7 ka-2, R4, 
LPGAœ-2
Rabbit Kidney
liver
Fatty acids
CYP4A8 PPl Rat Prostate,
kidney
?
CYP4A9 HL14 Aeon Human Liver 7
Cyp4a-10 A14, clone 1 Mouse ? 7
CYP4A11 HKco Human Kidney Fatty acids
Cyp4a-12 clone 2 Mouse ? 7
CYP4A12 ----- Guinea pig 7 ?
* Compiled from Gibson etal., 1993; and Nelson et a l, 1993.
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A laurate co-hydroxylase cytochrome P450, P4504A1, has been 
isolated from the colon, intestinal mucosa, and kidney of untreated rabbits 
(Kusunose et al., 1981, 1984; and Kaku et al., 1984), as well as from the liver of 
clofibrate-treated rats (Tamburini et al., 1984). Its cDNA has been cloned and 
characterised in the liver of clofibrate-induced rats (Hardwick et al., 1987; and 
Earnshaw et al., 1988). Cytochrome P4504A2 has been purified from renal 
microsomes of untreated male rats (Imaoka et al., 1990), and is a major 
constitutive form of cytochrome P450 in the kidney. It is also present in the liver 
of untreated male rats and is inducible by clofibrate. Antibodies raised against 
P4504A2 cross-react with cytochrome P450 purified from human renal 
microsomes (Funae and Imaoka, 1993). Cytochrome P4504A3 has been purified 
from hepatic microsomes of diabetic male rats treated with streptozotocin (Imaoka 
et al., 1988). The amino acid sequence of P4504A3 is 96% and 72% homologous 
to that of P4504A2 and 4A1, respectively (Kimura et al., 1989).
The ©-hydroxylation of prostaglandins has been shown to increase 
during pregnancy and to be induced following progesterone treatment in rabbit 
lung (Powell, 1978). The cytochrome P450 responsible for this regioselective 
oxidation was isolated and purified from lungs of pregnant or progesterone-treated 
rabbits (Williams et al., 1984; and Yamamoto et al., 1984). Prediction of amino 
acid sequence from its cDNA demonstrated a close similarity (74%) with rat 
cytochrome P4504A1 and was designated as cytochrome P4504A4 (Matsubara et 
al., 1987; and Nelson et al., 1993). However, preparation of cytochrome P4504A4 
from progesterone treated rabbit lung microsomes demonstrated negligible laurate 
hydroxylase activity compared to untreated rabbits (Williams et al., 1984; and 
Yamamoto et al., 1984). Homologous forms of cytochrome P4504A4 in rabbit
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liver were not induced following progesterone pretreatment, in contrast to the 
lung, which was markedly induced during pregnancy (Kikuta et al., 1989).
More recently, complementary cDNAs for cytochrome P4504A5, 
P4504A6, and P4504A7 were isolated from a rabbit kidney cDNA library 
(Yokotani et ah, 1989, 1991; and Johnson et al., 1990). Cytochrome P4504A6 is 
induced in both liver and kidney following clofibrate treatment, whereas P4504A5 
and P4504A7 are only expressed following induction in liver, but are 
constitutively expressed in kidney. Moreover, only P4504A7 was constitutively 
expressed in the small intestine (Yokotani et ah, 1989). Two other members of the 
cytochrome P4504A subfamily have been identified in human liver (Hardwick et 
al., personal communication, as quoted in Nelson et a l, 1993) and kidney 
(Kawashima et al., 1992; and Palmer et al., 1993), and designated cytochrome 
P4504A9 and P4504A11, respectively.
A rabbit lung cytochrome P450 catalysing both the co- and co-1 
hydroxylation of lauric acid, designated P4504B1, has been isolated, consisting 
506 amino acid residues which show a remarkable similarity with rabbit P4504A4 
and rat P4504A1, 54% and 53%, respectively (Gasser and Philpot, 1989). The 
orthologous counterpart to rabbit cytochrome P4504B1 is present in the lungs of 
untreated rat, mouse, guinea pig, monkey and hamster (Vanderslice et al., 1987) 
and is inducible by phénobarbital in rabbit liver. However, it is also detected in 
the liver of untreated rabbit and hamster (Robertson et a l, 1983; and Vanderslice 
et al., 1987), but not in the liver of other species including the rat (Vanderslice et 
al., 1987; and Nhamburo et al., 1989).
The cDNA-deduced amino acid sequence of rat lung P4504B1 
consists of 511 residues, and shows 87% identity to rabbit lung cytochrome 
P4504B1 (Gasser and Philpot, 1989; and Philpot et al., 1991). Furthermore, a
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human orthologue to rabbit cytochrome P4504B1 was purified from a lung cDNA 
library using rat cytochrome P4504A1 cDNA probe (Nhamburo et al., 1989), and 
shows 51%, 53%, and 52% amino acid sequence similarity to rat P4504A1 and 
4A2, and rabbit P4504A4, respectively. Although, this protein was constitutively 
expressed in the human lung, its mRNA could not be detected in the liver 
(Nhamburo et al., 1989).
The N-hydroxylation of aromatic amines, such as 2-aminofluorene, to 
reactive intermediates are catalysed by lung cytochrome P4504B1 (Vanderslice et 
al., 1987). Human cytochrome P4504B1, however, unlike the rabbit and rat 
orthologue was inactive towards metabolism of this compound, despite the 
presence of its mRNA in three out of the four lungs analysed (Nhamburo et al., 
1989). In rats, as in humans, cytochrome P4504B1-related mRNA was expressed 
in the lung but was undetectable in untreated livers. In addition, this mRNA was 
abundant in both rat kidney and intestine, and was not induced by phénobarbital 
treatment.
A newly identified member of the cytochrome P4504 family, 
designated P4504C1, was deduced from a cDNA obtained from the cockroach 
Blaberus discoidalis (Bradfield et al., 1991). The cDNA library was prepared 
from the fat bodies of cockroaches treated with the decapeptide hypertrehalosemic 
hormone (HTH). Cytochrome P4504C1 is a 511-residue protein which is 32-36% 
identical to mammalian P4504A and P4504B subfamilies. Although it is less than 
the 40% identity usually considered necessary for inclusion of a sequence in a 
preexisting P450 family (Nelson et al., 1993), it shares 13 amino acids within a 
peptide found exclusively in P450s of the 4 family. Expression of the cytochrome 
P4504C1 gene is elevated by both the starvation and exposure to HTH, suggesting
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the involvement of this P450 in energy-substrate mobilisation, which represent 
initial steps in fatty acid oxidation (Bradfield et a l, 1991).
Yet another member of the cytochrome P4504 family, P4504D1, has 
been characterised in Drosophila melanogaster (Gandhi et al., 1992). Sequence 
comparison demonstrates 30-36% identity with previously established members 
of the P4504 family. P4504D1 shares 12 out of 13 amino acids in the region 
previously described for cytochrome P4504C1, and on this basis was classified in 
the 4 family. Cytochrome P4504D1 is expressed in embryos, larvae, and adults, 
but not in pupae, and its catalytic activity is unknown.
1.4. Biological Response to the Administration o f  
Peroxisome Proliferators.
Peroxisome proliferators are a diverse group of chemicals (Table
1.2.) which, on administration to rodents (more particularly the mouse and rat), 
induce characteristic changes in the morphology and/or biochemistry of several 
tissues. They have been referred to as ‘chemically unrelated’ (Cohen and Grasso, 
1981) or ‘structurally dissimilar’ (Reddy and Lalwani, 1983) compounds but do 
appear to show some degree of similarity in their three-dimensional structures 
(Lewis and Lake, 1993). The hypolipidaemic drug clofibrate was the first such 
peroxisome proliferator to be identified although several other hypolipidaemic 
drugs, as well as herbicides, leukotriene antagonists and plasticisers, are also 
included in this list (Reddy and Lalwani, 1983; Lock et al., 1989; and Moody et 
al., 1991). The influence of peroxisome proliferators on the liver has been 
extensively investigated. The hepatic responses to peroxisome proliferators
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Table 1.2. Some compounds that cause peroxisome proliferation.
Peroxisome Proliferator Use References
Drugs
Acetylsalicylic acid Anti-Inflammatory Hruban et al., 1966
1-Benzylimidazole Anti-fungal Vamecq et al., 1987
Bifonazole Anti-fungal Horie etal., 1991
Bezafibrate Hypolipidaemic Fahimi et al., 1982
Ciprofibrate Hypolipidaemic Lalwani et al., 1983
Clofibrate Hypolipidaemic Hess et al., 1965
Methyl clofenapate Hypolipidaemic Moody and Reddy, 1974
Nafenopin Hypolipidaemic Reddy et al., 1973
Chlorpromazine Tranquilliser Vamecq et a l, 1987
POCA Hypoglycaemic Bone etal., 1982
Valproic acid Anti-epileptic Horie and Suga, 1985
Industrial Chemicals
Isooctane Industrial solvent Lock et al., 1987
Perfluorinated fatty acids Surfactants, flame retardants Ikeda et al., 1986
Prudhoe bay crude oil Crude petroleum mix Khan et al., 1989
Pesticides
Dimethrin Insecticide Hruban et al., 1974
Lactofen Herbicide Butler etal., 1988
Tridipane, 2,4-D, 2,4,5-T Herbicide Lundgren et al., 1987
Miscellaneous
Citral, Linalool Food flavourings Jaksonera/., 1987; and 
Roffey et al., 1990
DEHA Plasticiser Moody and Reddy, 1978
DEHP Plasticiser Reddy et al., 1976
Abbreviations are: DEHA, di-(2-ethylhexyl) adipate; DEHP, di-(2-ethylhexyl) 
phthalate; POCA, 2-[5-(4-chlorophenyl)pentyl] oxirane-2-carboxylate.
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include hepatomegaly, increase in relative content of peroxisomes and smooth 
endoplasmic reticulum, induction of cytochrome P450-dependent fatty acid (co-l)- 
and (o-hydroxylase activities, fatty acid 6-oxidation, carnitine acetyltransferase, 
and non-genotoxic hepatocarcinogenesis (Reddy and Lalwani, 1983; Hawkins et 
al, 1987; and Sharmaer^/., 1988a).
1.4.1. Hepatomegaly.
Peroxisome proliferation is consistently associated with hepatomegaly 
(an increase in the liver weight to body weight ratio) which arises from a 
combination of hypertrophy (associated with organelle proliferation) and 
hyperplasia (Reddy et a l, 1982; Hawkins et a l, 1987; and Styles et a l, 1988). 
Hypertrophy may be associated with a combined proliferation of the smooth 
endoplasmic reticulum and a contributory increase in mitochondrial numbers 
(Hawkins et a l, 1987). This liver enlargement may also be associated with mid- 
zonal and periportal accumulation of lipid droplets and an increase in 
phospholipid and total protein levels (Mann et a l, 1985; and Hawkins et a l, 
1987).
Comparative studies following the administration of hypolipidaemic 
agents to rodents demonstrated that hepatomegaly is a dose dependent 
phenomenon. The extent of hepatomegaly is also dependent upon the agent 
potency as well as its ability to induce peroxisome proliferation. Liver 
enlargement occurs rapidly in response to peroxisome proliferators 
administration, and reaches a steady state within two weeks of treatment 
initiation. It is maintained throughout treatment and returns to pretreatment levels 
within two weeks of the last administration (Reddy et al, 1982).
19
1.4.2. Peroxisome Proliferation and Associated Changes in 
Enzyme Composition.
Peroxisomes are membrane-bound cytoplasmic organelles present 
widely in animal and plant cells. The increase in hepatocyte size following 
administration of peroxisome proliferators is associated with the predominant 
increase in both peroxisome numbers and volume (Hawkins et al., 1987; and 
Moody et al, 1992). This latter induction is dose and chemical dependent which 
correlates with the degree of hepatomegaly (Moody and Reddy, 1978; and 
Marsman et al, 1988).
The peroxisomal fatty acid 6-oxidation system can be induced as much 
as 30-fold by peroxisome proliferators (Rao and Reddy, 1991). This enzyme 
system is different to that found in the mitochondrion, in that the first and rate 
limiting enzyme in the peroxisomal 6-oxidation spiral produces H2O2 as a side 
product and is insensitive to inhibition by cyanide (Conway et a l, 1989). A large 
and persistent increase in the activity of this H2O2 producing enzyme, namely 
fatty acyl-CoA oxidase, has been observed after treatment with DEHP. In 
contrast, peroxisome proliferators produce only a moderate increase (1.5- to 2- 
fold) in catalase activity, another peroxisomal enzyme. Substantial decreases in 
the activity of cytosolic glutathione peroxidases and glutathione-S-transferases, 
the enzymes responsible for H2O2 and hydroperoxide degradation, respectively, 
have also been observed following DEHP treatment (Lake et a l, 1987,1989).
Induction of carnitine acetyl transferase and palmitoyl-CoA oxidase in 
rat hepatocyte primary culture has been reported following administration of 
clofibrate, nafenopin, and a number of other peroxisome proliferators (Gray et al., 
1983).
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1.5. Peroxisomes and their Role in the fi- 
Oxidation o f Fatty Acids.
Morphologically, peroxisomes are characterised by a finely granular 
matrix that is surrounded by a single membrane. The current model of their 
biogenesis suggests that peroxisomes are formed by fusion fi*om pre-existing 
organelles (Fujiki et al., 1984; and Yamamoto and Fahimi, 1987). Peroxisome 
enzymology may vary considerably from one tissue to another and between 
species. Lipid-metabolising enzymes appear to form the major portion of the 
peroxisomal enzymes.
Three main functional cellular compartments responsible for fatty acid 
oxidation have been well distinguished in several tissues examined so far. These 
compartments include: (1) the extra-mitochondrial compartment comprising the 
endoplasmic reticulum, the cytosol and the outer mitochondrial membrane, (2) the 
peroxisomes, and (3) the mitochondrial matrix (Lock et al., 1989).
Peroxisomes are involved in 6-oxidation in plant cells and in 
eukaryotic microorganisms (Gerhardt, 1987; and Kunau et a l, 1987). In animal 
cells, peroxisomes and mitochondria are capable of fatty acid 6-oxidation. The 
activation of the fatty acids to their CoA derivatives is a prerequisite for 6- 
oxidation and estérification. The peroxisomal membrane contains two fatty acyl- 
CoA synthetases: the first one is most active towards long chain fatty acids 
(Mannaerts et al., 1982; and Bronfman et al., 1984), and the second enzyme is 
more active towards very long chain (>C2o) fatty acids (Singh and Poulos, 1988; 
and Lazo et al., 1990a). Long chain acyl-CoA synthetases are also found in the 
mitochondrial outer membrane and in the endoplasmic reticulum (Miyazawa et
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al., 1985). The endoplasmic reticulum, but not mitochondria, also contain very 
long chain acyl-CoA synthetase (Singh and Poulos, 1988; and Lazo et al., 1990b).
Although degradation of saturated fatty acids by peroxisomes and 
mitochondria occurs via a similar mechanism, the respective enzymes differ from 
each other in their catalytic and molecular properties. For instance, unlike the 
carnitine dependent cyanide-sensitive mitochondrial system, peroxisomal 6- 
oxidation enzymes are cyanide insensitive in vitro and do not require carnitine for 
the transport of the fatty acyl-CoA esters (Mannaerts et al., 1979; and Lazarow,
1982). Beta-oxidation of both mono- and di-carboxylic fatty acids consists of four 
consecutive reactions: (i) an initial oxidation step which results to the formation 
of a 2-trans-enoyl-CoA; (ii) a hydration step which includes conversion of 2- 
trans-enoyl-CoA to L-3-hydroxyacyl-CoA; (iii) a second oxidation step which 
comprises dehydrogenation of L-3-hydroxyacyl-CoA to 3-ketoacyl-CoA; and (iv) 
a final reaction which cleaves 3-ketoacyl-CoA to acetyl-CoA and an acyl-CoA 
(Lazarow, 1978,1982; and Hashimoto, 1987).
The sequence of 6-oxidation is shown in Figure 1.2. The first 
oxidation step in peroxisomal 6-oxidation is catalysed by a FAD-containing acyl- 
CoA oxidase, which produces hydrogen peroxide that is subsequently 
decomposed by catalase, also present in the peroxisomes. Extrahepatic and 
hepatic peroxisomes contain two and three acyl-CoA oxidases, respectively 
(Schepers et al., 1990; and Van Veldhoven et al., 1991) namely palmitoyl-CoA 
oxidase, pristanoyl-CoA and trihydroxycoprostanoyl-CoA oxidase. The second 
(hydration) and the third (dehydrogenation) steps of peroxisomal 6-oxidation are 
catalysed by a single protein (Osumi and Hashimoto, 1979), which is often called 
‘bifunctional protein’. The bifunctional protein also displays A ,^ A^-enoyl-CoA 
isomerase activity required for the oxidation of unsaturated fatty acids, and is.
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Figure 1.2. The sequence of peroxisomal 6-oxidation.
23
therefore, more correctly termed ‘trifunctional protein’ (Palosaari and Hiltunen,
1990). The final reaction stage of 6-oxidation catalysed by 3-ketoacyl-CoA 
thiolase cleaves 3-ketoacyl-CoA to acetyl-CoA (which is released) and an acyl- 
CoA (two carbon atoms shorter than the original molecule) which then re-enters 
the 6-oxidation spiral.
The peroxisomal fatty acid 6-oxidation cycle activity may be 
determined by either measuring overall activity of this cycle (such as cyanide- 
insensitive palmitoyl CoA oxidation) or by assaying the first, rate limiting, 
enzyme of the cycle namely acyl-CoA oxidase (Lazarow, 1981; and Small et al.,
1985).
1.6. Peroxisome Proliferators and Induction of 
Cytochrome P450.
The content of liver smooth endoplasmic reticulum has been shown to 
increase subsequent to the administration of peroxisome proliferators. This 
proliferation is accompanied by an increase in certain cytochrome P450 
isoenzymes and associated activities (Hawkins et al., 1987). The cytochrome 
P450 present in the microsomal fraction of liver and other organs, such as the 
kidney and lung, catalyse the NADPH- and oxygen-dependent metabolism of 
various lipophilic xenobiotics and endogenous chemicals. The peroxisome 
proliferator-related induction of cytochrome P450 is due to the induction of 
P4504A subfamily members (in particular P4504A1) and is normally measured as 
lauric acid (co-l)- and, particularly, co-hydroxylase activities (Parker and Orton, 
1980; and Gibson et al., 1982). As stated previously, co-hydroxylation plays an
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important role in the metabolism of saturated fatty acids, arachidonic acid, and the 
pharmacologically active eicosanoids (Powell, 1984; and Sumimoto et al., 1984).
The cytochrome P4504 family seems to be the most susceptible P450 to 
induction by peroxisome proliferators (Hardwick et a l, 1987; Hawkins et al., 
1987; Gibson, 1989; and Kimura et al., 1989). The interest in this family of P450s 
has arisen from the fact that all peroxisome proliferators examined to date are 
P4504 family inducers, and also due to the observation that hepatic induction of 
this family of P450s is a very early event in response to peroxisome proliferators.
Most information about peroxisome proliferation regulation of P450 
genes is derived from P4504A1 gene regulation studies (Hardwick et al., 1987; 
Gibson, 1989; and Kimura et al., 1989). A number of mechanisms have been 
proposed for understanding of the P450 gene regulation as they exist in multiple 
forms. The most common of these is transcriptional regulation which has been 
reported for many mammalian P450 isoenzymes, in particular P4501A1 (Nebert 
and Jones, 1989). Post translational regulation may be another form of gene 
modification, which is determined by multiple steps ranging from mRNA 
stabilisation to enzyme stabilisation via translation. In contrast to P4501A1, its 
closely related isoform, P4501A2, is regulated through increased stability and 
intranuclear processing of P4501A2 mRNA precursor (Silver and Krauter, 1990). 
Peroxisome proliferators transcriptionally activate the P4504A1 gene, resulting in 
increased steady state levels of cognate mRNAs resulting in induced apoprotein 
levels and enhanced fatty acid hydroxylase activities in responsive species such as 
the rat (Hardwick et al, 1987; Sharma et al., 1988a, 1988b, 1989b; and Bell et al,
1991).
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1.7. Hepatocarcinogenicity o f Peroxisome 
Proliferators in Rodents.
Tumour induction in rodent liver is the major toxicological concern 
with chemicals that induce peroxisome proliferation. The formation of tumours in 
rat and mouse by peroxisome proliferators, depending upon the carcinogen 
potency, requires continuous exposure for sixty to more than five hundred days. 
However, the progression of the tumour formation is not inhibited by termination 
of exposure to the carcinogen agent (Moody et al., 1990). Unlike classical 
genotoxic carcinogens, peroxisome proliferators neither produce mutations in the 
Ames test nor bind covalently to DNA after in vivo administration (Cohen and 
Grasso, 1981; Reddy and Lalwani, 1983; Reddy and Rao, 1989; and Lake et al., 
1990). Recently, a system for chromosomal recombination in yeast has been 
developed, which is inducible by a variety of non-genotoxic carcinogens 
(Schiestl, 1989). These include a number of carcinogens that are undetectable as 
mutagens by the Ames assay or with various other short-term tests. Examination 
of various peroxisome proliferators, including ciprofibrate, clofibrate, methyl 
clofenapate, nafenopin, and Wy-14643, with this system showed no evidence for 
induction of chromosomal recombination in yeast (Schiestl and Reddy, 1990). 
This finding further supports the non-genotoxic nature of peroxisome 
proliferators.
In contrast to the rodent hepatocarcinogenicity of peroxisome 
proliferators, no evidence exists for the involvement of the peroxisome 
proliferators in human carcinogenesis. However, as the mechanism of carcino­
genicity in rodents has not yet been clearly established, human risk assessment of 
peroxisome proliferators is still an open area for debate.
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1.7.1. Role of Oxidative Stress Hypothesis.
The oxidative stress hypothesis (Figure 1.3.) has been put forward by 
Reddy and co-workers (Reddy et al., 1982,1986; Reddy and Lalwani, 1983; and 
Rao and Reddy, 1987, 1991) to explain the formation of hepatocellular 
carcinomas by peroxisome proliferators. According to this model, treatment with 
peroxisome proliferators results in several-fold increases in the peroxisomal fatty 
acid 6-oxidation cycle with the associated increase in the formation of 
peroxisomal hydrogen peroxide (H2O2). Under normal conditions, the cell is 
protected from H2O2 (or more likely its metabolites such as hydroxyl radical) 
toxicity by peroxisomal catalase and cytosolic selenium-dependent glutathione 
peroxidase enzymes. The increased formation of H2O2 overcomes the ability of 
peroxisomal catalase, or other hydrogen peroxide degrading enzymes, to remove 
H2O2 from the cell. Therefore, the excess hydrogen peroxide either directly, or via 
other reactive oxygen species, results in several responses including enhanced 
lipid peroxidation, membrane damage and lipofuscin deposition (a characteristic 
hepatic response to all peroxisome proliferators), modulation of hepatic 
antioxidant levels and oxidative damage to DNA.
Evidence to support the oxidative stress hypothesis have been 
provided by different studies which have shown that treatment with peroxisome 
proliferators is associated with an increase in the hydrogen peroxide production 
from fatty acid substrates in liver homogenates and isolated hepatocytes (Inestrosa 
et al., 1979; Mannaerts et al., 1979; and Goel et al., 1986). Hydrogen peroxide is 
known to result in both in vitro formation of hydroxyl radicals (Elliott et al.,
1986) and in damage to DNA (Fahl et al, 1984).
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Figure 1.3. The oxidative stress hypothesis for the hepatocarcino­
genicity of peroxisome proliferators; 8-OH-dG, 8-hydroxydeoxyguanosine.
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8-Hydroxydeoxyguanosine (8-OH-dG) is a known product of DNA 
damage by oxygen radicals (Kasai et al., 1986; and Kasai and Nishimura, 1986), 
and its role in peroxisome proliferator-related carcinogenicity of rat liver has been 
documented (Kasai et al., 1989). These workers have shown that a single dose of 
a hepatocarcinogenic peroxisome proliferator, ciprofibrate, has no effect on levels 
of 8-OH-dG in rat hepatic DNA after 24 hours, whereas a 16 to 40 week treatment 
results in a progressive increase in the levels of 8-OH-dG in liver DNA. In other 
studies, ranging in duration from 2 days to 12 months (Table 1.3.), an increase in 
the levels of 8-OH-dG in rat hepatic DNA was noted in response to various 
peroxisome proliferators. In contrast to other peroxisome proliferators, nafenopin 
(a hepatocarcinogenic hypolipidaemic drug) caused no increase in 8-OH-dG 
levels in the liver DNA of rats, when administrated for 2 months (Hegi et al.,
1990).
These studies did not show any increase in 8-OH-dG levels of rat 
renal DNA, except after 12 months of treatment, which is consistent with the fact 
that peroxisome proliferation occurs predominantly in liver parenchymal cells 
(Takagi et al., 1990a, 1990b). Although the organ specific increase in 8-OH-dG 
levels by various peroxisome proliferators is an important fact, it is difficult to 
construct any clear correlations between degree of 8-OH-dG increase and ability 
of these compounds to cause either peroxisome proliferation or tumour formation.
Overall, no conclusive evidence for the oxidative stress hypothesis 
was provided by studies dealing with peroxisome proliferator-related damage to 
liver DNA in rodents. Although there is a strong association between the 
magnitude of hepatic peroxisome proliferation and hepatocarcinogenicity (Reddy 
et al., 1986; and Rao and Reddy, 1991), a number of exceptions have been 
reported (Bieri et al., 1988; Marsman et al., 1988; and Evans et al., 1992). For
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Table 1.3. Influence of peroxisome proliferator administration on 
formation of 8-hydroxydeoxyguanosine (8-OH-dG) in rat liver.
Compound Treatment Changes in 8-OH-dG References
Aluminium Single o.d. (48 hr) 2-Fold increase Takagi etal. 1993
clofibrate Daily o.d. (1 week) 2-Fold increase Takagi et al. 1990b
Diet (12 months) 2-Fold increase Takagi er a/. 1990a
Ciprofibrate Single o.d. (24 hr) No increase Kasai etal. 1989
Diet (16 weeks) 2-Fold increase Kasai etal. 1989
Diet (28 weeks) 2-Fold increase Kasai etal. 1989
Diet (40 weeks) 2-Fold increase Kasai etal. 1989
DEHA Diet (1 week) 2-Fold increase Takagi etal. 1990b
Diet (2 week) 2-Fold increase Takagi etal. 1990b
DEHP Single o.d. (48 hr) 2-Fold increase Takagi et al. 1990a
Daily o.d. (1 week) 2-Fold increase Takagi et al. 1990a
Diet (2 weeks) 2-Fold increase Takagi etal. 1990a
Diet (1 month) 2-Fold increase Takagi etal. 1990a
Diet (12 months) 2-Fold increase Takagi etal. 1990a
PFOA Single i.p. (3 days) 2-Fold increase Takagi et al. 1991
Single i.p. (1 week) 2-Fold increase Takagi et al. 1991
Diet (2 weeks) 2-Fold increase Takagi etal. 1991
PFDA Diet (2 weeks) 2-Fold increase Takagi etal. 1991
Simifibrate Single o.d. (48 hr) 2-Fold increase Takagi et al. 1990a
Daily o.d. (1 week) 2-Fold increase Takagi et al. 1990a
Diet (12 months) 2-Fold increase Takagi et al. 1990a
Nafenopin Diet (2 months) No increase Hegi etal.. 1990
Abbreviations are: DEHA, di-(2-ethylhexyl)adopate; DEHP, di-(2-ethylhexyl)phthalate; 
PFDA, perfluorodecanoic acid; PFOA, perfluorooecanoic acid; hr, hours; i.p., intra 
peritoneal; o.d., oral dose.
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example, feeding of rats with a diet containing either 0.1% Wy-14,643 or 1.2% 
DEHP led to a 100% and 10% liver tumour incidence, respectively, despite little 
difference in the magnitude of peroxisome enzyme induction between the two 
chemicals (Marsman et al., 1988). Therefore, the sustained oxidative stress 
hypothesis does not appear to be solely responsible for the formation of liver 
tumours by peroxisome proliferators in rodents.
1.7.2. Cell Replication.
It is a well known fact that an increase in liver size in response to 
peroxisome proliferators occurs within a few days of the treatment (Reddy and 
Lalwani, 1983). The liver size increase is associated with a burst of hepatocyte 
replication that peaks within the first few days and then rapidly decreases to 
almost control (i.e. very low) rates (Moody et al, 1977; and Reddy and Lalwani,
1983). The role of cell replication in the development of carcinogenesis initiated 
by genotoxic carcinogens is well recognised (Grisham et al., 1983), in which 
DNA damage will be fixed and converted to heritable genetic alterations. The role 
of this incidence in non-genotoxic carcinogen-induced tumours is not clear, but it 
has been considered to be a factor in the hepatocarcinogenicity of peroxisome 
proliferators by several studies (Butterworth et al., 1987; Smith-Oliver and 
Butterworth, 1987; Marsman et al., 1988; and Popp and Marsman, 1991). 
According to the cell replication hypothesis, any agent which causes chronic cell 
proliferation can indirectly be considered as a carcinogen, by increasing the 
frequency of spontaneous mutations and the chance of converting both 
endogenous and exogenous DNA damage into mutations (Ames and Gold, 1990, 
1991; and Popp and Marsman, 1991).
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Chronic administration of some peroxisome proliferators can produce 
a sustained stimulation of hepatocyte replicative DNA synthesis. For example, 
administration of 0.1% Wy-14,643 to rats produced an initial burst of hepatocyte 
proliferation for a few days, which decreased rapidly but remained at about ten 
times the control levels during one year of treatment. In contrast, administration 
of 1.2% DEHP caused a similar initial stimulation of replicative DNA synthesis 
which returned to control levels during a few days and remained at this level for 
up to a year (Marsman et al., 1988). This finding suggested a possible role of 
chronic liver proliferation in tumour formation, as the one year administration of 
Wy-14,643 results in 100% incidence of hepatocellular carcinomas compared to 
only 10% incidence in the hepatocytes of rats fed with DEHP for two years. 
Similarly, a report by Evans et al., 1992, indicated that at dose levels which result 
in a similar magnitude of hepatic peroxisome proliferation, only methyl- 
clofenapate and Wy-14643, but neither clofibric acid nor nafenopin, produced a 
sustained stimulation of replicative DNA synthesis and increased hepatic tumour 
incidence in male Sprague-Dawley rats following 40 weeks treatment. However, 
chronic enhancement of hepatocyte replication may not be the only requirement 
for the tumour response, since production of a tumour by DEHP was not 
consistent with increase in replication for up to one year (Marsman et al., 1988).
1.7.3. Promotion of Spontaneously Initiated Lesions by 
Peroxisome Proliferators.
The lack of initiating activity of peroxisome proliferators, including 
several chemicals (DEHP, clofibrate, nafenopin and Wy-14643) that cause a high 
incidence of hepatic tumours when fed for a sufficient period, suggests that
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peroxisome proliferators may have a primary effect on latter stages of tumour 
development. A number of studies have proposed that peroxisome proliferators 
can act as promotors of spontaneously initiated liver lesions (Cattley et al., 1991; 
and Kraupp-Grasl etal., 1991). These studies have demonstrated that peroxisome 
proliferators promote the development of a number of foci of altered cells and 
tumour cells in aged rats more than in younger animals. Based on this finding, 
these co-workers suggested that enhanced tumour production in older animals is 
due to the relatively high number of spontaneously initiated lesions. It is 
important to note that the level of peroxisome induction and the chronic 
hepatocyte proliferative effect in both young and old groups were the same 
(Cattley et al., 1991). The results of these two studies in combination with the 
lack of initiating activity of peroxisome proliferators, is consistent with the 
concept that the ability of peroxisome proliferators to produce liver tumours may 
be due to promotion of spontaneously initiated sites rather than to initiation of this 
incidence.
Taken collectively, the potency of a chemical to cause peroxisome 
proliferation and cell replication, associated with the ability to promote 
spontaneously, or otherwise, initiated cells appear to be potentially important 
factors in hepatocarcinogenicity. Further experimentation is required to clearly 
identify the precise mechanisms of peroxisome proliferation in hepatocarcino­
genicity in rodents, which may be useful in the assesment of any possible risk for 
humans exposed to various peroxisome proliferators.
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1.8. Possible Explanation for Co-Regulation o f  
P4504 Family and Peroxisome Proliferation.
Peroxisome proliferation and P4504 family induction appear to be 
closely linked phenomena (Lake et al., 1984; Sharma et al., 1988b; Chinje and 
Gibson, 1991; Dirven et al., 1991; and Gibson, 1992), based on direct evidence 
comparing induction and proliferation by a number of peroxisome proliferators 
and, also, on indirect evidence. For example, there is a species difference in 
response to induction of hepatic P4504A1 by peroxisome proliferators, with rats 
and mice being very responsive (Gibson, 1989), the hamster and rabbit 
considerably less sensitive, and the guinea-pig, monkey, and marmoset essentially 
refractory to induction (Makowska et al., 1991). This species difference in 
P4504A1 induction is closely mirrored by increases in peroxisomal 6-oxidation 
enzymes (Lake et al., 1989; and Lock et a l, 1989).
The exact underlying cellular mechanism connecting peroxisome 
proliferation and induction of the P4504 family remains to be fully explored. 
However, two different mechanisms have been proposed:
1.8.1. The Substrate Overload Hypothesis.
The close relationship between induction of P4504A1 and 
peroxisomal proliferation, and their linkage to lipid metabolism, has led to the 
suggestion for the existence of a mechanistic relationship between the two 
phenomena (Sharma et al., 1988a; and Lock et al., 1989). According to this 
proposal (Figure 1.4.), the peroxisome proliferator initially inhibits fatty acid 
oxidation of hepatocytes by the dual mechanism of inhibition of carnitine acyl
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Peroxisome proliferator
Induction of 
peroxisomal B-oxidation
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Figure 1.4. Possible inter-relationship between the induction of 
cytochrome P4504A1 and peroxisome proliferation (derived from Sharma et al., 
1988a; and Lock era/., 1989).
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transferase in the mitochondrion (Lock et a l, 1989), or sequestration of essential 
CoA by the peroxisome proliferator itself (Bronfman et al., 1986). Cytochrome 
P4504A1 synthesis is then induced possibly as a result of cellular medium and 
long chain fatty acid accumulation to maintain cellular lipid homeostasis. In this 
process, P4504A1 produces long chain dicarboxylic acids via fatty acid co- 
hydroxylation which either inhibit mitochondrial 6-oxidation or cannot be 
oxidised by this organelle (Sharma et al., 1988a; and Lock et al., 1989). It is 
proposed that these dicarboxylic acids may then be taken up by peroxisomes, and 
participate in part in the induction of peroxisomal 6-oxidation (Singh et al., 1984). 
The initial induction of P4504A1 has been supported by the observation of an 
early increase in the transcription of P4504A1 (approximately 30-60 minutes after 
administration of clofibrate) followed by induction of peroxisomal 6-oxidation 
after approximately 24 hours (Milton et al., 1990). This specific sequence of 
events has also been noted in the primary cultures of rat hepatocytes (Bieri et al.,
1991).
The above hypothesis is further substantiated by dual administration 
of clofibrate and the protein synthesis inhibitor cyclohexamide, which blocked 
both induction of P4504A1 activity and peroxisomal 6-oxidation. More 
importantly, P4504A1 mRNA remains high in the presence of cyclohexamide and 
clofibrate, whereas the acyl-CoA oxidase mRNA is not raised under the same 
experimental condition (Milton et al., 1990).
However, the above proposed mechanism may not be dependent on 
the induction of cytochrome P4504A1. There is a possible alternative regulatory 
mechanism (Figure 1.5.), in which the commonality of induction is related to 
structurally similar regulatory elements in the 5’ upstream flanking regions of the 
P4504A1 and acyl-CoA oxidase genes. Therefore, the peroxisome proliferator
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Figure 1.5. Postulated scheme for common regulation of the 
cytochrome P4504A1 and peroxisomal acyl-CoA oxidase genes; FABPs (fatty 
acid binding proteins).
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may directly interact with the common regulatory sequences or indirectly 
modulate gene expression by lipid perturbation. The lipid perturbation may be as 
a direct result of mitochondrial fatty acid 6-oxidation spiral inhibition (Lock et al., 
1989), or derived from lipids displaced from fatty acid binding proteins (Cannon 
and Eacho, 1991). This commonality of gene expression may also rationalise why 
peroxisome proliferators induce so many proteins. Additionally, this pattern may 
rationalise the existence of so many structurally diverse inducers of P4504A1 and 
acyl-CoA oxidase, in which the inducers may not all directly interact with the 
inducible genes, but may indirectly exert their actions via influencing lipid 
disposition, or a common perturbation of lipid biotransformation.
1.8.2. The Nuclear Receptor Hypothesis.
There have been many attempts to discover a hepatic cell component 
capable of binding peroxisome proliferators and to control gene activation. This 
has led to several controversial findings namely, the isolation of a cytosolic 
nafenopin-binding protein (Lalwani et al., 1983, 1987), the identification of 
albumin as a candidate (Milton et al., 1988), and the discovery of a 70 kDa heat 
shock protein (Alvares et al., 1990). The presence of a peroxisome proliferator 
binding protein and the peroxisome proliferators ability to activate gene 
transcription suggested a similar mechanism of action to that of the steroid 
hormones by these compounds. Recently, a nuclear receptor for the steroid 
hormone receptor superfamily has been cloned from mouse liver (Issemann and 
Green, 1990). This receptor could be activated by the addition of some of the 
well-known peroxisome proliferators and was, therefore, termed the Peroxisome 
Proliferator-Activated Receptor, PPAR (Issemann and Green, 1990,1991).
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The role of the PPAR in transcriptional gene activation of both 
peroxisomal acyl-CoA oxidase and cytochrome P4504A6 has been emphasised 
(Muerhoff et al., 1992). The PPAR contains both DNA-binding and ligand 
(peroxisome proliferator)-binding domains. A possible role of this receptor in the 
regulation of responsive genes following administration of peroxisome 
proliferators is depicted in Figure 1.6. According to this scheme, the inducer 
interacts with the ligand-binding domain and the binary peroxisome proliferator- 
PPAR complex then binds to response elements in the 5' regulatory region of 
responsive genes such as acyl-CoA oxidase and P4504A6 (Muerhoff et al., 1992). 
The similarity in response elements of these two functionally diverse enzymes (as 
shown by Muerhoff et al., 1992), rationalises on a molecular basis, why these two 
genes are ‘switched-on’ by peroxisome proliferators.
Recently, the rat (Gottlicher et al., 1992) andXenopus PPARs (Dreyer 
et al., 1992) have been isolated. The rat and mouse receptor proteins have been 
shown to be 97% identical with a particularly well-conserved ligand binding 
domain. Both saturated and unsaturated fatty acids can regulate and activate the 
rat PPAR (Gottlicher et al., 1992). This observation may emphasise the role of 
lipids and lipid metabolism, as stated earlier, in the induction of the P4504A 
subfamily by peroxisome proliferators. Therefore, it is possibe that a more 
complex regulation of the cytochromes P4504A exist, in which both exogenous 
peroxisome proliferators and/or endogenous fatty acids regulate P4504A 
induction.
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Figure 1.6. The possible role of the Peroxisome Proliferator Activated 
Receptor (PPAR) in hepatic pleiotropic responses to peroxisome proliferators 
(modified from Issemann and Green, 1990).
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More recently the human PPAR has also been isolated and sequenced 
(Sher et ah, 1993). It exhibits 91% sequence similarity to the mouse PPAR in its 
amino acid sequence, with the DNA-binding domains being almost identical. The 
human PPAR is capable of activating the rat palmitoyl-CoA oxidase and the 
rabbit P4504A6 genes in the presence of either nafenopin, clofibrate, or Wy- 
14643 (Sher et al., 1993). Dose response studies indicate that the human and 
mouse PPARs are approximately equally effective in the activation of both genes. 
However, the crucial question of human responsiveness to peroxisome 
proliferators still remains to be fully addressed. In this context, the evidence that 
human hepatocytes do not respond to cytochrome P4504A inducers (Elcombe and 
Mitchell, 1986) indicates that either human genes do not contain the necessary 
response elements to the PPAR, or that some other element of PPAR activation is 
absent in man, and this remains an important area for further investigations.
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1.9. Induction o f Cytochrome P450 Isoenzymes 
by Azole Antifungals.
The azole antifungal agents are synthetic compounds which display 
very high affinity for certain cytochromes P450. As previously stated, most of 
these can act as both inhibitors and inducers of the cytochrome P450-dependent 
mixed function oxidase system, depending on the time course of exposure to the 
xenobiotic (Rodrigues et a i, 1988). Clotrimazole and miconazole, and to a lesser 
extent ketoconazole, are potent inducers of monooxygenase system in rat liver, 
displaying selectivity toward the cytochrome P4502B and P4503A subfamilies 
(Rodrigues era/., 1988).
A new and highly effective member of N-substituted imidazole 
derivatives, bifonazole (Patzschke et al., 1983; Plemple et al., 1983; and 
Yamaguchi et al., 1983), but not the structurally-related clotrimazole (Figure. 
1.7.), has been shown to cause peroxisome proliferation in rat liver which is 
similar in nature to that produced by other peroxisome proliferators such as 
clofibrate and Wy-14,643 (Horie et al., 1991). Most peroxisome proliferators 
contain a carboxyl group in their structure (or can be metabolised to one), which 
may play a role in induction (Hertz et al., 1988; and Bronfman et al., 1989). In 
view of this, it is striking that neither bifonazole nor clotrimazole possess a 
carboxyl group in the parent compounds. As stated earlier, all peroxisome 
proliferators examined to date are inducers of the cytochrome P4504A subfamily, 
indicating the close relationship between these two enzyme systems (Lake et al., 
1984; Sharma et al., 1988a; Dirven et al., 1991; and Hozuka et al., 1991). 
However, the ability of bifonazole to modulate cytochromes P450, in particular 
the P4504A subfamily, in experimental animals has not yet been assessed.
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Figure 1.7. Chemical structures of bifonazole, clotrimazole 
and clofibrate (ethyl ester).
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1.10. Aims of the Present Study.
Concern about the long term human exposure to a variety of 
chemicals which are capable of causing peroxisome proliferation has been 
growing during the last several years. Such a concern is mainly based on the 
ability of prolonged exposure of peroxisome proliferators to produce liver 
tumours in rat and mouse, by non-genotoxic mechanisms. Peroxisome proliferation 
and induction of cytochrome P4504A member(s) are closely related phenomena, 
although their inter-relationship has not been fully defined. The proliferation of 
peroxisomes by the azole antifungal drug bifonazole, but not the structurally 
related clotrimazole was intriguing to investigate the co-induction of P4504A1 
and peroxisome proliferation in rat liver. Moreover, unlike most peroxisome 
proliferators, these latter azole antifungals lack a carboxylic acid moiety in the 
parent compounds.
The present study also aims to characterise the modulation of renal 
microsomal and peroxisomal parameters (particularly P4504A1 induction and 
peroxisome proliferation) following exposure of rats to bifonazole, clotrimazole 
and clofibrate, as this tissue is also a target organ for peroxisome proliferators.
Primary cultures of rat hepatocytes are useful system in which to 
investigate peroxisome proliferation and P4504A subfamily induction. The 
present work is also designed to explore the effect of a number of azole 
antifungals, including geniconazole, itraconazole, miconazole and UK-47265, as 
well as bifonazole, clotrimazole, and clofibrate on the P4504A subfamily using 
primary cultures of rat hepatocytes.
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Materials and Methods
2.1. Chemicals.
The standard chemicals and materials used in these studies were 
obtained from various suppliers and are listed below. Analytical grade solvents 
were either provided by the British Drug Houses Ltd (Poole, Dorset, UK) or 
Fisons (Loughborough, Leicestershire, UK).
Amersham International PLC (Buckinghamshire, UK):
Megaprime kit, nylon membrane, rat cytochrome P4501A1 ECL Western blotting 
kit (code number RPN 256), rat cytochrome P4502B1/2 ECL Western blotting kit 
(code number RPN 257), rat cytochrome P4503A ECL Western blotting kit (code 
number RPN 258), rat cytochrome P4502E1 ECL Western blotting kit (code 
number RPN 259), rat cytochrome P4504A1 ECL Western blotting kit (code 
number RPN 260), and rat NADPH-cytochrome P450 reductase ECL Western 
blotting kit (code number RPN 261).
Amersham Radiochemicals (Amersham, Buckinghamshire, UK):
[1-^^C] Arachidonic acid and [1-^^C] lauric acid.
Baver Research Centre (Wuppertal, Germany):
Bifonazole and clotrimazole.
Boehringer Mannheim UK Limited (Lewes. East Sussex, UK):
Agarose gel, collagenase A and lymphocyte separation medium.
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British Drug Houses Limited (Poole, Dorset, UK):
Ammonium persulphate, copper sulphate, ethylenediaminetetraaceticacid 
(EDTA), Folin-Ciocalteau phenol reagent, formaldehyde, glycerol, glycine, 
magnesium chloride, 2-mercaptoethanol, potassium chloride, potassium cyanide, 
potassium phosphate, sodium acetate trihydrate, sodium carbonate, sodium citrate, 
sodium dithionite, sodium dodecyl sulphate (SDS), sodium hydrogen carbonate, 
sodium potassium tartrate and sucrose.
Fisons (Loughborough, Leicestershire, UK):
Absolute ethanol, acetone, acetonitrile, chloroform, diethylether, dimethyl 
sulfoxide (DMSO), ethyl acetate, formamide, glacial acetic acid, glycerol, 
hydrochloric acid, methanol, propanol, sodium hydroxide, sodium chloride and 
trichloroacetic acid.
Gibco BRL (Uxbridge, Middlesex, UK):
Calcium-free Hanks balanced salt solution (lOx), fetal calf serum (mycoplasma 
screened virus free), gentamycin, insulin, L-glutamine, microtitre plates, RPMI 
1640 culture medium, sodium hydrogen carbonate and tissue culture dishes.
Molecular Probes (Eugene, OR, USA):
Ethoxyresorufin, pentoxyresorufin, and resorufin.
Pfizer Central Resarch (Sandwich, Kent, UK)
Geniconazole, itraconazole, miconazole and UK-47265.
Sigma Chemical Companv Limited (Poole, Dorset, UK):
Arachidonic acid, bromophenol blue, bovine serum albumin (BSA), calcium 
chloride, 4-chloro- 1-naphthol, clofibric acid, coenzyme A, cytochrome c, 
diethylpyrocarbonate (DEPC), dithiothreitol (DTT), donkey anti-sheep IgG
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(whole molecule) peroxidase conjugate, erythromycin, ethylene glycol-bis (6- 
amino ethyl ether) N,N,N',N'-tetraacetic acid (EGTA), ethylmorphine, FAD, goat 
anti-sheep IgG (whole molecule) biotin conjugate, HEPES biological buffer, 
hydrocortisone 21-hemisuccinate, 30% (v/v) hydrogen peroxide solution, Kodak 
X-AR 100 photographic film, lauric acid, methylene blue, MOPS buffer, MTT (3- 
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), NAD+, NADH, 
NADPH, nicotinamide, N,N-tetramethyl-ethylenediamine (TEMED), palmitoyl- 
CoA, streptavidin-biotinylated horseradish peroxidase complex, Triton X-100, 
trypan blue and Tris (Trizma) base.
Other suppliers:
Acrylagel and bis-acrylagel (National Diagnostics, Alyesbury, UK);
Anti-trifunctional peroxisomal enzyme serum (kind gift of Dr D Cinti, University 
of Conneticut Health Centre, CT, USA);
3MM Blotting paper (Whatman, Maidstone, Kent, UK);
Coomassie brilliant blue, dye reagent concentrate (Bio-Rad laboratories Limited, 
Hemel Hempstead, Hertfordshire, UK);
Electrophoretically homogeneous cytochrome P4504A1 and the corresponding 
anti- serum (provided by Dr EC Chinje, University of Surrey, Guildford, UK);
0.2 jj,M Minisart filter (Sartorious Limited, Epsom, Surrey, UK);
Nitrocellulose filters (Anderman and Co. Limited, Kingston-upon-Thames, UK);
Power packs (BioRad, Watford, Herts, UK);
RNAzol (Biogenesis Limited , Bournemouth, UK);
Slab gel apparatus (Hoefer Scientific Instruments, Newcastle, Staffs, UK).
All other chemicals were obtained from commercial sources and were 
of highest purity available.
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2.2. Animals.
Male closed colony Wistar albino rats (6 weeks old, 150-220 g body 
weight. University of Surrey Breeders) were housed in cages with sawdust 
bedding, and allowed food (Sprats Animal Diet No. 1, William Lilli Co., Surrey, 
UK) and water ad libitum. A  twelve-hour light/dark (0600-1800 hour light) cycle 
was maintained at 22°C and 50% relative humidity.
In some experiments (in vivo studies), the animals were treated by
gavage once daily for six days at the following dose levels: sodium clofibrate 250
mg/kg, bifonazole and clotrimazole each at two dose levels, 150 and 750 |imol/kg, 
and were killed 24 hours after last dose.
All the above compounds were administered in com oil as the vehicle, 
control animals were given com oil at 1 ml/kg by gavage.
2.3. Preparation and Culture o f Rat Hepatocytes.
2.3.1. Isolation and Culture of Hepatocytes.
Isolation of hepatocytes was based on methods described by Green et 
al., 1983; Paine and Legg, 1978; and Seglen, 1973. The untreated rat was ether 
anaesthetised and the liver was perfused under aseptic conditions with 300 ml of 
calcium-free Hanks balanced salt solution (HBSS) buffer containing 25 mM 
HEPES, 0.4% (v/v) sodium carbonate, 0.6 mM EGTA and 6.66 pg/ml BSA, 
followed by a 5-10 minutes perfusion with 0.025% (w/v) collagenase in calcium 
free HBSS buffer containing 25 mM HEPES, 0.4% (v/v) sodium carbonate, and 
0.06% (w/v) calcium chloride. The perfusion was performed at 37“C at a rate of 
25 ml/minute.
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Immediately following the collagenase perfusion, the liver was gently 
tom apart and cells were dispersed in approximately 25 ml of culture medium 
(RPMI 1640 containing 5%, v/v, fetal calf semm, 100 jig/ml gentamycin, 20 mM 
HEPES, 0.1 mM hydrocortisone 21-hemisuccinate, 1 |iM insulin, 2 mM L- 
glutamine, and 0.1%, v/v, sodium carbonate), and filtered through 111 \im 
polyethylene Spectra/Mesh. The cmde suspension of cells was then purified by 
centrifuging three times for 3 minutes at 50 g, and resuspended in the culture 
medium. The cells were plated onto 100 mm Petri dishes at a density of 6.5 x 10  ^
viable cells per 10 ml culture medium, using the trypan blue exclusion cell 
counting method (see below), and maintained at 37“C, in an incubator (5% 
€02/95% air), and allowed an attachment period of 3 hours.
The test chemicals were prepared as concentrated solutions in 
dimethyl sulfoxide (DMSO) and mixed with tissue culture medium so that the 
final concentration of DMSO was 0.4% (v/v), which had no effect on hepatocyte 
viability or response to cytochrome P4504A inducers (Gibson and Lake, 1991). 
Following the attachment period, treatment was commenced by replacing the 
tissue culture medium with fresh medium containing either 0.4% (v/v) DMSO 
(control cultures) or the test compounds dissolved in DMSO. Subsequently, the 
medium was changed every 24 hours and the cells retreated with fresh medium 
containing either the test compound or DMSO only.
After a 70 hours incubation period, the dishes of hepatocytes were 
washed twice with ice-cold KCl (154 mM containing 50 mM Tris-HCl buffer, pH 
7.4) and the hepatocytes were harvested by scraping into 1.25 ml of the latter 
buffer. The hepatocytes were homogenised by sonication with a probe ultra- 
sonicator, and aliquots of each homogenate stored at -80“C.
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2.3.2. Cell Viability Assays.
2.3.2.1. Trypan Blue Exclusion.
The ability of intact (Viable) cells to exclude the high molecular 
weight dye, trypan blue, was utilised in this assay in order to determine cell 
viability and cell yield prior to use. Freshly isolated hepatocytes were diluted with 
trypan blue (0.5%, w/v, in 0.85%, w/v, saline), mixed and applied to a 
haemocytometer. Cells were counted over a known area and their viability 
assessed.
2.3.2.2. MTT Test.
The hepatocytes viability following treatment with chemicals was 
estimated using the method of Mosmann, 1983; and Denizot and Lang, 1986. This 
method is based on the reduction by living cells of tétrazolium salt, MTT, to a 
blue form formazan product.
The assay was carried out in microtitre plates. Each well contained 
200 |il of supplemented RPMI 1640 medium containing 2.5 x 10  ^viable cells per 
ml. The plates were maintained at 37“C, in an incubator (5% 002/95% air), and 
allowed an attachment period of 3 hours. The medium was replaced after 3 hours 
with fresh medium containing the chemicals dissolved in 0.4% (v/v) DMSO and 
the plates maintained in the incubator for 24 hours.
Following the 24 hours incubation, the culture medium removed and 
50 pi of MTT solution (0.1%, w/v, in RPMI 1640 medium) was added to each 
well. The plates were gently shaken and incubated for 3 hours in the incubator. 
The medium was then replaced with 150 pi of propanol, and the plates were 
rigorously shaken using a microtitre plates shaker incubator Dynatech (Dynatech
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laboratories. West Sussex, UK) in order to ensure solubilisation of the blue 
formazan. The optical density of each well was measured using an automatic plate 
reader (Labsystems Multiskan Biochromatic), at 560 nm.
2.4. Collection and Preparation o f Blood Samples.
2.4.1. From Rats.
At the start of the seventh day after commencement of the treatment 
(i.e. 24 hours after the last dose), each rat was anaesthetised by inhalation of 
diethylether. Following anaesthesia, blood sample from the heart was collected 
into a syringe containing 1 ml of 3.8% (w/v) aqueous sodium citrate as anti­
coagulant. Each blood sample (6-7 ml) was transferred to a head space vial.
2.4.2. From Human.
Blood samples (25-50 ml) from healthy volunteers were freshly 
drawn into syringes, and immediately transferred to head space vials containing 
3.8% (w/v) aqueous sodium citrate (4-8 ml) as anticoagulant.
2.4.3. Separation of Blood Components.
The method used in the separation of blood components was a 
modification of the method described by Fost et al., 1991. Blood samples (5 ml) 
were centrifuged at 400 g for 5 minutes to separate blood plasma and blood cells. 
The separated plasma was stored at -20“C. The sedimented cells were resuspended 
in 3.5 ml physiological saline (0.9%, w/v) by vortexing and layered onto 15 ml
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lymphocyte separation medium (5.7%, w/v, ficoll 400 and 9%, w/v, sodium 
diatrizoate). Lymphocytes were isolated after centrifugation at 400 g for 30 
minutes. The fraction containing the lymphocytes was mixed with 2 ml 
physiological saline and centrifuged at 16000 g for 10 minutes. The sedimented 
lymphocytes were resuspended in 500 pi saline. Due to the sample size in rats, the 
lymphocytes from each experimental group were pooled, and stored at -20“C.
After the isolation of lymphocytes, the sedimented erythrocytes, 
granulocytes, and thrombocytes were resuspended in 5 ml physiological saline 
and stored at -20“C.
2.5. Preparation o f Subcellular Fractions.
Animals were sacrificed by cervical dislocation after blood collection. 
Microsomes were prepared by ultracentrifugation, using a modification of the 
method of Omura and Sato, 1964. The livers and kidneys were removed, blotted 
dry and weighed, and the livers perfused with ice cold 0.9% (w/v) saline to 
remove contaminating haemoglobin, and the kidneys decapsulated prior to 
homogenisation. The tissues were scissors-minced and homogenised in 250 mM 
sucrose, using a Potter-Elvehjem glass-Teflon homogeniser. Whole tissue 
homogenates were adjusted to 25% (w/v) by the addition of 250 mM sucrose, and 
aliquots were taken for the determination of peroxisomal enzymes, and stored at - 
80"C.
The remaining homogenate was centrifuged in a JA-17, 15x50 ml 
aluminium angle-head rotor in a Beckman J2-21 centrifuge at 12600 g and 4“C for 
30 minutes, to remove cell debris and mitochondrial fractions. The supernatant 
was decanted and centrifuged using a Beckman L7-65 ultracentrifuge with a Ti-70
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(12x10 ml titanium angle-head rotor) at 105,000 g for 60 minutes at 4“C. Aliquots 
of supernatant (cytosol) were frozen at -80“C. The microsomal pellet was 
suspended in the corresponding volume of ice-cold potassium phosphate buffer 
(50 mM containing 20%, v/v, glycerol, pH 7.25), using a motor driven Potter- 
Elvehjem glass-Teflon homogeniser, and stored as 1 ml aliquots at -80“C. Under 
these conditions the cytochrome P450 content and enzyme activity remained 
stable for several months (Milton, 1988).
2.6. Determination o f Total Protein Content.
The total protein content was determined by either the method of 
Lowry et al., 1951, or Bradford, 1976, with bovine serum albumin as the standard.
2.6.1. Lowry Method.
Bovine serum albumin stock solution (20 mg/ml in distilled water) 
was diluted with phosphate buffer (50 mM containing 20%, v/v, glycerol, pH 
7.25) to give a range of standards (8-40 pg) in a total volume of 100 pi. 
Microsomal and homogenate fractions were diluted with the above phosphate 
buffer, and blood fractions were diluted using 0.9% (w/v) saline. 400 pi distilled 
water was added to each tube (including the BSA standards) prior to the addition 
of 2.5 ml of a freshly prepared mixture of 1% (w/v) copper sulphate, 2% (w/v) 
sodium potassium tartrate, and 2% (w/v) sodium carbonate (in 100 mM sodium 
hydroxide), in the ratio of 1:1:100, respectively. After 10 minutes, 250 pi of 
Folin-Ciocalteau phenol reagent (diluted 1:1 with distilled water) was added to 
each tube, mixed and allowed to stand at room temperature for 30 minutes. The 
absorbance of the samples was recorded at 750 nm using a Kontron Uvikon 860
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spectrophotometer, and the protein concentration was calculated from the standard 
curve.
2.6.2. Bradford Method.
800 pi standards (bovine serum albumin, stock solution 0.1 mg/ml in 
distilled water, diluted with water to give a range of 1-20 pg/ml) and 
appropriately diluted hepatocyte samples were placed in test tubes. Following the 
addition of 200 pi coomassie brilliant blue G-250 (Bio-Rad dye reagent 
concentrate), the absorbance was measured at 595 nm against blank (after a period 
of 30 minutes) and the protein concentration of samples was calculated using the 
standard curve.
2 .7. Fluorimetric Enzyme Assays.
2.7.1. Ethoxyresorufin 0-deethylase Activity.
The activity was measured using the method of Burke and Mayer, 
1974. The 0-dealkylation of ethoxyresorufin was followed using a Perkin-Elmer 
LS-5 luminescence spectrophotometer, with the emission and excitation widths 
set at 2.5 and 10 nm, respectively. The excitation wavelength was 510 nm, with 
the emission wavelength set at 586 nm.
In a 3 ml disposable fluorimeter cuvette, containing 2 ml Tris-HCl 
buffer (100 mM, pH 7.8) at 37°C and 150 pi of 25% (w/v) microsomal 
suspension, 3 pi ethoxyresorufin (0.53 mM in DMSO) was added, mixed and a 
baseline recorded. The reaction was initiated by the addition of 10 pi NADPH (50 
mM in 1%, w/v, NaHCOg) and was monitored for 5 minutes (linear phase), and
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the initial gradient of the slope was calculated. The fluorimeter was calibrated by 
the addition of 10 pi aliquots of resorufin (0.1 mM, in DMSO) to the incubation 
mixture, comprising all the above components except the substrate. Results were 
expressed as pmoles resorufin formed/ minute/ mg microsomal protein.
2.7.2. Pentoxyresorufin 0-depentylase Activity.
This activity was determined using the method of Burke et al., 1985. 
The 0-deaIkylation of pentoxyresorufin was followed using a Perkin-Elmer LS-5 
luminescence spectrophotometer.
In a 3 ml disposable fluorimeter cuvette, containing 2 ml Tris-HCl 
buffer (100 mM, pH 7.8) at 37“C and 150 pi of 25% (w/v) microsomal 
suspension, 3 pi pentoxyresorufin (1 mM, in DMSO) was added, mixed and a 
baseline recorded. The reaction was initiated by the addition of 10 pi NADPH (50 
mM in 1%, w/v, NaHCOs) and the linear reaction rate recorded. The fluorimeter 
was calibrated by the addition of 10 pi aliquots of resorufin (0.1 mM, in DMSO) 
to the incubation mixture, comprising all the components except the substrate. 
Results were expressed as pmoles resorufin formed/ minute/ mg microsomal 
protein.
2.8. Spectrophotometric Enzyme Assays.
2.8.1. Cytochrome b5 Determination.
The cytochrome b$ content was determined using the method of 
Omura and Sato, 1964. Cytochrome b$ was measured as the difference spectrum 
between of reduced and oxidised forms.
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The microsomal suspensions were diluted with phosphate buffer (50 
mM containing 20%, v/v, glycerol, pH 7.25), mixed and divided equally between 
two 1.5 ml cuvettes. 25 pi of 2% (w/v) NADH (in 1%, w/v, NaHCOs) was then 
added to the test cuvette, mixed and the difference spectrum between 390-500 nm 
recorded, using a Kontron Uvikon 860 spectrophotometer. The cytochrome bs 
content was calculated using the difference in optical density between 410 and 
426 nm, using an extinction coefficient of 185 mM"^ cm'l for this wavelength 
couple, and expressed as nmol/ mg microsomal protein.
2.8.2. Determination of Total CO-Discernible Cytochrome 
P450.
The total amount of cytochrome P450 was determined using the 
method of Omura and Sato, 1964. This method is based on the reduction of the 
haemoprotein to the ferrous form by the addition of sodium dithionite, and 
subsequent complexation with carbon monoxide.
Microsomal samples and hepatocyte homogenates were diluted with 
phosphate buffer (50 mM containing 20%, v/v, glycerol, pH 7.25) and KCl (154 
mM containing 50 mM Tris-HCl buffer, pH 7.4), respectively. After addition of 
sodium dithionite, the sample was split between two 1.5 ml cuvettes and a 
baseline recorded between 400 and 500 nm, using Kontron Uvikon 860 
spectrophotometer. Carbon monoxide (at approximately one bubble per second) 
was then bubbled through the test cuvette for 25 to 40 seconds and the absorbance 
difference remeasured, over the wavelength range of 400 nm to 500 nm.
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The concentration of cytochrome P450 was calculated using the 
difference extinction coefficient (450-490 nm) of 91 mM"  ^cm'^, and expressed as 
nmoles P450/ mg microsomal protein.
2.8.3. Erythromycin and Ethylmorphine N-demethylase 
Activities.
The assays are based on the formation of formaldehyde during 
déméthylation of erythromycin and ethylmorphine, which were determined by an 
adaptation of the methods of Wrighton et a l, 1985, and Holtzman et al., 1968, 
respectively. The following incubation mixture was pre-incubated at 37 “C for 5 
minutes:
Potassium phosphate buffer (50 mM, pH 7.24) 600 pi
Magnesium chloride (150 mM) 100 pi
Microsomal suspension (4 mg protein/ml) 100 pi
Erythromycin or ethylmorphine (10 mM) 100 pi
The reaction was initiated by the addition of 100 pi of NADPH (50 
mM) to the incubation mixture. The reaction was allowed to proceed for 10 
minutes at 37“C before it was terminated by the addition of 500 pi ice cold 
trichloroacetic acid (12.5%, w/v). The tubes were left on ice for 5 minutes and 
centrifuged at 3000 g for 10 minutes. One ml of the supernatant was added to 1 ml 
of freshly prepared Nash reagent (4 M ammonium acetate containing 0.2%, v/v, 
acetyl acetone, pH 6.0) and incubated in a water bath at 60“C for 10 minutes. The 
tubes were allowed to cool and the absorbance of the test solutions determined at 
412 nm. Blanks and standard solutions of formaldehyde (0-150 pM) were 
prepared, and the results were expressed as nmol formaldehyde formed/ minute/ 
mg microsomal protein.
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2.8.4. Estimation of Cyanide-Insensitive Palmitoyl-CoA 
Oxidation.
The method utilised was that of Bronfman et al., 1979. The oxidation 
of palmitoyl-CoA results in the reduction of FAD and NAD'^. In mitochondria, 
these are re-oxidised by the cytochrome chain which can be blocked by cyanide. 
In peroxisomes, however, FADH is re-oxidised by molecular oxygen but the 
NADH accumulates and, therefore, an assay for NADH production in the 
presence of cyanide serves as a measure of the peroxisomal fatty acid oxidase 
system, as the palmitoyl CoA oxidase is the first and rate limiting enzyme in the 
system (Milton, 1988).
The assay medium (volume, 3 ml) containing, at a final concentration, 
BSA (255 pg/ml), coenzyme A (75 pM), DTT (4.2 pM), FAD (180 pM), KCN 
(3pM), NAD+ (555 pM), and nicotinamide (141 mM) in Tris-HCl buffer (60 mM, 
pH 8.3) was freshly prepared and stored on ice. Tissue homogenates were diluted 
1:1 with Tris-HCl buffer (60 mM containing 1%, v/v, Triton X-100, pH 8.3), and 
equilibrated for 2 minutes at 37“C to allow solubilisation of the peroxisomes to 
liberate the enzyme. To the 40 pi of the solubilized homogenate was added 2 ml 
of the reaction mixture and 940 pi of Tris-HCl buffer (60 mM, pH 8.3), and 
equilibrated for a further period of 5 minutes at 37“C. The reaction was initiated 
by the addition of 20 pi palmitoyl-CoA (75 pM in 60 mM Tris-HCl buffer, pH 
8.3), and the change in absorbance at 340 nm (37“C) was recorded using a 
Kontron Uvikon spectrophotometer. Results were expressed as nmoles NADH 
produced per minute per mg of homogenate protein using the molar extinction 
coefficient of 6220 M'^ cm"^  for NADH at 340 nm.
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2.8.5. NADPH-Cytochrome c (P-450) Reductase Activity.
This enzyme is localised in the microsomes and functions as a 
component of the monooxygenase system. The activity was measured essentially 
by the method of Williams and Kamin, 1962.
The following were added into two cuvettes:
Test Reference
Cuvette Cuvette
Tris-HCl buffer (100 mM, pH 7.5) 1.7 ml 1.8 ml
Cytochrome c (0.1 mM) 1.0 ml 1.0 ml
Microsomal suspension (25%, w/v) 0.2 ml 0.2 ml
NADPH (2%, w/v) 0.1 ml
Total volume 3.0 ml 3.0 ml
The reaction was initiated by the addition of lOOpl NADPH (2%, w/v, 
in 1%, w/v, NaHCOs), and was followed at 550 nm for 3 minutes in a Kontron 
Uvikon 860 spectrophotometer at room temperature. The initial velocity was 
taken as the measure of cytochrome c reductase activity and calculated using the 
extinction coefficient of 18.5 mM'l cm’ .^ Results were expressed as nmoles 
cytochrome c reduced per minute per mg of microsomal protein
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2.9. Lauric Acid Metabolism.
2.9.1. Incubation for Lauric Acid Metabolism.
The metabolism of lauric acid to ll-(co-l) and 12-(cû) hydroxylated 
products was determined using HPLC as described by Parker and Orton, 1980.
Incubation mixtures (final volume 2 ml) contained 0.5 to 1 mg of 
microsomal or hepatocyte protein and 0.1 mM lauric acid (200 mM stock solution 
in methanol, diluted to 1 mM in 500 mM Tris-HCl buffer, pH 7.4), including 0.1 
pCi [l^Cj-lauric acid (at a specific activity of 52.8 mCi/ mmol). The mixture was 
pre-incubated for 5 minutes at 37“C, prior to the addition of 40 pi of NADPH (40 
mM in 1%, w/v, NaHCOs) to initiate the reaction. Microsomal blanks contained 
1% (w/v) NaHCOs instead of NADPH. The reaction was allowed to proceed for 5 
to 10 minutes at 37“C before it was terminated by the addition of 300 pi of HCl (3 
M).
The incubation mixture was extracted into 10 ml diethylether on a 
rotary mixer for 20 minutes. The tubes were then spun at 1000 g for 5 minutes, to 
clarify the phases, after which the upper (ether) layer was transferred to a test tube 
and evaporated to dryness under a stream of nitrogen. The tubes were sealed and 
stored at -20“C prior to HPLC separation.
2.9.2. Reverse-Phase High Performance Liquid Chromato- 
graphy.
The dried ether extracts were dissolved in 150 pi eluting solvent 
(water : methanol : acetic acid, 45:55:0.05 by volume). A 100 pi aliquots was 
injected into a reverse phase HPLC using a Micropak MCH-10 column (30x0.4
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cm, Varian Associates Limited, Walton-on-Thames, UK), using a linear gradient 
of 45% water : 55% methanol (containing 0.1%, v/v, acetic acid) to 100% 
methanol over a 40 minutes period, at a flow rate of 1 ml/minute.
The elute was passed through a Berthold LB 506 C-1 Radioactivity 
Monitor (Lab-Impex, Twickenham, UK), containing a 200 pi flow cell and 
interfaced with a microprocessor (Motorola 68B09 CPU). This was linked to a 
PC-IV 286 AT-Compact computer (Opus Technology pic, Redhill, UK), enabling 
quantitative analysis of lauric acid metabolism. The (co-l)- and co-hydroxylated 
products successively eluted followed by the unchanged lauric acid substrate. The 
rates of hydroxylation were calculated from the fractional conversion of substrate 
to C O - and (co-l)-hydroxy products, obviating the need for the estimation of 
recovery of radioactive products. Relative percentages of the substrate 
conversions were obtained on data print-outs after correction for background 
counts. The rate of formation (RF) of individual metabolites was quantified using 
the following formula:
RF = L (nmol) x M (%) / T (min) x C (mg)
L = nmol original substrate (lauric acid) in the incubation mixture
M = percentage of substrate converted to metabolite
T = incubation time in minutes
C = total amount of protein in the incubation mixture (mg)
RF is then expressed as: nmol product formed/ minute/ mg of protein. 
Alternatively, the rate of product formation may be expressed per nmol 
cytochrome P450 by dividing RF by the cytochrome P450 content (nmol/ mg of 
protein).
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2.10. Arachidonic Acid Metabolism.
The method used in the determination of arachidonic acid metabolism 
was carried out essentially as described by Capdevila et al, 1985. The products of 
arachidonic acid metabolism were isolated from a constantly stiired incubation 
mixture containing either human or rat blood components or, control or induced 
rat liver or kidney microsomes, in the presence of 10 mM magnesium chloride, 
150 mM potassium chloride, and Tris-HCl buffer (50 mM, pH 7.5), in a final 
volume of 2 ml.
After temperature equilibration at 25“C for 5 minutes with constant 
stirring, sodium arachidonate (at a specific activity of 1.2 mCi/ mmol) was added 
to a final concentration of 0.1 mM. The reaction was initiated by the addition of 
NADPH (1 mM final concentration). The incubation was carried out at 37“C in a 
shaking water bath, allowed to proceed for 20 minutes, and terminated by the 
addition of 4 ml ethyl acetate containing 12.5 mM HCl and 0.1% (w/v) butylated 
hydroxy-toluene (BHT) as anti-oxidant. Following two further extractions with 
ethyl acetate (3 ml), the combined extracts were dried under a stream of nitrogen 
(N2 ). About 95% of the added radioactivity was reported to be recovered in the 
organic extracts under this procedures (Capdevila et al., 1985), and, therefore, no 
correction for recoveries was applied to my data. The extracts were stored at - 
80“C before HPLC separation.
The dried ethyl acetate extracts were reconstituted in 150 pi of 
starting solvent (water : acetonitrile, 70:30, containing 0.1%, v/v, acetic acid). The 
metabolites were separated by reverse phase HPLC on a Micropak MCH-10 
column (30x0.4 cm, Varian Associates Limited, Walton-on-Thames, UK) using a 
linear elution gradient ranging from 30% to 100% acetonitrile (containing 0.1%,
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v/v, acetic acid), at a flow rate of 1 ml/minute for 50 minutes. The elution profile 
of the radioactive products was monitored using a Berthold LB 506 C-1 
Radioactivity Monitor (Lab-Impex, Twickenham, UK), containing a 200 pi flow 
cell and interfaced with a microprocessor (Motorola 68B09 CPU). This was 
linked to a PC-IV 286 AT-Compact computer (Opus Technology pic, Redhill, 
UK), enabling quantitative analysis of arachidonic acid metabolism, essentially as 
described for lauric acid metabolites quantification.
2.11. Western Blot Analysis.
Western blotting involves the electrophoretic transfer of separated 
proteins from polyacrylamide gels to nitrocellulose sheets, which are then 
subjected to immunological analysis. The methods used were modifications of the 
basic procedures of Towbin et al., 1979, Burnette, 1981, and reviewed by Bers 
and Garfin, 1985.
2.11.1. Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE).
The method of Laemmli, 1970, was routinely employed to resolve the 
microsomal proteins. Electrophoresis was performed at room temperature using a 
vertical slab gel assembly (Hoefer Scientific Limited), in which the gel was 
assembled in a glass and perpex cassette.
All samples were diluted in sample solubilisation buffer (62.5 mM 
Tris-HCl buffer containing 0.001%, w/v, bromophenol blue, 15%, v/v, glycerol, 
5%, v/v, 2-mercaptoethanol, and 2.3%, w/v, SDS, pH 6.8), boiled for 2 minutes.
64
and subjected to a 10% (w/v) SDS-polyacrylamide| gel electrophoresis. The 
following lyophilised proteins of known molecular weights were supplied in a kit, 
either from Sigma (Poole, Dorset) or Amersham (Buckinghamshire, UK);
Sigma (prestained markers):
a2-macroglobulin (human plasma) 180,000 Da
6-galactosidase (E.coli) 116,000 Da
Fructose-6-phosphate kinase (rabbit muscle) 84,000 Da
Pyruvate kinase (chicken muscle) 58,000 Da
Fumarase (porcine heart) 48,500 Da
Lactic acid dehydrogenase (rabbit muscle) 36,500 Da
Triosephosphate isomerase (rabbit muscle) 26,600 Da
Amersham (biotinylated markers):
Phosphorylase b subunit 97,400 Da
Catalase subunit 58,100 Da
Alcohol dehydrogenase subunit 39,800 Da
Carbonic anhydrase 29,000 Da
Trypsin inhibitor 20,100 Da
Lysozyme 14,300 Da
For cytochrome P4504A1 Western blots, 0.5 pmol of purified 
cytochrome P4504A1 was loaded per track as an authentic marker. Samples were, 
in general, loaded on an equiprotein basis and electrophoresis was carried out with 
a constant current of 20 mA for the stacking gel (125 mM Tris-HCl buffer, pH 6.8 
containing 0.1%, w/v, SDS, 10%, w/v, acrylamide, 0.27%, w/v, bis-acrylamide, 
0.05%, w/v, freshly prepared ammonium persulphate, and 0.08%, v/v, TEMED), 
and 40 mA for the separating gel (150 mM Tris-HCl buffer, pH 8.8 containing 
0.04%, w/v, SDS, 3%, w/v, acrylamide, 0.08%, w/v, bis-acrylamide, 0.01%, w/v, 
freshly prepared ammonium persulphate, and 0.2%, v/v, TEMED). On completion 
of gel electrophoresis, the gels subjected to immunoblotting analysis.
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2.11.2. Electrophoretic Transfer and Immunochemical 
Staining.
The lower separating gel, was removed from the gel cassette, and 
immersed in transfer buffer (20 mM Tris-HCl containing 150 mM glycine and 
20%, v/v, methanol) for a period of 45 minutes prior to transfer to a nitrocellulose 
sheet. This stage allows the gel to shrink, therefore, avoiding disruption of the 
bands during transfer. The transfer was achieved by the use of an electrophoretic 
transfer apparatus (BIORAD) at room temperature and a constant voltage of 30 V 
overnight.
Following electrophoretic transfer, the nitrocellulose sheet was 
blotted in phosphate buffer saline containing 1% (w/v) bovine serum albumin and 
0.2% (v/v) Triton X-100 (PBSBT) for 2 hours at room temperature. Two 
subsequent washes with PBSBT were carried out at this temperature on a shaker. 
The PBSBT was then replaced with fresh PBSBT containing primary antibody 
(anti-cytochrome P4501A1, anti-cytochrome P4502B1/2, anti-cytochrome 
P4502E1, anti-cytochrome P4503A, or anti-cytochrome P4504A1, reconstituted 
in 300 \il of PBS 1:200 dilution, Amersham kit; or anti-peroxisomal trifunctional 
protein, 1:1500 dilution), and incubated for 1 hour at room temperature followed 
by three washes with PBSBT. The membrane was then probed with an anti-rabbit 
Ig-biotinylated secondary antibody for 1 hour at room temperature. Following 
three washes with PBSBT, the membrane was exposed to a streptavidin- 
horseradish peroxidase conjugate for 30 minutes at room temperature, which 
binds to the biotinylated secondary antibody. After three subsequent washes with 
PBSBT, the nitrocellulose sheet was detected either using enhanced 
chemiluminescence reagents utilising the bound horseradish peroxidase to 
catalyse the oxidation of luminal in the presence of hydrogen peroxide, or in the
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case of trifunctional protein, developed in Tris-HCl buffer (100 mM containing 
0.6 mg/ml 4-chloro-1 -naphthol and 1:5000 hydrogen peroxide). The latter 
reaction was terminated when judged appropriate by rinsing the membrane several 
times with distilled water.
2.12. RNA Analysis.
2.12.1. Total RNA Extraction.
Extraction of RNA was based on the method of Chomczynski and 
Sacchi, 1987. To prevent degradation by RNases, precautions must be taken to 
ensure sterility of all equipment and solutions. All aqueous solutions were made 
with a solution of 0.1% (w/v) diethylpyrocarbonate (DEPC) sterilised water.
Tissue samples were broken into pieces in a pre-cooled pestle and 
mortar using liquid nitrogen, and a 100-200 mg sample of tissue was taken and 
finely ground in liquid nitrogen. The powdered tissue was scraped into a pre­
cooled tube, immediately 2 ml of cold RNAzol B solution (guanidium 
isothiocyanate, phenol and 2-mercaptoethanol) was added, and the tissue 
homogenised using a polytron blender, kept on ice. Following the addition of 200 
|Xl of ice cold chloroform, the mixture was shaken for 15 seconds, left on ice for 
30 minutes, and centrifuged at 12000 g for 15 minutes. The upper aqueous phase 
was then carefully removed, mixed with an equal volume of isopropanol, and left 
on ice for 40 minutes. The RNA was then pelleted by centrifugation at 12000 g 
for 15 minutes, washed with 5 ml of 75% (v/v) ethanol, and centrifuged at 7500 g 
for 15 minutes. The pellet was dried at room temperature, resuspended in 100 |xl 
DEPC water, and stored at -80*C.
67
2.12.2. Northern Blot Analysis.
This method was based on the method of Sambrook et al., 1989, 
relying on the binding properties of nucleic acids to complementary sequences of 
DNAorRNA.
Onto a 2% (w/v) agarose gel, containing formaldehyde, 20 |ig RNA 
was loaded in each lane. The gel was placed in a tank of lOxMOPS buffer [250 
mM 3-(N-morpholino)-propanesulfonic acid, 62 mM sodium acetate, and 12.5 
mM EDTA, pH 7.0] and electrophoresed at 100 mV for 2 to 3 hours. Following a 
30 minutes wash with DEPC water, the gel was capillary transferred to a nylon 
membrane for a period of 48 to 72 hours. The transferred RNA was bound to the 
membrane by exposure to UV radiation for 3 minutes. The membrane was then 
sealed in a plastic bag with a few ml of 5xSSC (75 mM sodium citrate and 750 
mM sodium chloride), and kept at 4°C until required for probing.
2.12.3. DNA Probe Synthesis.
A DNA probe derived from rat cytochrome P4504A1 gene (2.1 kb) 
by Eamshaw et aL, 1988, was used in this work.
2.12.4. Detection of Homologous RNA Sequences.
Prehybridisation and probing were carried out according to the 
method of Church and Gilbert, 1984.
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2.12.4.1. Prehybridisation.
The membrane was incubated with prehybridisation buffer (500 mM 
sodium phosphate buffer, pH 7.0 containing 50%, v/v, deionised formamide, 1 
mM EDTA, and 7%, w/v, SDS) in a rotary oven at 42°C, for 2 hours.
2.12.4.2. Radiolabelling of the P4504A1 cDNA Probe.
The cDNA was labelled using dCTP containing ^^P (obtained freshly 
from ICN Flow, Buckinghamshire, UK), using the Amersham Megaprime kit. 
This kit uses the DNA polymerase action of the Klenow fragment of 
DNApolymerase I tosynthesisecomplementary strands to those of the cDNA used 
as the probe. The resultant synthesised DNA will contain the dCTP radiolabel, 
and will, therefore, cause darkening on exposure to photographic film.
2.12.4.3. Probing of the Nylon Membrane.
Following the radiolabelling of the probe, the cDNA probe was added 
to the Prehybridisation buffer and incubated overnight in a rotary oven at 42"C. 
Precautions (e.g. perspex shielding and careful monitoring) were taken whenever 
radiolabelled DNA was being used. The first incubation step (prehybridisation) 
was in order to reduce non-specific binding of the probe to the nylon membrane. 
The second hybridisation stage allowed the probe to bind to any RNA sequences 
of complementary sequence to the cDNA probe.
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2.12.4.4. Washing of the Probed Membrane.
The membrane was washed in a solution of SSC buffer in a rotary 
oven to remove radiolabelled probe bound to unrelated molecules, and also to 
ensure that the probe was only bound to RNA sequences of high base sequence 
homology. The probe hybridisation to RNA sequences can be reduced by altering 
the incubation temperature and the salt concentration in the buffer, so that only 
sequences of relatively high homology will bind to the probe. In order to avoid 
exceeding the optimum, hybridisation conditions, washes were performed in a 
stepwise fashion of increasing temperature and reducing salt concentration until 
the membrane background radiation count was relatively low in comparison to the 
samples.
2.12.4.5. Autoradiography of the Membrane.
The washed membrane was placed in a light-sealed cartridge with 
Kodak X-AR 100 photographic film, stored in a black plastic bag (to avoid light 
contamination) for a minimum period of 24 hours at -80"C (which sharpens the 
focus on the autoradiography film). The film was developed using a Fuji medical 
film processor, and quantified using a CS-9000 Dual Wavelength Flying-spot 
Scanning Densitometer (Shimadzu Corp., Japan).
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2.12.5. Staining of RNA Blots.
The method of Wilkinson et aL, 1991, was used to determine the 
amount of RNA loaded in each lane of RNA blots.
Following cDNA probe hybridisation and autoradiography, the 
membrane was stripped by stirring in a boiling solution of 0.1% (w/v) SDS (lauryl 
sulphate sodium salt) and allowing to cool for 30 minutes. This washing stage was 
repeated until all the radioactivity were removed from the membrane. The 
membrane was then immersed and agitated in a methylene blue stain (0.03%, w/v, 
methylene blue in 300 mM sodium acetate, pH 5.2) for 30 to 60 seconds, followed 
by rinsing with distilled water for 1 to 2 minutes until the filter background was 
substantially reduced. The stained blot was then quantified using a CS-9000 Dual 
Wavelength Flying-spot Scanning Densitometer (Shimadzu Corp., Japan).
2.13. Statistics.
The main effects of treatments were analysed by one factor analysis 
of variance (ANOVA), and evaluated by Duncan new multiple range. In all cases, 
significance levels were at either 5% (P<0.05) or 1% (P<0.01).
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72
Effect of Azoic Antifungal Drugs on Rat Liver: 
Induction of the Microsomal Cytochrome P4504A 
Subfamily and Peroxisome Proliferation
3.1. Introduction.
The imidazoles are nitrogen heterocycles which display very high 
affinity for cytochromes P450, the terminal oxygenase of the mixed-function 
oxidase system. They are used extensively in clinical therapy, and include the 4,5- 
disubstituted imidazoles as H2-antagonists (e.g. cimetidine), and many N- 
substituted imidazoles (e.g. ketoconazole) are used in the treatment of topical and 
systemic fungal diseases (Henry and Sisler, 1984). The antifungal imidazoles 
effectively inhibit ergosterol biosynthesis in yeast cells by inhibiting the sterol 
14a-demethylase, a microsomal cytochrome P450-dependent system. This latter 
inhibition causes an accumulation of 14a-methylsterols which is incorporated into 
the bilayer of fungal membranes. The presence of the 14a-methylsterol is 
believed to disrupt the close packing of acyl chains of phospholipids, resulting in 
limited fungal growth (Mason et al., 1985).
Azole antifungal drugs such as clotrimazole can act as both inhibitors 
and inducers of the cytochrome P450-dependent mixed function oxidase system, 
depending on the time course of exposure to the xenobiotic (Rodrigues et al., 
1988). Although clotrimazole will inhibit most cytochromes P450 studied to date, 
they induce the activity of members of the cytochrome P4502B and 3A 
subfamilies in particular (Rodrigues et al., 1988).
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The administration of clofibrate and various other hypolipidaemic 
agents including non-therapeutic compounds such as the phthalate ester 
plasticisers, results in several characteristic hepatic changes in rodents. These 
induced hepatic responses include hepatomegaly, proliferation of smooth 
endoplasmic reticulum and induction of cytochrome P4504A1-dependent fatty 
acid omega hydroxylase activity, peroxisome proliferation with associated 
changes in enzyme composition, and alteration in mitochondrial number and 
structure with concomitant increase in certain enzyme levels (Orton and Higgins, 
1979; Gibson et aL, 1982; Reddy et aL, 1982; and Sharma et aL, 1988a). These 
sub-cellular changes are toxicologically important as sustained proliferation of 
peroxisomes in rodents is frequently associated with the development of 
hepatocellular carcinomas. This has led to the suggestion that peroxisome 
proliferators constitute a novel class of non-genotoxic hepatocarcinogens (Reddy 
et aL, 1980; Lalwani et aL, 1981; and Reddy and Lalwani, 1983).
In particular, the relationship between the xenobiotic-mediated 
induction of cytochrome P4504A1 and peroxisome proliferation is at present still 
not clear. Various suggestions including the presence of a common or related 
organelle biogenesis (Zaar et aL, 1987), or a cytosolic ‘receptor protein’ (Lalwani 
et aL, 1983), have been proposed. The presence or absence of such a receptor in 
the induction phenomenon could readily explain the well-documented tissue, sex, 
and species differences in response to these agents, but the existence of this 
putative receptor as described by Reddy and co-workers still remains a matter of 
debate (Milton et aL, 1988).
Although the peroxisome proliferators have clearly different physico­
chemical properties, many of them consist of a carboxylic acid function adjacent 
to a hydrophobic backbone. Carboxylic acid functions may either be present
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initially in the peroxisome proliferators, or derived by metabolic oxidation of the 
respective alcohol or aldehyde group, or by ester cleavage (Hertz et aL, 1988; and 
Lock et aL, 1989). The importance of this carboxylic acid group is not clear at 
present, but may be related to CoA formation and/or CoA sequestration and 
subsequent perturbation of lipid metabolism and homeostasis (Bronfman et aL, 
1986; and Sharma et aL, 1988a). Alternatively, the carboxyl group may be an 
important chemical determinant of binding of P4504A1 inducers (peroxisome 
proliferators) to the recently described mouse Peroxisome Proliferator-Activated 
Receptor, PPAR, a member of the nuclear hormone receptor superfamily 
(Issemann and Green, 1990,1991; and Green, 1992).
l-(p,a-Diphenylbenzyl) imidazole [bifonazole, Bayh 4502, 
(Mycospor®), Bayer, Leverkusan] is a new antifungal imidazole derivative 
(Patzschke et aL, 1983; Plemple et aL, 1983; and Yamaguchi et aL, 1983), 
structurally related to clotrimazole (Figure. 1.7.), but its ability to modulate 
cytochromes P450 in the liver of experimental animals has not been described to 
date. This fact, coupled to the observation that bifonazole causes proliferation of 
peroxisomes which is similar in nature to that induced by other peroxisome 
proliferators such as clofibrate and nafenopin, and as such, has toxicological 
implications (Horie et aL, 1991). As all peroxisome proliferators studied to date 
are inducers of the cytochrome P4504A subfamily (Sharma et aL, 1988a, 1988b; 
Dirven et aL, 1991; Hozuka et aL, 1991; and Gibson, 1992), it was of interest to 
study the ability of bifonazole to induce the cytochrome P4504A subfamily in rat 
liver, and to compare this induction with that of clotrimazole, which has a similar 
structure, and also clofibrate, a classical peroxisome proliferator and P4504A1 
inducer.
75
3.2. Results.
Pretreatment of rats with bifonazole, clotrimazole, and clofibrate 
resulted in increases in the liver to body weight ratios, except in the case of 
clotrimazole at the low dose level, and was particularly pronounced by the high 
dose treatment with clotrimazole (Figure 3.1.). The total carbon monoxide- 
discernible cytochrome P-450 specific content of liver microsomes was increased 
significantly by the high dose level of bifonazole and clotrimazole low & high 
dose levels (Table 3.1.). Significant increases in the cytochrome b5 specific 
content was only observed in the clotrimazole low dose group (Table 3.1.). Only 
clotrimazole treatment at the high dose level caused a small, but significant, 
increase in NADPH-cytochrome c(P450) reductase activity (Table 3.1. & Figure
3.2.).
Reverse phase HPLC analysis demonstrated that bifonazole and 
clofibrate treatment preferentially induced the 12-hydroxylation of lauric acid as 
compared to the 11-hydroxylase activity in rat liver microsomes (Figure 3.3.), as 
exemplified by the 12/11 metabolite ratio of 2 in control and approximately 4 in 
the treated groups (Table 3.2.). Total 11- and 12-hydroxylation has been shown to 
be induced by peroxisome proliferators by other workers (Lake et al., 1984), and 
our laboratory has shown lauric acid to be a suitable marker substrate for 
cytochrome P4504A1 activity (Gibson et aL, 1982; and Tamburini gf a/., 1984), 
although, it should be noted that other P4504A subfamily members have 
substantial fatty acid co-hydroxylase activity (Gibson and Lake, 1991). Significant 
increases in the lauric acid 11-hydroxylase activity was observed in all the test 
groups except cltorimazole pretreated animals (Figure 3.3.). In addition, 
bifonazole pretreatment resulted in hepatic peroxisome proliferation, as assessed 
by palmitoyl-CoA oxidation in fatty acid 6-oxidation, a characteristic feature of
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Figure 3.1. Modulation of liver weight per body weight in rat. 
Animals (6 per group) were pretreated with bifonazole, clotrimazole or clofibrate 
as in the legend to Table 3.1. Abbreviations for the individual inducers are: 
C,control; CF,clofibrate; BFL,bifonazole at the low dose; BFH,bifonazole at the 
high dose; CLL,clotrimazole at the low dose; CLH, clotrimazole at the high dose. 
Statistical analysis was by one factor ANOVA and Duncan new multiple range. 
*P<0.01 (significantly different from control and low dose of clotrimazole).
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Table 3.1.
Effect of treatment with clofibrate, bifonazole and clotrimazole on 
some liver parameters.
Trpntmpnt Total NADPH-cytochrome c
Cytochrome P450 Cytochrome (P450) reductase 
(dose levels) (maximum abs, nm)(nmol/mg protein) (nmol/mg protein)(nmol/minute/mg protein)
CONTROL
Com oil, 1 ml/kg 449-450 0.73 ±0.03 0.38 ±0.02 72.3 ±2.3
Clofibrate
1 mmol/kg 450-452 0.94 ±0.08 0.34 ±0.02 87.3 ±3.3
Bifonazole 
150 fimol/kg 
750 pmol/kg
451
450
0.82 ±0.07 
1.17 ±0.03*
0.36 ± 0.02 
0.35 ±0.01
87.1 ±1.1 
51.9 ±2.1
Clotrimazole 
150 pmol/kg 
750 iimol/kg
449-450
450-451
1.63 ±0.2** 
2.68 ±0.1**
0.49 ± 0.02** 
0.35 ±0.02
89.5 ±1.5 
119.0 ±9.5**
Values are expressed as mean ± SEM from 5 animals. Rats were treated with 
single daily gavage administration of the compounds for 6 days. Controls 
received the corresponding volume of com oil (1 ml/kg). All animals were 
killed 24 hours after the last treatment. Statistical analysis was by one factor 
ANOVA and Duncan new multiple range. Significantly different from control at 
*P<0.05 or **P<0.01.
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Figure 3.2. Western blot analysis of NADPH-cytochrome c(P450) 
reductase. Rats were pretreated with bifonazole, clotrimazole or clofibrate as 
described in Table 3.1., and Western blot analysis carried out as described in 
Materials and Methods Chapter (Section 2.11.). Five micrograms of microsomal 
protein (from pooled microsomal fractions) were loaded on each track. Lane (1) 
phénobarbital pretreatment as positive control; (2) clofibrate pretreatment; (3) 
clotrimazole at the high dose; (4) clotrimazole at the low dose; (5) bifonazole at 
the high dose; (6) bifonazole at the low dose; (7) control microsomes; (8) ECL 
(enhanced chemiluminescence) molecular weight markers.
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Figure 3.3. Influence of control and test groups on the 11- and 12- 
hydroxylation of lauric acid by rat liver microsomes. Rats (5 animals per group) 
were pretreated with bifonazole, clotrimazole or clofibrate as described in Table
3.1., microsomal homogenates prepared and lauric acid 11- (11-LAOH) and 12- 
(12-LAOH) hydroxylase activities determined by reverse phase HPLC as 
described in Materials and Methods Chapter (Section 2.9.). Abbreviations for the 
individual inducers are: C,control; CF,clofibrate; BFL,bifonazole at the low dose; 
BFH,bifonazole at the high dose; CLL,clotrimazole at the low dose; 
CLH,clotrimazole at the high dose; *P<0.01 (significantly different from control); 
+P<0.01 (significantly different from clotrimazole).
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Table 3.2.
Influence of clofibrate, bifonazole and clotrimazole pretreatment on 
fatty acid hydroxylation and B-oxidation in rat liver L
Treatment Lauric acid Lauric acid Palmitoyl CoA
(dose levels) 11-hydroxylase 12-hydroxylase 6-oxidation
CONTROL
Com oil, 1 ml/kg 1.4 ±0.2 2.9 ±0.4 5.0 ±0.5
Clofibrate
1 mmol/kg 2 .8  ± 0 .1 * + 11.4 ±0.2*+ 58.3 ± 5.7*+
Bifonazole
150 pmol/kg 2.8 ±0.2*+ 10.1 ±0.4*+ 39.3 ±3.1*+
750 jimol/kg 2.3 ±0.1*+ 9.7 ±0.4*+ 27.6 ±4.4*+
Clotrimazole
150 jLtmol/kg 1.8 ± 0 . 1 2.8 ±0.4 8.5 ± 1.3
750 jimol/kg 0.9 ±0.05 2.7 ±0.3 2.5 ±0.1
1 All activities are expressed as nmol product formed/minute/mg of protein and 
represent the mean ± SEM from 5 animals. Statistical analysis was by one factor 
ANOVA and Duncan new multiple range;
*P<0.01 (significantly different from control);
+P<0.01 (significantly different from clotrimazole).
81
the P4504A subfamily inducers (Sharma et aL, 1988b; Dirven et aL, 1991; and 
Hozuka et aL, 1991), whereas clotrimazole was without effect (Table 3.2.).
Incubation of [l-^^CJ-arachidonic acid with rat liver microsomes in 
the presence of NADPH and molecular oxygen under conditions favouring 
primary metabolism, and analysing of samples by reverse-phase high performance 
liquid chromatography showed a complex pattern of metabolites. Figures 3.4. 
and 3.5. show the metabolite profile of arachidonic acid obtained for such studies 
with rat liver microsomal fractions. The fractions derived from livers of either 
control (untreated male rats), clofibrate-induced, bifonazole-treated, or 
clotrimazole-induced. The formation of metabolites appear to be cytochrome 
P450 dependent, as separate experiments have shown that omission of NADPH 
from the incubation media resulted in no apparent metabolism (Figure 3.5.). Due 
to the lack of authentic standards, extensive characterisation and identification of 
these peaks was not possible. However, based on other reports (Capdevila et aL, 
1985) and previous experiments carried out in our laboratory, some tentative 
qualitative and quantitative analyses were made, even though the metabolic 
profiles were not exactly the same. Four major peaks were common in all the 
chromatograms. These were designated as peaks I, II, III, and IV, with retention 
times of approximately 26,26.5, 29.3, and 30 minutes, respectively.
Induction of the cytochrome P450 isozyme mediating co- and (co-l)- 
hydroxylation of arachidonic acid by clofibrate has been unambiguously 
demonstrated by Gibson et aL, 1982; and Sharma et aL, 1989a. In my studies, 
pretreatment of rats with clofibrate and bifonazole resulted in a significant 
increase in the rate of formation of a peak with retention time of approximately 
30 minutes (peak IV, Table 3.3.). The peak eluting at approximately 29.3 
minutes (peak III, Figure 3.4.) showed a slight increase in the case of clofibrate
8 2
Table 3.3.
Rate of formation of arachidonic acid metabolites by clofibrate, 
bifonazole and clotrimazole treated liver microsomes.
Treatment
(dose levels)
Peak I 
(25-26 min)
PeakU 
(26-27 min)
Peak n i 
(29-30 min)
Peak IV 
(30-31 min)
CONTROL
Com oil, 1 ml/kg 264+20 389+28 182+12+ 523+64+
Clofibrate
1 mmol/kg 267+30 615+95*+ 239+44- 968+112**"
Bifonazole 
150 |imol/kg 509±48**^ 1123±64**" 371+42**" 881±154*-
Clotrimazole
150 jimol/kg 206±27 375±42 90±13 131±19
Values are expressed as pmol product formed/minute/mg of protein (mean ± SEM 
from 5 animals). The time in brackets for each peak is the retention time in 
minutes. Statistical analysis was by one factor ANOVA and Duncan new multiple 
range. Significantly different from control at *P<0.05 or **P<0.01; significantly 
different from clotrimazole at +P<0.05 or *^P<0.01.
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Figure 3.4. Metabolite profiles formed by NADPH-dependent 
oxygenation of [l-i'^Cj-arachidonate by different liver microsomal preparations. 
Incubation and analysis of metabolites were as described under Materials and 
Methods Chapter (Section 2.10.). The chromatograms shown were obtained using 
microsomes from clofibrate (A), bifonazole (B) or clotrimazole-induced rats (C); 
20:4, arachidonic acid.
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Figure 3.5. Lack of arachidonic acid metabolites formation in rat 
liver microsomes in the absence of NADPH (A); metabolite profile of untreated 
rat microsomes in the presence of NADPH (B). Arachidonic acid (1.2 mCi/ 
mmole, 0.1 mM) was incubated with rat microsomes for 20 min at 37“C, under 
the conditions described in Materials and Methods Chapter (Section 2.10.); 20:4, 
arachidonic acid.
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and an apparent significant increase in bifonazole induced group. Based on these 
findings and previous studies on hypolipidaemic-induced arachidonic acid 
metabolism (Bains et ah, 1985; Capdevila et aL, 1985; and Sharma et aL, 1989a), 
Peaks III and IV were tentatively postulated as (co-l)- and co-hydroxy arachidonic 
acid metabolites, respectively, and according to the report by Sharma et aL, 
1989a, cytochrome P4504A1 is probably the enzyme responsible for the co- 
hydroxylation of arachidonic acid. Table 3.3. shows that the rate of formation of 
peak IV in clofibrate and bifonazole-induced groups were approximately 1.9- and 
1.7-fold over that of control rat microsomes, respectively.
The above conclusion on bifonazole induction of the P4504A 
subfamily was further substantiated by Western blot analysis. Figure 3.6. 
demonstrates that bifonazole induces a protein of similar molecular weight to 
authentic P4504A1 (in a similar manner to clofibrate), whereas this immuno­
chemical analysis demonstrates no induction with clotrimazole pretreatment. This 
pattern of azole-dependent induction was also mirrored by immunochemical 
analysis for the peroxisomal trifunctional protein (Figure 3.7.). Due to lack of the 
authentic trifunctional protein as a standard, this protein was identified by its co­
migration with prestained molecular weight markers. The molecular weight of 
approximately 80 kDa observed for this peroxisome associated polypeptide is in 
agreement with that of previously reported (Reddy et aL, 1981). To further 
substantiate the above induction phenomenon and to explore the mechanism of 
induction, RNA was extracted from the livers and steady state levels of 
cytochrome P4504A1 mRNA analysed by Northern blotting with a cytochrome 
P4504A cDNA probe, as described in Materials and Methods Chapter (Section
2.12.). As shown in Figure 3.8., there is a substantial increase in cytochrome 
P4504A1 mRNA after clofibrate and bifonazole treatment, whereas this response
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Figure 3.6. Western blot analysis of cytochrome P4504A1. Rats were 
pretreated with bifonazole, clotrimazole or clofibrate as described in Table 3.1., 
and Western blot analysis carried out as described in Materials and Methods 
Chapter (Section 2.11.). Five micrograms of microsomal protein (from pooled 
microsomal fractions) were loaded on each track. Lane (1) authentic cytochrome 
P4504A1 (0.5 pmol); (2) clotrimazole at the high dose; (3) clotrimazole at the low 
dose; (4) bifonazole at the high dose; (5) bifonazole at the low dose; (6) clofibrate 
pretreatment; (7) control microsomes; (8) enhanced chemiluminescence molecular 
weight markers.
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Figure 3.7. Western blot analysis of the peroxisomal trifunctional 
protein. Rats were pretreated with bifonazole, clotrimazole or clofibrate as described in 
Table 3.1., and Western blot analysis carried out as described in Materials and Methods 
Chapter (Section 2.11.). Twenty micrograms of total liver homogenate protein was 
loaded on each track (pooled from 5 animals). Lane (1) prestained molecular weight 
standards, (2 & 8) control homogenate; (3 & 9) clofibrate pretreatment; (4 & 10) 
bifonazole at the low dose; (5 & 11) bifonazole at the high dose; (6 & 12) clotrimazole 
at the low dose; (7 & 13) clotrimazole at the high dose.
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Figure 3.8. Northern blot analysis for cytochrome P4504A1 mRNA 
in Rat liver. Rats were pretreated with bifonazole, clotrimazole or clofibrate as 
described in Table 3.1., and Northern blot analysis carried out as outlined in 
Materials and Methods Chapter (Section 2.12.2.). Equal amount of RNA (20 pg) 
were loaded in each track conesponding to RNA derived from control (lanes 1 & 
2), clofibrate (lane 3), bifonazole at the low dose (lanes 4 & 5) and clotrimazole at 
the low dose (lanes 6 & 7) induced rats.
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was not marked for clotrimazole treatment, consistent with the fatty acid 
hydroxylase activities, Western blot, and trifunctional protein data in Tables 3.2. 
& 3.3. and Figures 3.6. & 3.7., respectively.
The ability of bifonazole and clotrimazole to induce other cytochrome 
P450 families is shown in Table 3.4. The 0-deethylation of ethoxyresorufin was 
only stimulated by clotrimazole treatment (Figure 3.9.). High bifonazole and low 
clotrimazole dose levels very markedly induced the 0-depentylation of 
pentoxyresorufin (Table 3.4.). None of the treatments produced any increase in 
the activities of ethylmorphine or erythromycin N-demethylase, which are often 
used as marker activities for the cytochrome P4503A subfamily (Figure 3.10.). 
Immunoblot analysis demonstrated that bifonazole did not induce P4502E1 
(Figure 3.11.), but did increase the level of P4501A1; clotrimazole also very 
slightly induced this protein, as can be deduced from the original gel (Figure
3.12.). All the treatment groups induced P4502B1/2, and the induction seen by 
bifonazole and clotrimazole was apparently dose-dependent and greater than for 
clofibrate (Figure 3.13.). Immunoblotting with anti-cytochrome P4503A showed 
that clotrimazole at the high dose level was a more potent inducer of PCN- 
inducible P450s (Figure 3.14.).
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Figure 3.9. Modulation of control and treated groups on dealkylation 
of ethoxy- and pentoxyresorufin by rat liver microsomes. Rats (5 animals per 
group) were pretreated with bifonazole, clotrimazole or clofibrate as described in 
Table 3.1. Activities of ethoxy- (EROD) and pentoxyresorufin 0-dealkylase 
(PROD) were determined as described in Materials and Methods Chapter (Section 
2.7.). Abbreviations for the individual inducers are: C,control; CF,clofibrate; 
BFL,bifonazole at the low dose; BFH,bifonazole at the high dose; 
CLL,clotrimazole at the low dose; CLH,clotrimazole at the high dose; ^P<0.01 
(significantly different from control); ^P<0.05 (significantly different from 
clofibrate); ^P<0.05 (significantly different from BFL); ^P<0.05 (significantly 
different from BFH); ®P<0.01 (significantly different from CLH).
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Table 3.4.
Hepatic microsomal mixed-function oxidase activities in the rat 
pretreated with either clofibrate, bifonazole or clotrimazole.
Treatm ent
(dose levels)
Ethylmorphine-
N-demethylase^
Erythromycin-
N-demethylase^
7-Ethoxyresomfin-
0-deethylase^
7-Pentoxyresomfin-
0-depentylase^
CONTROL
Com oil, 1 ml/kg 11.3 ±0.4® 2.5±0.lde 41.2 ±2.4 6.4 ±0.6
Clofibrate
1 mmol/kg 7.7 ±0.3® 1.5 ±0.1 41.2 ±7.7 11.5 ±2.3
Bifonazole 
150 pmol/kg 
750 |imol/kg
12.7 ±0.5® 
6.9 ±0.1®
2.4 + O.lde 
1.1 ±0.1
22.9 ±3.3 
35.5 ±3.1
7.6 ± 1.6
104.4 ±24abce
Clotrimazole
150 )imol/kg 
750 pmol/kg
8.6 ±0.1® 
3.0 ±0.01
1.8 ±0.1 
1.1 ±0.1
91.3± ISabcd 
127.8 ±2iabcd
221.3 ± 3 3 abcde 
8.5 ±1.9
Values are mean ± SEM from 5 animals and expressed as ^nmol product 
formed/minute/mg protein or ^pmol product formed/minute/mg protein. 
Statistical analysis was by one factor ANOVA and Duncan new multiple range; 
^P<0.01 (significantly different from control); 
l)p<0.05 (significantly different from clofibrate);
^P<0.05 (significantly different from low dose of bifonazole);
^P<0.05 (significantly different from high dose of bifonazole);
®P<0.01 (significantly different from high dose of clotrimazole).
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Figure 3.10. Effect of pretreatment with clofibrate and 2 anti-fungal 
agents on N-demethylation of ethylmorphine and erythromycin by rat liver 
microsomes. Animals (5 per group) were pretreated as described in the legend to 
Table 3.1. Ethylmorphine and erythromycin N-demethylase activities were 
determined as described in Materials and Methods Chapter (Section 2.8.3.). 
Abbreviations for the individual inducers are: C,control; CF,clofibrate; 
BFL,bifonazole at the low dose; BFH,bifonazole at the high dose; 
CLL,clotrimazole at the low dose; CLH,clotrimazole at the high dose; ^P<0.05 
(significantly different from clofibrate); ^P<0.05 (significantly different from high 
dose of bifonazole); ®P<0.01 (significantly different from high dose of 
clotrimazole); ^P<0.01 (significantly different from low dose of clotrimazole).
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Figure 3.11. Western blot analysis for cytochrome P4502E1. Rats 
were pretreated with bifonazole, clotrimazole or clofibrate as outlined in Table
3.1., and Western blot analysis carried out as described in Materials and Methods 
Chapter (Section 2.11.). Five micrograms of microsomal protein (from pooled 
microsomal fractions) were loaded on each track. Lane (1) isoniazid induced 
microsomes as positive control; (2) clotrimazole at the high dose; (3) clotrimazole 
at the low dose; (4) bifonazole at the high dose; (5) bifonazole at the low dose; (6) 
clofibrate pretreatment; (7) control microsomes; (8) enhanced chemiluminescence 
molecular weight markers.
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Figure 3.12. Western blots employing anti-cytochrome P4501A1 
polyclonal antibodies. Immunoblot was carried out with rat anti-cytochrome 
P4501A1 (from rabbit), followed by donkey anti-rabbit Ig-biotinylated species- 
specific whole antibody, and streptovidin-horseradish peroxidase conjugate. Five 
micrograms of microsomal protein (from pooled microsomal fractions) were 
loaded on each track. Lane (1) B-naphthoflavone treated microsomes as positive 
control; (2) clotrimazole at the high dose; (3) clotrimazole at the low dose; (4) 
bifonazole at the high dose; (5) bifonazole at the low dose; (6) clofibrate 
pretreatment; (7) control microsomes; (8) enhanced chemiluminescence molecular 
weight markers.
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Figure 3.13. Western blots employing anti-cytochrome P4502B1/2 
polyclonal antibodies. Protein samples were resolved by electrophoresis in a 10% 
(w/v) SDS-polyacrylamide gel and transferred electrophoretically to a nitro­
cellulose paper. The immunoblot was performed with rat anti-cytochrome 
P4502B1/2, followed by donkey anti-rabbit Ig-biotinylated species-specific whole 
antibody, and streptovidin-horseradish peroxidase conjugate. Solubilised 
microsomes (5 jig protein) were derived from: Lane (1) phénobarbital pretreated 
(positive control); (2) clotrimazole at the high dose; (3) clotrimazole at the low 
dose; (4) bifonazole at the high dose; (5) bifonazole at the low dose; (6) clofibrate 
pretreatment; (7) control microsomes; (8) enhanced chemiluminescence molecular 
weight markers.
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Figure 3.14. Western blots employing anti-cytochrome P4503A 
polyclonal antibodies. Immunoblot was carried out with rat anti-cytochrome 
P4503A (from rabbit), followed by donkey anti-rabbit Ig-biotinylated species- 
specific whole antibody, and streptovidin-horseradish peroxidase conjugate. Five 
micrograms of microsomal protein (from pooled microsomal fractions) were 
loaded on each track. Lane (1) enhanced chemiluminescence molecular weight 
markers; (2) control microsomes; (3) clofibrate pretreatment; (4) bifonazole at the 
low dose; (5) bifonazole at the high dose; (6) clotrimazole at the low dose; (7) 
clotrimazole at the high dose; (8) pregnenolone-16a-carbonitrile treated 
microsomes (positive control).
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3.3. Discussion.
A recent publication by Japanese workers has shown that the azole 
antifungal drug bifonazole, but not the closely-related clotrimazole, is a 
peroxisome proliferator (Horie et al., 1991). However, there has been no 
systematic study on the effect of bifonazole on cytochrome P450, in particular 
P4504A subfamily, which is believed to be induced by all peroxisome 
proliferators studied so far (Lake et al., 1984; Sharma et al., 1988b; Dirven et al., 
1991; Hozuka é ta l, 1991; and Gibson, 1992). Therefore, the potential inducing 
ability of bifonazole in the induction of P4504A1 has been investigated, and 
compared with clotrimazole which is a known P4503 family inducer (Rodrigues 
e ta l, 1988).
It appears from the present study that the hepatomegaly observed with 
clotrimazole is a dose dependent effect. Low dose of clotrimazole did not produce 
significant hepatomegaly compared to the control. Coincidental with 
hepatomegaly induced by the test compounds, there was an induction of the total 
P450. Although clofibrate and the low dose of bifonazole did not cause a 
significant change in the total P450, there was induction of lauric acid co-l and co­
hydroxylase activities. Only clofibrate and bifonazole at low and high dose levels 
induced the lauric acid co-hydroxylase activity (indicative of the P4504A 
subfamily induction), 3.9-, 3.5- and 3.4-fold, respectively, whereas clotrimazole 
did not influence this latter activity. Based on their relative abilities to induce 
lauric acid co-hydroxylase activity, immunochemical reactivity with an antibody 
raised against P4504A1, and Northern blotting with a cytochrome P4504A1 
cDNA probe, my results indicate that bifonazole, but not the structurally related
9 8
clotrimazole, is an inducer of the cytochrome P4504A subfamily in rat liver 
microsomes.
There are at least three closely related enzymes in the P4504A 
subfamily in rat liver, namely P4504A1, P4504A2, and P4504A3 (Kimura et al., 
1989; Sundseth and Waxman, 1992; and Nelson etal., 1993), and which of these 
enzymes are induced by bifonazole is not clear at present as they all display lauric 
acid co-hydroxylase activity (Aoyama et al., 1990; and Diaz et al., 1993), and the 
antibody to P4504A1 using 4-chloro-1 -naphthol as a substrate (data not shown) 
recognises additional proteins that are probably P4504A2 and/or P4504A3 
(Hardwick et al., 1987; Sharma et al, 1989b; and Aoyama et al., 1990). However, 
because the cytochrome P4504A1 cDNA hybridisation experiment was carried 
out under relatively strict conditions of stringency, it seems that, at least, 
cytochrome P4504A1 is induced. In this context, it is useful to note that 
clotrimazole induction of the P4503 family is crucially dependent on the time 
course. This is because the inducer metabolites may bind to cytochrome P450, 
thus, interfering with haemoprotein analysis and activity determinations. The 
latter event may apparently mask any induction (Rodrigues et al., 1988), which 
may explain the apparent contradiction between the Western blot data (Figure 
3.14.) and the corresponding catalytic activity (Table 3.4.). This was not the case 
for P4504A1 induction by clotrimazole, because the Western blotting analysis of 
P4504A1 apoprotein with the corresponding antibody revealed no clotrimazole- 
dependent induction, but substantial bifonazole-dependent induction of P4504A1 
apoprotein (Figure 3.6.).
I have also studied the role of the cytochrome P4504A subfamily 
proteins in the metabolism of arachidonic acid using control, clofibrate-, 
bifonazole-, and clotrimazole-treated microsomes. The liver microsomal
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cytochrome P450 system metabolises arachidonic acid to a variety of oxygenated 
products such as epoxyeicosatetraenoic acid (EETs), hydroxyeicosatetraenoic acid 
(HETEs), and co- and (co-l)-hydroxyeicosatetraenoic acid (Capdevila et al., 1985). 
The peaks observed in all the HPLC chromatograms in my studies probably 
represents metabolites derived from these pathways, however, their rigorous 
identification and full characterisation was not addressed in my current study.
Studies by others, using ciprofibrate-induced microsomes (Capdevila 
et al., 1985), showed a clear stimulation in oxidation of metabolites with retention 
times corresponding to authentic co- and (co-l)-alcohol standards, with a marked 
decrease in the ability of the liver microsomal suspension to catalyse both EET 
and HETE formation. In a similar experiment where azole compounds were 
employed , there was a significant enhancement of the tentatively identified co­
oxidation product in clofibrate- and bifonazole-induced microsomes, however, 
contrary to the report by Capdevila et al., 1985, other unidentified metabolites 
were still detected in my studies. This different pattern may be explained by 
considering the following factors. First of all, the HPLC column used in my study 
was different to that used by Capdevila et al., 1985 (Micropak-Cig), and secondly 
the inducers used in this study (clofibrate and bifonazole) were different to that 
employed by them (ciprofibrate). Finally, an epoxide hydrolase inhibitor 1,2 
epoxy-3,3,3-trichloropropane (to minimise the further metabolism of epoxides to 
diols) was not included in my study. The omission of this inhibitor could result in 
the formation of diol metabolites; the incubation period (20 minutes employed in 
this study compared to 5 minutes used by Capdevila and co-workers, 1985) may 
also play a role in the formation of these metabolites (Jajoo et al., 1992).
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The induction of the P4504A subfamily and the fact that bifonazole 
induces peroxisomal palmitoyl-CoA oxidation (Table 3.2.) and trifunctional 
protein (Figure 3.7.), and the associated hepatomegaly (Figure 3.1.) would 
classify bifonazole as a typical peroxisome proliferator (Reddy and Lalwai, 1983; 
Sharma et al., 1988b; Dirven et al., 1991; and Hozuka et al., 1991). Until 
recently, it was considered that most peroxisome proliferators contained a 
carboxyl group in their structure or could be metabolised to one (Hertz et al., 
1988; Bronfman et a l, 1989; and Lock et al., 1989). Emerging evidence, 
however, suggests that this need not always be the case and non-carboxylate 
peroxisome proliferators have been described including dehydroepiandrosterone 
(Wu et al., 1989), and certain leukotriene antagonists such as the tetrazole 
alkoxyacetophenones (Eacho et al., 1986). Thus, it would appear that bifonazole 
may be a member of this latter group of non-carboxylate peroxisome proliferators.
The 0-deethylation of ethoxyresorufin, an enzyme reaction that is 
largely catalysed by P4501A1, was not stimulated by bifonazole treatment, 
whereas immunoblot analysis using anti-P4501Al showed an increase in the level 
of this enzyme. This apparent contradiction could be due to inhibition of enzyme 
activity by the formation of a complex between bifonazole and/or its metabolite(s) 
with P450. The slight increase in cytochrome P4501A1 protein in clotrimazole- 
pretreated groups, as evidenced by Western blotting, was paralleled by a small 
increase in ethoxyresorufin 0-deethylase activity (2- to 3-fold). This increase in 
activity was also reported by Rodrigues et al., 1988, although, they were unable to 
detect an induction of P4501A1 apoprotein by Western blotting. In contrast to the 
slight induction of P4501A1 by clotrimazole in my study, Hostetler et al., 1989, 
reported a selective induction of P4501A2 by clotrimazole. This contrary
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observation may be due to the difference in sex (female), dosage (150 mg/kg), and 
duration (three days) employed by them.
Despite the results of Western blotting, the high dose of clotrimazole 
and the low dose of bifonazole did not induce the 0-depentylation of 
pentoxyresorufin. Rodrigues et aL, 1988, also observed a similar pattern with 
clotrimazole. In the case of clotrimazole at high dose, data must be interpreted 
with caution because the microsomes were frozen, thawed, re-frozen and thawed 
again, and this may have destroyed P450. However, if the P450 was not destroyed 
by this procedure, an alternative explanation may be extensive metabolite 
production, complex formation and, therefore, less activity by the high dose level 
of clotrimazole. In the case of bifonazole, it may be the low dose induces 
P4502B2 whereas the high dose induces P4502B1 and/or 2B2 (as the antibody 
reacts with both proteins). Alternatively, it may be because of induction plus 
complexation by the low dose of bifonazole, therefore less activity, or bifonazole 
may induce another P450s with the same molecular weight in addition to 
P4502B1/2 proteins that is recognised by this antibody but does not metabolise 
pentoxyresorufin.
The induction of the cytochrome P4503A subfamily by the test 
compounds was not observed, based on catalytic activity, whereas an induction 
was evident when the cytochrome P4503A apoprotein was immunoquantitated. 
This has also been reported by Rodrigues et al., 1988. Therefore, based on 
immunoblotting data, bifonazole induces P4501A1 and 2B1/2 proteins and the 
P4503A subfamily, clotrimazole induces P4502B1/2 proteins, the P4503A 
subfamily, and to a lesser extent P4501A1, whereas clofibrate induces 
P4502B1/2.
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3.4. Conclusion.
The results of this work show that bifonazole, but not clotrimazole, is 
a potent inducer of the cytochrome P4504A subfamily, and probably cytochrome 
P4504A1 in particular. In addition, my studies have further substantiated the 
observation that the carboxylate moiety is not essential for the induction of 
hepatic peroxisomes and enzymes of peroxisomal 6-oxidation system (reported by 
Horie et al., 1991), and the induction of cytochrome P4504A1.
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CHAPTER 4
Ejfect o f  Azole Antifungal D rugs on R at K idney: 
Induction o f  the M icrosom al Cytochrom e P4504A  
Subfamily and Peroxisom e Proliferation
104
Effect of Azole Antifungal Drugs on Rat Kidney: 
Induction of the Microsomal Cytochrome P4504A 
Subfamily and Peroxisome Proliferation
4.1. Introduction.
According to recent investigations, kidneys possess the enzymatic 
machinery necessary to catalyse the metabolism of xenobiotics. One such system 
is the cytochrome P450-dependent monooxygenase, and its concentration in the 
kidney is about ten per cent of hepatic cytochrome P450 (Tarloff et al., 1990). 
This finding has led to the suggestion that in overall xenobiotic metabolism, 
kidneys play a relatively small role. However, extrahepatic P450s may be 
important in the metabolism of compounds targeted to extrahepatic tissues, as 
with certain substrates like chloroform where the metabolic activity of renal 
cytochrome P450 may exceed that of the liver, when expressed as a function of 
total cytochrome P450 concentration (Smith and Hook, 1984).
A wide range of compounds including the fibrate hypolipidaemic 
drugs (e.g. clofibrate and ciprofibrate), chlorophenoxy acid herbicides, the 
phthalate ester plasticisers (di-(2-ethylhexyl)phthalate), analgesics, specific diets 
(e.g. high fat diets), certain polychlorinated biphenyl isomers, perfluoro fatty 
acids, and certain pathophysiological states such as diabetes, have been shown to 
produce peroxisome proliferation (Reddy and Lalwani, 1983; Lock etal., 1989; 
and Moody et al., 1991). Peroxisome proliferators cause morphological and/or 
biochemical changes in several tissues including the testis, thyroid, intestine, 
adrenals, brown adipose tissue, heart, kidneys, and liver (Reddy and Lalwani,
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1983; Lock et a l, 1989; and Moody et a i, 1991). Peroxisome proliferation is the 
major cellular response of kidneys to peroxisome proliferators with a 
corresponding induction of the peroxisome proliferation-associated 80,000 
molecular weight polypeptide, and an increase in the activity of peroxisomal 6- 
oxidation enzymes (Hawking et al, 1987).
Concern about the use of peroxisome proliferators has arisen as they 
are known to induce various cytochrome P450 mixed-function oxidases, which 
can precede peroxisome proliferation, and in prolonged exposure can lead to a 
tumourigenic state by a non-genotoxic mechanism. The increased production of 
hydrogen peroxide and subsequently the hydroxide radical, which may 
overwhelm protective enzymes within the hepatocytes and cause DNA changes 
(e.g. the oxidative stress hypothesis), and the propensity of peroxisome 
proliferatores to induce hepatocyte replication have both been proposed as 
contributing to carcinogenesis by this class of compounds (Bentley et al., 1988; 
Moody et al., 1991; and Reddy, 1990).
The imidazole agents are well established drugs for the treatment of 
topical and systemic mycoses that appear to act by a common mechanism of 
action, i.e. inhibition of a cytochrome P450-dependent enzyme that is involved in 
the synthesis of ergosterol (Vanden Bossche, 1985). The first two azoles 
developed for human use were clotrimazole (Biichel et al., 1972) and miconazole 
(Godefroi et al., 1969). In the case of clotrimazole, brief courses of treatment 
caused the induction of liver microsomal enzymes, which also destroyed its 
antifungal activity because of increasing the metabolism of the drug (Lyman and 
Walsh, 1992).
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Bifonazole is a recently developed antifungal imidazole derivative 
introduced by Bayer (Leverkusan), and is structurally related to clotrimazole 
(Figure 1.7.). The influence of bifonazole on cytochromes P450 in the liver of 
experimental animals, in particular induction of the cytochrome P4504A 
subfamily, and peroxisome proliferation were described in the previous Chapter 
(3). The present study was designed to investigate the modulation of the renal 
mixed-function oxidase, in particular the cytochrome P4504A subfamily, and 
peroxisome proliferation by this antifungal, as well as, the comparative induction 
potential of clofibrate and clotrimazole in this tissue.
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4.2. Results.
Pretreatment of rats with bifonazole, clotrimazole, and clofibrate 
resulted in no significant change observable in kidney weight alone, however, for 
the group of animals treated with the high dose of clotrimazole the kidney weight 
to body weight ratio is slightly, but not significantly, increased (Figure 4.1.). The 
total carbon monoxide-discernible cytochrome P450 specific content of kidney 
microsomes wçre increased significantly by the high dose of bifonazole pretreated 
animals, which showed an approximate 3-fold increase over control and clofibrate 
treated animals, and an approximate 2-fold increase over bifonazole at the low 
dose and clotrimazole at the both dose levels (Table 4.1.). The high dose of 
bifonazole and the low dose of clotrimazole significantly increased the 
cytochrome bs specific content of kidney microsomes over control, clofibrate, and 
bifonazole low dose pretreated animals (Table 4.1.). The specific contents 
observed for these two mixed function oxidase parameters were one tenth to one 
twentieth of that observed in the liver samples (Chapter 3). The level of NADPH- 
cytochrome c(P450) reductase activity is markedly suppressed for clofibrate, the 
low dose of bifonazole, and the high dose of clotrimazole pretreated animals, 
compared to the control, bifonazole high, and clotrimazole low dose groups 
(Table 4.1. & Figure 4.2.).
SDS-polyacrylamide gel electrophoretic analysis, using a polyclonal 
antibody (raised in rabbit) to the trifunctional protein of the peroxisomal 6- 
oxidation spiral (Figure 4.3.), demonstrated that bifonazole at the both dose levels 
(but not clotrimazole) induces this polypeptide( in a similar manner to clofibrate), 
as can be deduced from the original gel. The observed molecular weight of 
approximately 80 kDa for this peroxisome associated polypeptide, is in agreement
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Figure 4.1. Modulation of kidney weight per body weight in rat. 
Animals (6 per group) were pretreated with bifonazole, clotrimazole or clofibrate, 
as in the legend to Table 4.1. Abbreviations for the individual inducers are: 
C,control; CF,clofibrate; BFL,bifonazole at the low dose; BFH,bifonazole at the 
high dose; CLL,clotrimazole at the low dose; CLH, clotrimazole at the high dose.
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Table 4.1.
Effect of pretreatment with clofibrate, bifonazole and clotrimazole on 
some rat kidney parameters.
Trpntm pnt Total NADPH-cytochrome c 
Cytochrome P450 Cytochrome bs (P450) reductase 
(dose levels) (maximum abs, nm)(pmol/mg protein) (pmol/mg protein)(nmol/minute/mg protein)
CONTROL
Com oil, 1 ml/kg 451-453 48.4 ±9.1 16.8 ± 3.6 44.5 ± 6.9+
Clofibrate
1 mmol/kg 451-452 49.6 ±6.9 14.7 ±2.5 24.6 ±1.8
Bifonazole
150 pmol/kg 450-452 76.2 ±19.2 13.4 ±1.9 28.7 ± 2.9
750 |imol/kg 451-453 147.8 ±16.6* 27.2 ±1.5** 44.0 ±5.9+
Clotrimazole
150 jimol/kg 452-454 79.4 ±12.6 26.8 ±7.5** 49.6 ±7.3+
750 pmol/kg 453-454 80.7 ± 8.3 19.3 ±2.1 20.9 ±2.6
Values are expressed as mean ± SEM from 5 animals. Rats were treated with 
single daily gavage administration of the compounds for 6 days. Controls 
received the corresponding volume of com oil. All animals were killed 24 hours 
after the last drug administration. Statistical analysis was by one factor ANOVA 
and Duncan new multiple range. Significantly different from the other groups at 
P<0.01 (*); significantly different from control, clofibrate and bifonazole low 
dose at P<0.05 (**); significantly different from clofibrate, low dose of 
bifonazole and high dose of clotrimazole at P<0.05 ("^ ).
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Figure 4.2. Western blot analysis of NADPH-cytochrome c(P450) 
reductase. Rats were pretreated with bifonazole, clotrimazole or clofibrate, as in 
Table 4.1., and Western blot analysis carried out as outlined in Materials and 
Methods Chapter (Section 2.11.). Five micrograms of microsomal protein (from 
pooled microsomal fractions) were loaded on each track. Lane (1) phénobarbital 
pretreatment as positive control; (2) clotrimazole at the high dose; (3) 
clotrimazole at the low dose; (4) bifonazole at the high dose; (5) bifonazole at the 
low dose; (6) control microsomes; (7) clofibrate pretreatment; (8) enhanced 
chemiluminescence molecular weight markers.
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Figure 4.3. Western blot analysis of the peroxisomal trifunctional 
protein. Rats were pretreated with bifonazole, clotrimazole or clofibrate, as 
described in Table 4.1., and Western blot analysis carried out as outlined in 
Materials and Methods Chapter (Section 2.11.). Twenty micro grams of total 
homogenate protein was loaded on each track (pooled from 5 animals). Lane (1) 
clotrimazole at the high dose, (2) clotrimazole at the low dose; (3) bifonazole at 
the high dose; (4) bifonazole at the low dose; (5) clofibrate pretreatment; (6) 
control homogenate; (7) prestained molecular weight standards.
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with previous reports (Osumi and Hoshimoto, 1979; and Reddy et al., 1981). 
Only clofibrate pretreatment resulted in significant increase in renal cyanide- 
insensitive palmitoyl-CoA oxidation activity of the peroxisomal 6-oxidation spiral 
(Table 4.2.).
Reverse phase HPLC analysis of renal microsomal laurate 
hydroxylation in response to clofibrate, bifonazole or clotrimazole treatments are 
shown in Table 4.2. Small, but significant, increases in the lauric acid 12- 
hydroxylase activity was observed in groups of animals pretreated with bifonazole 
or clofibrate, but not in cltorimazole pretreated animals (Table 4.2.). None of the 
test groups markedly increased the lauric acid 11-hydroxylase activity (Table
4.2.).
Western blotting analysis of rat renal microsomes, by comparing the 
effects of various treatments on cytochrome P4504A1 apoprotein levels (Figure 
4.4.), demonstrated that bifonazole (in a similar manner to clofibrate) increases 
the level of cytochrome P4504A1 apoprotein, whereas this analysis shows no 
induction following clotrimazole pretreatment. The above induction phenomenon 
was further substantiated to explore the mechanism of induction. Following RNA 
extraction from the kidneys, steady state levels of cytochrome P4504A1 mRNA 
were analysed by Northern blotting with a cytochrome P4504A1 cDNA probe, as 
described in Materials and Methods Chapter (Section 2.12.). The results of this 
analysis demonstrates a substantial increase in cytochrome P4504A1 mRNA after 
clofibrate and bifonazole treatment (Figure 4.5.), whereas this response was not 
marked for clotrimazole treatment, in accordance with the fatty acid hydroxylase 
activity (Table 4.2.), Western blot (Figure 4.4.), and trifunctional protein data 
(Figure 4.3.).
113
Table 4.2.
Influence of clofibrate, bifonazole and clotrimazole pretreatment on 
fatty acid hydroxylation and 8-oxidation in rat kidney k
Treatment Lauric acid Lauric acid Palmitoyl CoA
(dose levels) 11-hydroxylase 12-hydroxylase 6-oxidation
CONTROL
Com oil, 1 ml/kg 0.41 ±0.04 1.34 ±0.06 15.0 ± 2.8
Clofibrate
1 mmol/kg 0.46 ±0.05 1.59 ±0.09* 23.5 ±2.4*+
Bifonazole
150 iimol/kg 0.45 ±0.04 1.58 ±0.08* 17.2 ±2.3
750 |imol/kg n.d. n.d. 16.6 ±1.5
Clotrimazole
150 jimol/kg 0.42 ±0.03 1.36 ±0.07 10.1 ± 1.3
750 pmol/kg n.d. n.d. 10.8 ± 1.0
1 All activities are expressed as nmol product formed/minute/mg of protein and 
represent the mean ± SEM from 5 animals. Statistical analysis was by one factor 
ANOVA and Duncan new multiple range; n.d., not determined;
*P<0.05 (significantly different from control);
+P<0.01 (significantly different from clotrimazole).
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Figure 4.4. Western blot analysis of renal cytochrome P4504A1 using 
a rat liver polyclonal antibody. Rats were pretreated with bifonazole, clotrimazole 
or clofibrate, as outlined in Table 4.1., and the analysis carried out as described in 
Materials and Methods Chapter (Section 2.11.). Five micrograms of microsomal 
protein (from pooled microsomal fractions) were loaded on each track. Lane (1) 
enhanced chemiluminescence molecular weight markers; (2) authentic 
cytochrome P4504A1 (0.5 pmol); (3) clotrimazole at the low dose; (4) bifonazole 
at the low dose; (5) clofibrate pretreatment; (6) control microsomes.
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8Figure 4.5. Northern blot analysis for cytochrome P4504A1 mRNA 
in rat kidney. Rats were pretreated with bifonazole, clotrimazole or clofibrate as 
described in Table 3.1., and Northern blot analysis carried out as outlined in 
Materials and Methods Chapter (Section 2.12.2.). Amount of RNA loaded in each 
track corresponding to RNA derived from control (lane 1, 10 |Xg; lane 2, 20 jig), 
clofibrate (lane 3, 20 jig; lane 4, 30 |ig), bifonazole at the low dose (lane 5, 40 |ig; 
lane 6, 20 |ig), and clotrimazole at the low dose (lane 7, 20 |ig; lane 8, 10 |Lig) 
induced rats.
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Figure 4.6. Lack of arachidonic acid metabolites formation in rat 
kidney microsomes in the absence of NADPH (A); metabolite profile of untreated 
rat kidney microsomes in the presence of NADPH (B). Incubation, separation of 
metabolites by reverse phase HPLC, and radiochemical detection were performed 
as described in Material and Methods Chapter (Section 2.10.); 20:4, arachidonic 
acid.
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Incubation of [ 1 - C] -arachidonic acid with rat kidney microsomes in 
the presence of NADPH and molecular oxygen under conditions favouring 
primary metabolism, and analysis of samples by reverse phase HPLC, resulted in 
the formation of peaks with retention times of 29.3 and 30 minutes (Figure 4.6.), 
that in the previous Chapter (Three) were tentatively identified as (o)-l)- and (O- 
hydroxyarachidonic acid, respectively. Unlike the (control) liver (Chapter Three), 
the peak eluting at approximately 30 minutes was a major metabolite in control 
kidney microsomes, as has also been reported by Sharma et al., 1989a. 
Furthermore, no significant increase in the formation of this peak has observed in 
any of the azole test groups (data not shown). The formation of these metabolites 
appear to be cytochrome P450 dependent, as separate experiments have shown 
that omission of NADPH from the incubation media resulted in no apparent 
metabolism (Figure 4.6.).
The effect of bifonazole and clotrimazole on other cytochrome P450 
families are shown in Table 4.3. The 0-dealkylation of ethoxyresorufin (Figure
4.7.) and pentoxyresorufin (Table 4.3.) were significantly increased only by 
bifonazole at high dose level. Additionally, Western immunobloting analysis 
using polyclonal antibodies against P4501A1 (Figure 4.8.), P4502B1/2 (Figure
4.9.), and P4503A (Figure 4.10.) demonstrated that only high dose of bifonazole 
slightly increases these protein levels, as can be deduced from the original gels, 
further underscoring the biochemistry findings.
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Table 4.3.
Renal microsomal mixed-function oxidase activities in the rat 
pretreated with either clofibrate, bifonazole or clotrimazole.
7-Ethoxyresorufin-O-deethylase 7-Pentoxyresorufin-O-depentylase 
Treatment pmol/minute/ pmol/minute/
(dose levels) protein nmol P450 mg protein nmol P450
CONTROL
Com oil, 1 ml/kg 2.9 ± 0.2 58.8 ± 2.?dhm 3.1 ±0.1 62.9±2.7Ghm
Clofibrate
1 mmol/kg 2.5 ± 0.3 49.4±6.2hm 3.3 ±0.1 66.3 ± 1.7Ghm
Bifonazole
150 |imol/kg 3.2±0.2ik 41.3±2.8hm 3.0 ±0.1 39.0±0.9f
750 pmol/kg 4.0 + 0.4bcdim 26.8 ±2.7 3.6±0.2adh 24.4 ±1.1
Clotrimazole '
150 |imol/kg 1.9 ±0.2 23.7 ±2.2 3.0 ±0.2 37.2 ±1.8^
750 pmol/kg 2.1 ±0.2 26.0 ±2.1 3.3 ±0.3 41 .4±3 .lf
Values are expressed as mean ± SEM from 5 animals. Statistical analysis was by 
one factor ANOVA and Duncan new multiple range. Significantly different from 
control at ^P<0.05 or ^P<0.01; significantly different from clofibrate at ^P<0.01; 
significantly different from low dose of bifonazole at ^P<0.05 or ®P<0.01; 
significantly different from high dose of bifonazole at ^P<0.01; significantly 
different from low dose of clotrimazole at ^P<0.05 and ^P<0.01; significantly 
different from high dose of clotrimazole at ^P<0.05 or ^P<0.01.
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Figure 4.8. Western blots employing an anti-cytochrome P4501A1 
polyclonal antibody. Protein samples were resolved by electrophoresis in a 10% 
(w/v) SDS-polyacrilamide gel, and transferred electrophoretically to a 
nitrocellulose paper. The immunoblot was performed with rat anti-cytochrome 
P4501A1, followed by donkey, anti-rabbit Ig-biotinylated species-specific whole 
antibody, and streptavidin-horseradish peroxidase conjugate. Solubilised 
microsomes (5 |ig protein) were derived from: Lane (1) B-naphthoflavone 
pretreated (positive control); (2) clotrimazole at the high dose; (3) clotrimazole at 
the low dose; (4) bifonazole at the high dose; (5) bifonazole at the low dose; (6) 
clofibrate pretreatment; (7) control microsomes; (8) enhanced chemiluminescence 
molecular* weight markers.
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Figure 4.9. Western blots employing an anti-cytochrome P4502B1/2 
polyclonal antibody. The immunoblot was carried out with rat anti-cytochrome 
P4502B1/2 (from rabbit), followed by donkey, anti-rabbit Ig-biotinylated species- 
specific whole antibody, and streptavidin-horseradish peroxidase conjugate. Five 
micrograms of microsomal protein (from pooled microsomal fractions) were 
loaded on each track. Lane (1) phénobarbital microsomes as positive control; (2) 
clotrimazole at the high dose; (3) clotrimazole at the low dose; (4) bifonazole at 
the high dose; (5) bifonazole at the low dose; (6) clofibrate pretreatment; (7) 
control microsomes; (8) enhanced chemiluminescence molecular weight markers.
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Figure 4.10. Western blot analysis for cytochrome P4503A. Rats 
were pretreated with bifonazole, clotrimazole or clofibrate as outlined in Table 
4.1., and Western blot analysis carried out as described in Materials and Methods 
Chapter (Section 2.11.). Five micrograms of microsomal protein (from pooled 
microsomal fractions) were loaded on each track. Lane (1) pregnenolone-16a- 
carbonitrile treated microsomes (positive control); (2) clotrimazole at the high 
dose; (3) clotrimazole at the low dose; (4) bifonazole at the high dose; (5) 
bifonazole at the low dose; (6) clofibrate pretreatment; (7) control microsomes; 
(8) enhanced chemiluminescence molecular weight markers.
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4.3. Discussion.
Unlike the liver (Chapter 3), no kidney enlargement was observed in 
rats pretreated with clofibrate, bifonazole or clotrimazole (Figure 4.1.), which is 
in agreement with previous reports on hypolipidaemic agents (Hawkins et aZ., 
1987), and chlorotrifluoroethylene trimer and tetramers (Diaz et al., 1993). In 
general, there are good indications that the fatty acid-metabolising enzyme 
complement is similar in the kidney and liver, although substantial quantitative 
tissue differences exist in control and induced states (Sharma et al., 1989b). The 
involvement of renal microsomes in 0)-hydroxylation of fatty acid was established 
by Ichihara et al., 1969, and the existence of at least one haemoprotein species 
with a preference for fatty acid co-hydroxylation has been reported in rat kidney 
cortex microsomes (Jakobsson et al., 1970). Saturated fatty acids of medium 
chain length such as lauric acid, display a high affinity for kidney cytochrome 
P450, and subsequent studies by Sharma et al., 1989b, confirmed that cytochrome 
P4504A1 (or a closely related isoenzyme of the same gene subfamily) is a major 
constitutive form of renal microsomal cytochrome P450 responsible for co- 
hydroxylation of lauric acid.
Although a significant increase in the total P450 specific content was 
only observed in the group of animals pretreated with high dose of bifonazole 
(Table 4.1.), there was a small (1.2-fold) increase in lauric acid co-hydroxylase 
activity (indicative of P4504A subfamily induction) by clofibrate and bifonazole 
(Table 4.2.). Based on the ability to induce lauric acid co-hydroxylase activity, 
cytochrome P4504A1 apoprotein (Figure 4.4.), and cytochrome P4504A1 mRNA 
(Figure 4.5.), my results indicate that bifonazole, but not clotrimazole, is a weak 
inducer of the cytochrome P4504A subfamily in rat kidney microsomes.
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Cytochrome P4504A1 and 4A3 mRNAs are present at low levels in 
kidney and inducible by clofibrate in a similar manner to liver (Kimura et a l, 
1989; and Aoyama et al., 1990). In contrast, cytochrome P4504A2 mRNA level 
in the kidney of untreated rats (which are present at very low levels in the liver of 
untreated rats) is similar to the hepatic level of this isoenzyme following 
maximum induction. It is not clear at present which of these latter isoenzymes are 
increased by bifonazole as they all catalyse co- and (co-l)-hydroxylation of lauric 
acid (Imaoka and Funae, 1986; and Aoyama et al., 1990). In addition, as observed 
in Western blotting analysis of hepatic microsomes (Chapter 3), and previous 
reports (Hardwick et al., 1987; and Sharma et al., 1989b), the antibody to 
P4504A1 using 4-chloro-1 -naphthol as a substrate (data not shown) recognised 
two bands in renal microsomes. A major band with lower molecular weight of 
approximately 51.5 kDa (consistent with that of authentic homogenous hepatic 
cytochrome P504A1), and a minor band with molecular weight of almost 52 kDa 
that is probably P4504A2 and/or P4504A3 as discussed in the Chapter Three. 
However, because the cytochrome P4504A1 cDNA hybridisation experiment was 
carried out under relatively strict conditions of stringency, it seems that, at least, 
cytochrome P4504A1 is induced.
Peroxisome proliferation is the major cellular response of the kidney 
to peroxisome proliferators, with a corresponding increase in peroxisomal B- 
oxidation enzymes and induction of the peroxisome proliferation associated
80,000 molecular weight polypeptide ( Hawkins et al., 1987). In my study SDS- 
polyacrylamide gel electrophoretic analysis of trifunctional protein (Figure 4.3.) 
demonstrated that clofibrate and bifonazole induce this protein. However, activity 
of cyanide insensitive palmitoyl-CoA oxidation was significantly increased only 
by microsomes from clofibrate pretreatment, and the slight increase observed by
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bifonazole at both dose levels (Table 4.2.) was not significant. It should be noted 
that kidney peroxisomal enzymes, however, are more refractory to induction than 
their liver counterpart, as peroxisome proliferators such as mono-(2- 
ethylhexyl)phthalate and acetyl salicylic acid (aspirin) did not induce peroxisomal 
palmitoyl-CoA oxidation activity at all (Sharma et al., 1989b), and bifonazole 
could additionally be one of these weak kidney inducers.
According to the report by Sharma et al., 1989a, arachidonic acid 
serves as an excellent endogenous substrate for cytochrome P4504A1 in rat liver 
and kidney. In agreement with their report and unlike the control liver (Chapter 
3), the peak eluting at approximately 30 minutes (postulated as co-hydroxy- 
arachidonic acid) is a major metabolite. Nevertheless, my study did not provide 
any evidence of arachidonic acid metabolite induction by the test compounds, as 
reported for clofibrate by Sharma et al., 1989a. However, these latter authors only 
observed a 1.4-fold induction in co-hydroxylation of arachidonic acid which does 
not represent an extensive induction. In this context, it is useful to point out that 
the increased level of lauric acid co-hydroxylase activity by clofibrate and 
bifonazole in my experiments was lower than that of observed by Sharma et al., 
1989a. This apparent discrepancy may be due to the time course difference (three 
days by them) or a difference in the HPLC column (Gig Micropak 0.46 cm x 15 
cm, MCH-10, used by them) between the two studies.
Consistent with immunoblot analysis using anti-P4501Al (Figure
4.8.), bifonazole at the high dose significantly increased the O-deethylation of 
ethoxyresorufin (Figure 4.7.), an enzyme reaction that is largely catalysed by 
P4501A1. However, it should be noted that this induction is marginal. Despite 
report by Tarloff et al., 1990, for the absence of the P4502B subfamily in rat 
kidney. Western blotting analysis (Figure 4.9) displayed a faint band for
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microsomes derived from the group of animals treated with high dose of 
bifonazole, that is further supported by pentoxyresorufin 0-depentylase assay 
(Table 4.3.). In addition, a similar increase in the levels of cytochrome P4503A 
subfamily apoproteins was evident following the Western blot analysis (Figure
4.10.). Therefore, it appears from this data that only bifonazole at the high dose 
level is able to cause only slight increases in cytochromes P4501A1 and 
P4502B1/2 proteins, and the P4503A subfamily.
4.4. Conclusion.
The present results have shown that bifonazole, but not clotrimazole, 
induces the renal cytochrome P4504A subfamily and probably cytochrome 
P4504A1 in particular, in a similar manner to liver (Chapter Three), but to a lesser 
extent. In addition, the results of this work show that the carboxylate moiety is 
not essential for the induction of renal peroxisomes and cytochrome P4504A1.
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In Vitro Effects of Azole Antifungal Drugs on the 
Cytochrome P4504A Subfamily
5.1. Introduction.
Cytochrome P450 comprises of a family of haemoproteins which are 
involved in the metabolism of a wide variety of endogenous and exogenous 
compounds. Some forms of this superfamily are present constitutively, whereas 
others are induced to high levels upon exposure to certain foreign compounds 
(Conney, 1986; Guengerich, 1987; Sharma et a l, 1988a; and Waxman, 1988). 
Cytochromes P450 offer the organism the ability to metabolise (primarily by 
hydroxylation) a very large number of structurally diverse environmentally 
derived chemicals, thus facilitating their excretion, and is probably the reason for 
the remarkably large number of these isoenzymes. Additionally, the P450s are 
responsible for the biotransformation of large number of endogenous compounds 
including fatty acids, leukotrienes, prostaglandins, steroids and vitamins.
Many of the P450s are inducible by several xenobiotics such as azole 
antifungal drugs, barbiturates, ethanol, polycyclic aromatic hydrocarbons, and 
polyhalogenated biphenyls, resulting in substantial alterations in P450 tissue 
complements, as these xenobiotics may additionally ‘switch off’ or substantially 
reduce the expression of constitutive isoenzymes (Guengerich, 1991; and Porter 
and Coon, 1991).
Primary cultures of hepatocytes are widely used to study various 
aspects of cytochrome P450 regulation, drug metabolism, and related cytotoxicity 
(Sirica and Pitot, 1980; Guillouzo, 1986; and Paine, 1990). Although there is a
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rapid decline of the basal level of cytochrome P450 during the first 24 hours in 
culture (Paine, 1990), primary cultures of rat hepatocytes retain the capacity to 
respond to some P450-inducers by increasing the synthesis of specific mRNAs 
and proteins and enhancing associated catalytic activities (Elshourbagy et al., 
1981; Newman and Guzelian, 1982; Lake et al., 1983; Steward et al. 1985; and 
Bars et al., 1989).
Primary cultures of rat hepatocytes are a useful model in which to 
investigate the effects of peroxisome proliferators (Gray et al., 1985; Feller et al., 
1987; Kocarek and Feller, 1987; and Lake et al., 1988). Morphological and 
biochemical responses of this model to peroxisome proliferators are in excellent 
agreement with in vivo studies (Esbenshade et al., 1990). Reproduction of the in 
vivo induction of P4504A1 in particular, indicates that inducers act directly on the 
liver (Lake et a l, 1986). Therefore, this system serves as an ideal way to 
investigate structure-inducer relationships, rapid determination of inducer 
potencies, and also to determine susceptibility of species to induction without the 
complications associated with inducer bioavailability to the target organ and 
pharmacokinetic differences between inducers (Esbenshade etal., 1990).
Azole antifungal agents are synthetic compounds with one or more 
five-membered rings, containing either two (imidazole) or three (triazole) nitrogen 
atoms in each ring. In the experiments described in this Chapter, induction of the 
cytochrome P4504A subfamily by six azole antifungi drugs, including three 
imidazoles (bifonazole, clotrimazole, and miconazole) and three triazoles 
(geniconazole, itraconazole, and UK-47265), as well as clofibrate using the rat 
primary hepatocyte culture system has been studied.
*2-(lH-1,2,4-triazol-1 -yl)-1 -( IH-1,2,4-triazol- 1-ylmethoxy)-1 -phenylethane
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5.3. Results.
The culture of rat hepatocytes for 70 hours led to a drop in the total 
carbon monoxide-discernible cytochrome P450 specific content compared to that 
present in freshly isolated cells (Figure 5.1.). The addition of clofibrate, 
bifonazole, clotrimazole, geniconazole, miconazole or UK-47265 to the cell 
culture medium, however, maintained total cytochrome P450 levels at 85-150% of 
the level found in freshly isolated hepatocytes (Figure 5.1.). Clofibrate and all the 
azole compounds examined, except itraconazole, produced concentration- 
dependent increases in the cytochrome P450 levels which were significantly 
higher than those present in control cells cultured for 70 hours (0.4%, v/v, 
DMSO). This induction was over a concentration range of 2.5 to 10 |iM for 
bifonazole (Figure 5.2.), 75 to 500 jiM for clofibrate (Figure 5.3.), 1 to 5 |iM for 
clotrimazole (Figure 5.4.), 1 to 50 jiM for geniconazole (Figure 5.5.), 0.25 to 50 
jiM for miconazole (Figure 5.6.), and 0.25 to 25 |iM for UK-47265 (Figure 5.7.). 
Results for itraconazole over a concentration range of 0.025 to 25 p.M are 
presented in Figure 5.8.
Reverse phase HPLC analysis demonstrated that the levels of 11- and 
12-hydroxylation of lauric acid were lower in control cells cultured for 70 hours 
than in freshly isolated cells (Figure 5.9.). In agreement with the in vivo study 
(Chapter Three), addition of bifonazole or clofibrate to the cell culture medium 
significantly increased the lauric acid 1 1 - and 1 2 -hydroxylase activities over 
freshly isolated cells and control cells cultured for 70 hours. The maximal 
increase of these latter activities were obtained at 10 |iM and 500 |iM with 
bifonazole and clofibrate, respectively. The lauric acid 12-hydroxylase activity, in 
the case of bifonazole, was induced 8.7- and 3.7-fold as compared to the activities
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Figure 5.1. Total cytochrome P450 modulation by azole antifungal 
agents and clofibrate. Hepatocytes were isolated, cultured, and treated for 70 
hours under conditions described in the Materials and Methods Chapter (Section
2.3.) prior to harvesting for the total P450 determinations. Values are means of 6  
dishes from three animals. Abbreviations for the individual inducers are: FIC, 
freshly isolated cells; CON, control (0.4%, v/v, DMSO); CLF, clofibrate (0.5 
mM); BIF, bifonazole (0.01 mM); CLT, clotrimazole (0.005 mM); GEN, 
geniconazole (0.05 mM); ITR, itraconazole (0.025 mM); MIC, miconazole (0.05 
mM); UK-, UK-47265 (0.025 mM). Statistical analysis was by one factor 
ANOVA and Duncan new multiple range. *P<0.05 or **P<0.01 (significantly 
different from control).
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Figure 5.2. Effect of bifonazole on total cytochrome P450 (A), and
11- (ll-LAOH) and 12- (12-LAOH) hydroxylation of lauric acid (B) using rat 
hepatocyte culture. Bifonazole was added to the culture medium as described in 
the Materials and Methods Chapter (Section 2.3.). Values are expressed as the 
mean ± SEM of 6  dishes from three animals. Statistical analysis was by one 
factor ANOVA and Duncan new multiple range;
*P<0.05 or **P<0.01 (significantly different from control).
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Figure 5.3. Effect of clofibrate on total cytochrome P450 (A), and
11- (ll-LAOH) and 12- (12-LAOH) hydroxylation of lauric acid (B) using rat 
hepatocyte culture. Clofibrate was added to the culture medium as described in 
the Materials and Methods Chapter (Section 2.3.). Values are expressed as the 
mean ± SEM of 6  dishes from three animals. Statistical analysis was by one 
factor ANOVA and Duncan new multiple range;
*P<0.05 or **P<0.01 (significantly different from control).
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Figure 5.4. Effect of clotrimazole on total cytochrome P450 (A), 
and 11- (ll-LAOH) and 12- (12-LAOH) hydroxylation of lauric acid (B) using 
rat hepatocyte culture. Clotrimazole was added to the culture medium as 
described in the Materials and Methods Chapter (Section 2.3.). Values are 
expressed as the mean ± SEM of 6  dishes from three animals. Statistical 
analysis was by one factor ANOVA and Duncan new multiple range;
*P<0.01 (significantly different from control).
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Figure 5.5. Effect of geniconazole on total cytochrome P450 (A), 
and 11- (ll-LAOH) and 12- (12-LAOH) hydroxylation of lauric acid (B) using 
rat hepatocyte culture. Geniconazole was added to the culture medium as 
described in the Materials and Methods Chapter (Section 2.3.). Values are 
expressed as the mean ± SEM of 6  dishes from three animals. Statistical 
analysis was by one factor ANOVA and Duncan new multiple range;
*P<0.01 (significantly different from control).
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Figure 5.6. Effect of miconazole on total cytochrome P450 (A), 
and 11- (ll-LAOH) and 12- (12-LAOH) hydroxylation of lauric acid (B) using 
rat hepatocyte culture. Miconazole was added to the culture medium as 
described in the Materials and Methods Chapter (Section 2.3.). Values are 
expressed as the mean ± SEM of 6  dishes from three animals. Statistical 
analysis was by one factor ANOVA and Duncan new multiple range;
*P<0.05 or **P<0.01 (significantly different from control).
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Figure 5.7. Effect of UK-47,265 on total cytochrome P450 (A), 
and 11- (ll-LAOH) and 12- (12-LAOH) hydroxylation of lauric acid (B) using 
rat hepatocyte culture. UK-47,265 was added to the culture medium as 
described in the Materials and Methods Chapter (Section 2.3.). Values are 
expressed as the mean ± SEM of 6  dishes from three animals. Statistical 
analysis was by one factor ANOVA and Duncan new multiple range;
*P<0.05 or **P<0.01 (significantly different from control).
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Figure 5.8. Effect of itraconazole on total cytochrome P450 (A), 
and 11- (ll-LAOH) and 12- (12-LAOH) hydroxylation of lauric acid (B) using 
rat hepatocyte culture. Itraconazole was added to the culture medium as 
described in the Materials and Methods Chapter (Section 2.3.). Values are 
expressed as the mean ± SEM of 6  dishes from three animals. Statistical 
analysis was by one factor ANOVA and Duncan new multiple range.
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Figure 5.9. Influence of azole antifungals and clofibrate on the 11- 
and 1 2 -hydroxylation of lauric acid using rat heratocytes primary culture. 
Hepatocytes were isolated, cultured, and dosed for 70 hours prior to harvesting 
and lauric acid 11- (ll-LAOH) and 12- (12-LAOH) hydroxylase activities 
determined by reverse phase HPLC as described in the Materials and Methods 
Chapter (Section 2.9.). Abbreviations for the individual inducers are: FIC, freshly 
isolated cells; CON, control (0.4%, v/v, DMSO); CLF, clofibrate (0.5 mM); BIF, 
bifonazole (0.01 mM); CLT, clotrimazole (0.005 mM); GEN, geniconazole (0.05 
mM); ITR, itraconazole (0.025 mM); MIC, miconazole (0.05 mM); UK-, UK- 
47265 (0.025 mM). Statistical analysis was by one factor ANOVA and Duncan 
new multiple range. *P<0.01 (significantly different from control); +P<0.01 
(significantly different from freshly isolated cells).
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present in control (cells cultured for 70 hours) and freshly isolated cells, 
respectively. For clofibrate, this activity was 9.7- and 4.4-fold greater than 
activities for control cells cultured for 70 hours and freshly isolated cells, 
respectively. The lauric acid 11-hydroxylase activity, was induced 6.9- and 3-fold 
over control (cells cultured for 70 hours) and freshly isolated cells, respectively. 
Clofibrate induction of this activity was 7.6- and 3.3-fold greater than the 
activities for control cells cultured for 70 hours and freshly isolated cells, 
respectively. None of other azole antifungals examined showed increases in the 
lauric acid 1 1 - and 1 2 -hydroxylase activities as compared to control cells cultured 
for 70 hours.
Western blotting analysis of hepatocyte homogenates derived from 
the azole antifungal treatments was performed using a polyclonal antibody against 
purified cytochrome P4504A1 (Figures 5.10. & 5.11). The data demonstrates 
that over the 70 hours culture period, only bifonazole (in a similar manner to 
clofibrate) maintains the level of cytochrome P4504A1 apoprotein, as present in 
the freshly isolated cells.
High concentrations of bifonazole and clofibrate did not increase the 
activities of lauric acid 11- and 12-hydroxylase and the total cytochrome P450 
any further (Figures 5.2. & 5.3.). In the case of bifonazole this change 
corresponded with signs of the marked hepatocyte toxicity at a concentration of 
30 |iM as judged by the MTT test (data not shown). Although the total 
cytochrome P450 and 11- and 12-hydroxylation of lauric acid were significantly 
induced by bifonazole at the higher concentrations of 7.5 and 10 p.M (Figure
5.2.), they were detectably cytotoxic (data not shown). The toxicity assay did not 
show cytotoxicity by clofibrate.
140
97.4 kDa
58.1 kDa 
39.8 kDa
29.0 kDa
20.1 kDa
14.3 kDa
8
Figure 5.10. Imunochemical analysis of rat hepatocytes using anti­
cytochrome P4504A1 polyclonal antibody. Hepatocytes were isolated, cultured, 
and dosed for 70 hours prior to harvesting as described in the Materials and 
Methods Chapter (Section 2.3.). Five micrograms of protein were loaded on each 
track. Lane (1) enhanced chemiluminescence molecular weight markers; (2) 
itraconazole (0.0001 mM); (3) miconazole (0.01 mM); (4) bifonazole (0.01 mM); 
(5) clotrimazole (0.001 mM); (6) clofibrate (0.5 mM); (7) freshly isolated cells; 
(8) control (0.4%, v/v, DMSO).
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Figure 5.11, Western blot analysis of rat hepatocytes using anti­
cytochrome P4504A1 polyclonal antibody. Hepatocytes were isolated, cultured, 
and dosed for 70 hours prior to harvesting as described in the Materials and 
Methods Chapter (Section 2.3.). Five micrograms of protein were loaded on each 
track. Lane (1) enhanced chemiluminescence molecular weight markers; (2) UK- 
47265 (0.01 mM); (3) geniconazole (0.05 mM); (4) bifonazole (0.01 mM); (5) 
clotrimazole (0.001 mM); (6 ) clofibrate (0.5 mM); (7) freshly isolated cells; (8 ) 
control (0.4%, v/v, DMSO).
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To determine EC50 values for the induction of lauric acid 11- and 1 2 - 
hydroxylase activities, concentration-response curves over a range of 0.5 to 10 
|iM (for bifonazole) and 25 to 500 |iM (for clofibrate) were constructed (Figures 
5 .1 2 . to 5.15.), and EC50 values were obtained by regression analysis of the linear 
parts of the concentration-response curves. The induction of lauric acid 11- 
hydroxylase activity by bifonazole and clofibrate was characterised by EC5 0  
values of 1.0 |iM and 160 }iM, respectively. The corresponding EC50  values for 
the induction of 12-hydroxylase activity by bifonazole and clofibrate were 1.8 |iM 
and 80 |xM, respectively.
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Figure 5.12. Effect of bifonazole on lauric acid 1 1 -hydroxylation in 
monolayers of hepatocytes maintained for 70 hours in culture. Bifonazole was 
added to the culture medium as described in Section 2.3. of the Materials and 
Methods Chapter. Data are the mean ± SEM of 6  dishes from three animals (EC50  
= 1.0 jiM).
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Figure 5.13. Influence of bifonazole on lauric acid 12-hydroxylase 
activity in monolayers of hepatocytes maintained for 70 hours in culture. 
Bifonazole was added to the culture medium as indicated in Section 2.3. of the 
Materials and Methods Chapter. Data are the mean ± SEM of 6  dishes from three 
animals (EC50 = 1 . 8  jiM).
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Figure 5.14. Clofibrate induction of lauric acid 1 1 -hydroxylase 
activity in rat hepatocyte culture. Clofibrate was added to the culture medium as 
described in the Materials and Methods Chapter (Section 2.3.). Each point 
represents the mean ± SEM of 6  dishes from three animals (EC50 =160 jiM).
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Figure 5.15. Clofibrate induction of lauric acid 12-hydroxylase 
activity in rat hepatocyte culture. Clofibrate was added to the culture medium as 
described in the Materials and Methods Chapter (Section 2.3.). Each point 
represents the mean ± SEM of 6  dishes from three animals (EC50  = 80 |iM).
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5.4. Discussion.
The results described in this Chapter are consistent with previous 
reports (Lake et al., 1984; and Esbenshade et al., 1990) in that enzymatic changes 
in the in vivo study (Chapter Three) can be produced in primary culture of rat 
hepatocytes. Exposure of rat hepatocytes to azole antifungals used in this study 
showed that only bifonazole (similar to clofibrate) induces the cytochrome 
P4504A subfamily. From the six azole antifungals used, hydroxylation of 11- and
12-lauric acid (Figure 5.9.), and the level of cytochrome P4504A1 apoprotein 
(Figures 5.10. & 5.11.) were only induced by bifonazole over a concentration 
range of 0.5 to 10 |iM.
Cytochromes P4502B1/2 proteins and the P4503A subfamily were 
previously shown to be induced by clotrimazole and miconazole in rat liver 
(Rodrigues et al., 1988). In my previous in vivo study (Chapter Three), the above 
mentioned induction by clotrimazole was further substantiated, and bifonazole 
was also capable of inducing P4501A1 and 2B1/2 proteins, and the P4503A and 
4A subfamilies. In cultured hepatocytes, all of the imidazole antimycotic drugs 
studied, except itraconazole, maintained total cytochrome P450 levels over 70 
hours culture period as compared to the freshly isolated cells (Figure 5.1.). 
Therefore, although clotrimazole, geniconazole, miconazole, and UK-47265 did 
not induce hydroxylation of lauric acid (indicative of the P4504A subfamily 
induction) or cytochrome P4504A1 apoprotein level, they probably induce other 
P450 isoenzymes as reported for clotrimazole and miconazole (Rodrigues et al., 
1988 and Chapter 3). However, the observed decrease in the total cytochrome 
P450 levels (Figure 5.4.), following cell treatment with higher concentrations of 
clotrimazole (10 and 25 }iM), could be due to the cytotoxicity of this compound at
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these two concentrations (data not shown). The lack of ability by itraconazole to 
maintain the levels of total cytochrome P450 over 70 hours culture period is in 
agreement with the previous reports that itraconazole does not appear to possess 
any activity toward enzymes of monooxygenase system (Lavrijsen et ah, 1986; 
and Damanhouri et al., 1988).
As observed in the immunochemical analysis of hepatic microsomes 
(Chapter Three), the antibody to P4504A1 (Figures 5.10 & 5.11.) recognised two 
bands in hepatocyte homogenates. There are at least three closely related enzymes 
in the P4504A subfamily in rat liver, namely P4504A1, P4504A2, and P4504A3 
(Kimura et ah, 1989; Sundseth and Waxman, 1992; and Nelson et al., 1993), and 
it is not clear at present that which of these enzymes are induced by bifonazole as 
they all display lauric acid co-hydroxylase activity (Aoyama et al., 1990; and Diaz 
et al., 1993). However, as discussed in Chapter Three it appears that, at least, 
cytochrome P4504A1 is induced, and the additional proteins are probably 
P4504A2 and/or P4504A3.
The apparent EC50  values of bifonazole and clofibrate for the 1 1- and
12-hydroxylation of lauric acid demonstrated that bifonazole is 160 and 44 times 
more potent than clofibrate, respectively. However, bifonazole induction of lauric 
acid 12-hydroxylase was lower than that of observed with clofibrate (Figure 5.9.), 
which could be due to cytotoxicity of bifonazole (data not shown) at high 
concentrations (7.5 and 10 jiM). Therefore, the induction phenomenon is 
accompanied with cytotoxicity that may mask the true extent of induction.
With both inducers, no steady state plateau in 11- and 12-lauric acid 
hydroxylase dose response curves following maximum response was observed 
(Figures 5.12 to 5.15.), and the apparent maximum response was followed by a 
drop in values. Apparently, this latter phase is due to cytotoxicity as confirmed by
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the MTT assay in the case of bifonazole (data not shown). Although the MTT test 
did not demonstrate cytotoxicity with clofibrate (data not shown), it should be 
pointed out that this assay is only a gross indication of cytotoxicity in 
mitochondria, and in the case of clofibrate it may be more subtle to measure the 
cytotoxicity, as clofibrate may cause some other changes in cell that inhibits the 
induction phenomena but does not destroy mitochondria and, therefore, the assay 
for reduction of MTT to a formazan product can not reveal any cytotoxicity. Thus, 
the calculated EC5 0  probably does not represent actual values, as cytotoxicity 
masks the true values, and the EC50 must be considered as an apparent EC50 .
5.4. Conclusion.
The present study in rat hepatocyte primarily cultures has shown that 
from the six employed azole antifungal drugs examined, only bifonazole induces 
the cytochrome P4504A subfamily and probably cytochrome P4504A1 in 
particular, which is in agreement with the result of my in vivo study (Chapter 3).
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Investigation of the Presence of the Cytochrome 
P4504A Subfamily In Rat and Human Blood
6.1. Introduction.
A novel form of microsomal cytochrome P450, cytochrome P4504A1, 
responsible for the co-hydroxylation of fatty acids in the liver has been shown to 
be induced by peroxisome proliferators in susceptible species (Parker and Orton, 
1980; Gibson et al., 1982; Tamburini et al., 1984; and Sharma et al., 1989a). 
Peroxisome proliferators are structurally diverse group of compounds that 
produce similar changes such as hepatomegaly, proliferation of smooth 
endoplasmic reticulum and induction of cytochrome P450, peroxisomes 
proliferation with associated changes in enzyme composition, and mitochondrial 
changes in liver of experimental animals. The major toxicological concern 
relating to peroxisome proliferators is the fact that, following long-term exposure, 
they produce non-genotoxic carcinogenesis (Reddy et al., 1980; and Hawkins et 
al, 1987).
Most reported studies have focused on the expression of hepatic 
cytochromes P450 by different inducers. Recently, however, there has been an 
increasing number of studies concerned with extrahepatic metabolism. Song et ah, 
1990, measured cytochrome P4502E1 by immunochemical method in peripheral 
lymphocytes cultured for 4 days in patients with insulin-dependent diabetes 
mellitus. However, they have not been able to detect this isoenzyme in 
lymphocytes collected from healthy volunteers. This may be due to the absence of 
this isoenzyme or, alternatively, it may be due to the detection sensitivity of the 
assay.
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The cytochrome P4501A1 gene is expressed at low levels in 
peripheral blood lymphocytes. Cosma et a l, 1992, determined expression of 
P4501A1 mRNA in mitogen-stimulated culture of peripheral lymphocytes from 
creosote-exposed railroad workers using conventional RNA hybridisation 
techniques. Also Vanden Heuvel et a l, 1993, measured activity of cytochrome 
P4501A1 by ethoxyresorufm 0-deethylase (EROD) in mitogen-stimulated human 
blood lymphocytes. However, EROD activity could not be detected in 
nonstimulated, uninduced lymphocytes, due to extremely low levels of this 
isoenzyme. Therefore, Vanden Heuvel et a l, 1993, introduced a reverse 
transcriptase polymerase chain reaction method to quantitate cytochrome 
P4501A1 mRNA levels in resting as well as mitogen-stimulated human blood 
lymphocytes.
The hepatic induction of cytochrome P4504A1 and proliferation of 
peroxisomes (Chapter Three) by the azole antifungal drug, bifonazole, was an 
incentive to investigate the extrahepatic effect of this drug, as well as the 
induction potential of clofibrate and clotrimazole. In Chapter Four their effects on 
the renal mixed-function oxidase system and peroxisomes were described. 
Cytochrome P4504A subfamily induction by azole antifungals using rat 
hepatocyte primary cultures were examined in Chapter Five. The aim of this 
chapter was, therefore, to investigate the existence and/or inducibility of the 
cytochrome P4504A subfamily in rat blood components, and in particular 
lymphocytes. I have also investigated this aspect in human blood components.
153
62. Results and Discussion.
Blood samples were collected and separated into three components : 
(1 ) plasma, which contained platelets; (2 ) erythrocytes, granulocytes and 
thrombocytes; and (3) lymphocytes, as described in Materials and Methods 
Chapter (Section 2.4.).
6.2.1. Rat Blood.
The total carbon monoxide-discernible cytochrome P450 specific 
content was undetectable in rat blood components (data not shown). Incubation of 
the above three rat blood components with lauric acid in the presence or absence 
of NADPH, either collected from control or treated groups (clofibrate, bifonazole, 
or clotrimazole), followed by reverse phase HPLC analysis did not produce any 
detectable metabolites (data not shown). This finding led to a suggestion that this 
fatty acid is not a suitable substrate for investigation of cytochrome P4504A1 in 
the rat blood, or that this particular isoenzyme is not expressed in any of the blood 
components studied.
Arachidonic acid is the main polyunsaturated fatty acid in blood and 
vascular cells, and is metabolised to a variety of oxygenated products by three 
main pathways. These are (i) the cyclo-oxygenase system that produce 
prostanoids, (ii) various lipoxygenase products, and (iii) NADPH-dependent 
cytochrome P450 epoxygenase metabolites (Lagarde et al., 1989). Arachidonic 
acid was used as a substrate subsequent to the finding that no metabolites were 
identified following incubation of the blood samples with lauric acid. Figure 6.1. 
shows chromatograms of rat plasma incubated with arachidonic acid in the
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Figure 6.1. Reverse phase separation of arachidonic acid metabolites 
generated by control rat plasma in the absence (A) or presence of NADPH (B). 
Arachidonic acid (1.2 mCi/ mmole, 0.1 mM) was incubated with rat plasma (42 
mg protein) for 20 minutes at 3TC  under the conditions described in Materials 
and Methods Chapter (Section 2.10.); 20:4, arachidonic acid.
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presence or absence of NADPH. Irrespective of the presence of NADPH, both 
chromatograms show similar patterns with peaks eluted at 16.1, 28.3, 28.7 and
33.2 minutes. Incubation of erythrocytes, granulocytes, and thrombocytes with 
arachidonic acid demonstrated a different NADPH-independent profile (Figure
6.2.) with additional peaks compared to the plasma incubation. Chromatograms 
shown in Figures 6.3. and 6.4. are related to the incubation of lymphocytes 
derived from control or treated animals. These chromatograms show that 
pretreatment of rats with clofibrate, bifonazole or clotrimazole did not cause an 
induction as compared to the control group. Due to the lack of authentic 
standards, characterisation and identification of these peaks was not possible. 
However, the formation of metabolites appear to be cytochrome P450- 
independent, as omission of NADPH from the incubation media did not effect the 
metabolic profile.
6.2.2. Human Blood.
Cytochrome P450 was not spectrophotometrically detectable in 
human blood components (data not shown). Incubation of the three human blood 
components with lauric acid, in the presence or absence of NADPH, followed by 
reverse phase HPLC analysis did not lead to formation of any metabolite (data not 
shown), as has been previously described for the rat blood components.
Incubation of arachidonic acid with samples of human plasma or 
erythrocytes, granulocytes and thrombocytes with or without NADPH did not 
demonstrate any metabolism of substrate (Figure 6.5.). When lymphocytes were 
incubated with arachidonic acid, a complex pattern of metabolites emerged 
(Figure 6 .6 ). Again, the metabolism was not NADPH-dependent. It appears that
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Figure 6.2. Reverse phase HPLC chromatograms of arachidonic acid 
metabolites from rat erythrocytes, granulocytes and thrombocytes (35 mg protein) 
incubated with [ 1 -^ C ]-arachidonate (1.2 mCi/ mmole, 0.1 mM) at 37“C as 
described in the Materials and Methods Chapter (Section 2.10.). Chromatograms: 
rat erythrocytes, granulocytes and thrombocytes in the absence (A) or presence of 
NADPH (B); 20:4, arachidonic acid.
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Figure 6.3. Formation of arachidonic acid metabolites in the absence 
(A) or presence of NADPH (B). Rat lymphocytes suspension (3 mg protein) were 
incubated with arachidonic acid (1.2 mCi/ mmole, 0.1 mM) for 20 minutes at 
37“C as described in the Materials and Methods Chapter (Section 2.10.); 20:4, 
arachidonic acid.
158
i ]
Clofibrate-treated
Gross total: 27987 çpm
© U.-4
•
. :
 ^ j
20:4
■
i
■ :
i 1 
■ A ■ 1 ■ I
!(;
:
i
''"'3
;
5 30  35  4 0 4ÎL m i n 113 15 23
B
51©J
J
cpm
É•ÿ
Bifonazole-treated
Gross total: 19457 cpm
j  i i :
:: 20:4
M 
\
5 13 15 20  25 33 35  43  4 i i m i n ]
^  ©jcpm
i r
4:
i
1
Clotrimazole-treated
Gross total: 7495 cpm
A ■ S
20:4
10 20 2 c  30 3 c  40  4i [ rn in]
Figure 6.4. Metabolism of arachidonic acid by lymphocytes (3 mg 
protein) collected from rats pretreated with clofibrate, bifonazole or clotrimazole. 
In vitro incubation, separation of metabolites by reverse phase HPLC, and 
radiochemical detection was carried out as outlined in the Materials and Methods 
Chapter (Section 2.10.). (A) clofibrate-pretreated; (B) bifonazole-pretreated; (C) 
clotrimazole-pretreated; 20:4, arachidonic acid.
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Figure 6.5. Lack of arachidonic acid metabolites formation in human 
blood components : plasma, 35 mg protein (A); erythrocytes, granulocytes and 
thrombocytes, 47 mg protein (B). Incubation of arachidonic acid (1.2 mCi/ 
mmole, 0.1 mM) was carried out at 37“C for 20 minutes in the presence of 
NADPH and O2  as described in the Materials and Methods Chapter (Section 
2.10.); 20:4, arachidonic acid.
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Figure 6.6. Reverse phase HPLC separation of arachidonic acid 
metabolites produced by human lymphocytes (3 mg protein) in the absence (A) or 
presence of NADPH (B). Arachidonic acid (1.2 mCi/ mmole, 0.1 mM) was 
incubated with human lymphocytes for 20 minutes at 37“C under the conditions 
described in the Materials and Methods Chapter; 20:4, arachidonic acid.
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the formation of these metabolites are cytochrome P450-independent, as omission 
of NADPH from the incubation media did not effect the metabolic profile. 
Alternatively, the level of endogenous NADPH may be responsible for this 
pattern of metabolites.
Due to the difficulties encountered for achieving a large yield of 
lymphocytes from whole fresh blood for enzyme assays, it may be better to study 
expression and induction in lymphocyte culture systems.
6.3. Conclusion.
The results of this preliminary study did not provide any evidence for 
the presence of cytochrome P4504A subfamily in rat or human blood. The lack of 
evidence, however, may be due to the detection sensitivity of the assays used.
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General Discussion
Imidazole-containing compounds are extensively used clinically, 
primarily as antifungal agents or as Hi-receptor antagonists. Such compounds are 
closely associated with inhibition of the mixed-function oxidase system leading to 
clinically important drug interactions (Serlin et al., 1979). However, imidazole- 
containing chemicals may also act as enzyme inducing agents. Phenylimidazole is 
an enzyme inducing agent which displays similarities towards the phenobarbital- 
type inducers (Murray et al., 1985). Indeed, imidazole is itself an inducer and, at 
least in the rabbit, it enhances the synthesis of the same cytochrome P450 protein 
that is associated with induction by chronic treatment with alcohol (Koop et al., 
1985). Miconazole and ketoconazole, but not itraconazole, administered 
intragastrically to rats stimulate a number of hepatic mixed-function oxidase 
activities (Lavrijsen et al., 1986). Administration of clotrimazole and miconazole, 
and to a lesser extent ketoconazole, have been associated with the induction of the 
monooxygenase system in rat liver, displaying selectivity towards the cytochrome 
P4502B and P4503A subfamilies (Rodrigues et al., 1988). However, no 
systematic study has been carried out on the effect of azole antifungal drugs on 
the P4504A subfamily induction and its relationship to peroxisome proliferation.
Recent Japanese work has shown that the azole antifungal drug 
bifonazole, but not the structurally-related clotrimazole (Figure 1.6.), is a 
peroxisome proliferator (Horie et al., 1991). Concomitant with peroxisome 
proliferation is the induction of an enzyme of cytochrome P450, namely 
cytochrme P4504A1 (Sharma et al., 1988a; Dirven et al., 1991; and Hozuka et a l,
1991). My results on the relative cytochrome P4504A1 and peroxisome
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proliferation induction potencies of bifonazole and clofibrate, but not 
clotrimazole, in the rat liver (Chapter 3), rat kidney (Chapter 4), and the primary 
cultures of rat hepatocytes (Chapter 5), further substantiates the close relationship 
between induction of cytochrme P4504A1 and the peroxisome proliferation 
phenomena.
7.1. Comparison of the In Vivo and In Vitro 
Induction of the Cytochrome P4504A 
Subfamily by Azole Antifungai Drugs.
Results from my in vivo (Chapter 3) and in vitro (Chapter 5) studies 
revealed that bifonazole (similar to clofibrate), but not clotrimazole, induces the 
cytochrome P4504A subfamily in rat liver microsomes and primary cultures of rat 
hepatocytes. In vivo, bifonazole and clofibrate induced lauric acid co-1 and 
particularly co-hydroxylase activities. The co-hydroxylase activity (indicative of 
the P4504A subfamily induction) was induced 3.5-, 3.4- and 3.9-fold by 
bifonazole at both dose levels of 150 and 750 mM and clofibrate at IM (250 
mg/kg), respectively. Saturated fatty acids like lauric acid, display a high affinity 
for kidney cytochrome P450, and member(s) of cytochrome P4504A subfamily 
are apparently responsible for renal co-hydroxylation of lauric acid (Sharma et al., 
1989b). The results of my study on rat kidney microsomes demonstrated a small 
increase (1.2-fold) in lauric acid co-hydroxylase activity by bifonazole and 
clofibrate (Chapter 4).
In my in vitro studies, using rat hepatocyte primary cultures, 
bifonazole, over a concentration range of 0.5 to 10 |xM, induced lauric acid co-1 
and co-hydroxylase activities 2.9- to 6.9- and 3.5- to 8.7-fold, respectively. With
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clofibrate over a concentration range of 50 to 500 [xM, these latter enzyme 
activities were induced 3- to 7.6- and 3.6- to 9.7-fold, respectively. Although 
clofibrate induction of lauric acid co-hydroxylase was higher than that observed 
with bifonazole, comparison of their apparent EC50  values for the induction of 
lauric acid co-1- and co-hydroxylase activities demonstrated that bifonazole is 160 
and 44 times more potent than clofibrate, respectively. Therefore, the lower extent 
of lauric acid co-hydroxylase induction noted with bifonazole may be due to the 
cytotoxicity of bifonazole at high concentrations which may mask the true extent 
of induction.
Further support for the induction of the P4504A subfamily by 
bifonazole was obtained following the in vivo and in vitro induction of 
cytœhrome P4504A1 apoprotein (estimated at 51.5 kDa) by Western blotting 
analysis (Chapters 3, 4 & 5). Furthermore, the antibody against P4504A1 
recognised additional proteins (estimated at 52 kDa) which are probably P4504A2 
and/or P4504A3 (Hardwick et a l, 1987; Sharma et a l, 1989; and Aoyama et al., 
1990). However, since the cytochrome P4504A1 cDNA hybridisation 
experiments (Chapters 3 & 4) were carried out under relatively strict conditions of 
stringency, it appears that at least cytochrome P4504A1 is induced.
The close relationship between induction of the P4504A subfamily 
and peroxisome proliferation was also apparent in my in vivo study (Chapter 3). 
The bifonazole-dependent induction of the P4504A subfamily was coupled with 
its ability to induce peroxisomal palmitoyl-CoA oxidation and the trifunctional 
protein. These findings, in conjugation with the ability of bifonazole to produce 
hepatomegaly (Chapter 3) and induction of other peroxisomal enzymes (Horie et 
al., 1991), would classify bifonazole as a typical peroxisome proliferator.
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In view of the results presented in Chapter 5, neither clotrimazole nor 
any of the other azole antifungals studied, namely itraconazole, geniconazole, 
miconazole, and UK-47265, induced hydroxylation of lauric acid or cytochrome 
P4504A1 apoprotein. However, all of the azole agents studied, except 
itraconazole, maintained the levels of total cytochrome P450 over the 70 hours 
culture period. Therefore, they are probably capable of induction of other P450 
isoenzymes as been reported for clotrimazole and miconazole in the induction of 
cytochromes P4502B1/2 proteins and the P4503A subfamily in rat liver 
(Rodrigues et al., 1988; and Chapter 3). However, unlike rat liver, clotrimazole 
was not able to induce the P4502B1/2 proteins and the P4503A subfamily in rat 
kidney (Chapter 4) as judged by PROD^ and Western blotting analysis.
The lack of ability of itraconazole to maintain the levels of total cytochromes 
P450 over 70 hours culture period is in agreement with previous reports 
(Lavrijsen et al., 1986; and Damanhouri et al., 1988). This characteristic, in 
combination with the high affinity of itraconazole for fungal cytochrome P450 
(Formtling, 1988), shows that itraconazole is probably far more selective for 
fungal enzymes than their mammalian counterparts, an important concept in 
clinical drug interactions.
In addition to induction of the P4504A subfamily, bifonazole also 
induced other P450 isoenzymes in rat liver and kidney. The hepatic levels of 
cytochromes P4501A1 and P4502B1/2 proteins, and the P4503A subfamily were 
induced by bifonazole at both dose levels of 150 and 750 |imol/kg (Chapter 3). In 
the kidney (Chapter 4), only the high dose (750 |imol/kg) of bifonazole was 
capable of slight induction of these P450s. Therefore, it seems that bifonazole can 
act as a general inducer of cytochrome P450 with substantial tissue differences.
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Taken collectively, based on the relative abilities to induce lauric acid 
co-hydroxylase activity, immunochemical reactivity with an antibody raised 
against P4504A1, and Northern blotting with a cytochrome P4504A1 cDNA 
probe, my results indicate that bifonazole, but not the structurally related 
clotrimazole, is an inducer of the cytochrome P4504A subfamily in rat liver 
microsomes, primary culture of rat hepatocytes, and to a lesser extent, rat kidney 
microsomes.
7.2. Structural Diversity o f Cytochrome P4504A1 
Inducers and Peroxisome Proliferators.
Peroxisome proliferators are a diverse group of chemicals which 
possess clearly different physico-chemical properties. A characteristic feature of 
most peroxisome proliferators with diverse chemical structures is the presence of 
an acidic function which may play a role in induction (Bronfman et al., 1986; 
Hertz et al., 1988; and Lock et al., 1989). This acidic function is normally a 
carboxyl group either present free in the parent compound or one that can be 
unmasked by metabolism. An example of the latter is clofibrate wherein after in 
vivo administration, the ester is cleaved to clofibric acid (Cayen, 1983).
The importance of this carboxyl group is not clear at present but may 
be related to the formation of acyl-CoA thioesters. Some peroxisome proliferators 
are known to form acyl-CoA thioesters which have been proposed as the possible, 
common pharmacologically active species of these compounds (Bronfman et al., 
1986, 1989). In less than 30 minutes exposure to hypolipidaemic peroxisome 
proliferators, relatively high intracellular levels of their acyl-CoA derivatives are
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attained in isolated rat liver cells (Bronfman et al., 1992). This suggests possible 
roles for the involvement of these CoAs in various biological responses induced 
by peroxisome proliferators, via sequestration of CoA and subsequent 
perturbation of lipid metabolism and homeostasis (Bronfman et a l, 1986, 1989), 
triggering peroxisome proliferation (Sharma et al., 1988a). On the other hand, the 
activity of protein kinase C can be potentiated by acyl-CoA thioesters of 
hypolipidaemic peroxisome proliferators, further supporting the involvement of 
these species in the biological properties of peroxisome proliferators (Bronfman et 
al., 1989). Protein kinase C is a key enzyme involved in some cellular process, 
including receptor function, cellular differentiation, and carcinogenesis 
(Nishizuka, 1986; and Berridge, 1987).
The acid function, however, does not need to be a carboxyl group for 
the induction of cytochrome P4504A1 and peroxisome proliferation, based on the 
observation that a number of peroxisome proliferators exist containing chemical 
grouping which are bioisosteres of the carboxyl group. The latter group of 
chemicals includes Fomesafen (a N-methylsulphonyl-2-nitrobenzamide 
derivative) which has a sulphonamide moiety (Figure 7.1.), and many tetrazole- 
substituted acetophenone derivatives such as the leukotriene antagonist 
LY171883 (1-[2-hydroxy-3-propy 1-4-[4-( 1 //-tetrazole-5-yl)butoxy] phenyl]- 
ethanone), and 4-THA (2-hydroxy-3-propyl-4-[6-(tetrazol-5-yl)hexyloxy] 
acetophenone). Figure 7.1., which contain an acidic tetrazole moiety (Lock et al., 
1989).
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Figure 7.1. Chemical structures of some peroxisome proliferators 
containing chemical groups bioisosteric with the carboxyl group.
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The latter class of compounds have been reported to elicit peroxisome 
proliferation and elevate the expression of the hepatic Fatty-Acid-Binding Protein, 
FAB? (Cannon and Eacho, 1991). FABP is a 14 kDa cytosolic protein which 
binds and transports endogenous fatty acids (e.g. arachidonic acid and a number 
of its metabolites) and other hydrophobic ligands throughout the cell (Peeters et 
al., 1989). It is, therefore, plausible that the potencies of these peroxisome 
proliferators may be due to their ability to bind to FABP and subsequently 
displacement of an endogenous ligand from its binding site. The biological 
significance of fatty acid displacement from FABP by peroxisome proliferators is 
not clear at present, but these lipids may sequester CoA, as reported by Bronfman 
and other workers, with the concomitant perturbation of lipid homeostasis. 
However, it is also possible that peroxisome proliferators disturb cellular 
functions that are normally regulated by FABP (Peeters et al., 1989).
The structure diversity of chemicals capable of causing peroxisome 
proliferation must be considered in any attempt to rationalise their biological 
responses. Although peroxisome proliferators are structurally diverse, three- 
dimensional structural analysis of a number of these chemicals have demonstrated 
structural similarities. For example, structural similarities between clofibrate and 
mono-(2-ethylhexyl) phthalate (Lake et al., 1987), and between clofibric acid and 
three other peroxisome proliferators, namely nafenopin, DL-040, and LY171883 
(Lake et al., 1988), have been reported by molecular modelling techniques. 
Additionally, some other studies have shown structural similarities between 
clofibric acid, Wy-14643, LY 171883, and Fomesafen (Lewis and Lake, 1993). 
Although two of these peroxisome proliferators (LY171883 and Fomesafen) do 
not contain a free carboxyl group, they possess a tetrazole moiety and a
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sulphonamide group in their structures, respectively, which both are bioisosteres 
of the carboxyl group (Lock et a l, 1989).
Molecular graphics of S(+)-bifonazole and clofibric acid using the 
COSMIC package is shown in Figure 7.2., and illustrates the structural 
similarities between key groups (phenyl rings, carboxyl acid and imidazole ring) 
of these two compounds, which may well rationalise the ability of bifonazole to 
elicit peroxisome proliferation and P4504A1 induction. The enantioselectivity in 
induction of P4504A1 and peroxisome proliferation has previously been reported. 
An in vivo study using a clofibrate analogue, [2-[4-(4-chlorophenyl)benzyloxy]-2- 
phenylacetic acid], demonstrated a stereoselectivity in both induction of P4504A1 
and peroxisome proliferation, with the R(-)-enantiomer being more potent than 
the corresponding S(+)-isomer (R/S activity ratio of approximately 3), and the 
potency of the racemic mixture being intermediary between the two isomers 
(Chinje and Gibson, 1991). Additionally, in vitro investigation of the 
stereoselectivity of peroxisome proliferation potency of 2-ethylhexanoic acid, a 
metabolite of the plasticiser di-(2-ethylhexyl) adipate, demonstrated that the S(+)- 
enantiomer is the most potent inducer (S/R activity ratio of approximately 1.6), 
with the racemic mixture exhibiting an intermediary potency between the two 
isomers (Macherey et al., 1992). Therefore, the better structural overlap of the 
S(+)-enantiomer of bifonazole with clofibric acid than the R(-)-antipode, may 
suggest that the S(+)-enantiomer is a more potent inducer of P4504A1 and 
peroxisome proliferation than the corresponding R(-)-isomer.
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Figure 7.2. Molecular graphie plots of bifonazole (BF) and 
clofibric acid (CFA).
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The three-dimensional structural similarities between apparently 
structurally diverse peroxisome proliferators, together with their ability to regulate 
many genes with diverse functions in rodent liver, suggests that they may have a 
common mechanism of action. Two proposed mechanisms for the initiation of 
peroxisome proliferation in rodent liver involves either an interaction with a 
receptor protein (Lalwani et al., 1983, 1987; and Alveares et al., 1990), or a 
perturbation of lipid metabolism (Sharma et al., 1988a; and Lock et al., 1989). 
However, these two mechanisms may not be necessarily mutually exclusive (Lock 
et al., 1989). Involvement of a receptor in the initiation of hepatic peroxisome 
proliferation was strongly supported by the isolation of a novel member of the 
steroid hormone receptor superfamily from mouse liver, that could be activated by 
peroxisome proliferators, the so called Peroxisome Proliferator Activated 
Receptor (PPAR).
7.2.1. Possible Direct Interaction of Peroxisome Proliferators 
and P4504A1 Inducers with the PPAR.
Several PPARs have been isolated so far: one in mouse (Issemann and 
Green, 1990), one in rat (Gottlicher et al., 1992), three mXenopus (Dreyer et al.,
1992), and one in human (Sher et al., 1993). This multiplicity of PPARs, even 
within one species (Dreyer et al., 1992), would rationalise species difference in 
induction response (Gibson, 1989; Lock et al., 1989; and Makowska, 1991), and 
may help to explain why so many diverse cytochrome P4504A inducers exist, a 
proposal that awaits further experimentation.
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The PPAR recognise Peroxisome Proliferation Response Element(s), 
PPRE, located upstream of the inducible rat acyl-CoA oxidase gene (Tugwood et 
al., 1992), in the gene coding for the multifunctional protein (Bardot et al., 1993), 
and the rabbit cytochrome P4504A6 gene, the major rabbit kidney lauric acid co­
hydroxylase (Muerhoff et al., 1992). It has also been shown that PPAR activation 
of these genes occurs through heterodimer formation with the retinoid X receptor 
a , RXRa (Kliewer et al., 1992; and Bardot et al., 1993), and 6, RXRB (Keller et 
al., 1993). In addition, retinoids can induce peroxisomal 6-oxidation activities in 
vivo (Keller et al., 1993), and in vitro (Hertz and Bar-Tana, 1992; and Farrants et 
al., 1993). There is a close relationship between increased expression of genes 
required for the 6-oxidation of long chain fatty acids (Reddy et al., 1986), and 
genes of the cytochrome P4504A subfamily (Hardwick et al., 1987; Eamshaw et 
al., 1988; Kimura et a l, 1989; and Sharma et al, 1989b). The linkage between 
induction of the cytochrome P4504A subfamily and peroxisome proliferation, 
associated with the evidence provided by my study (Chapters 3, 4, & 5), suggests 
that the induction of cytochrome P4504A1 may also be mediated by this receptor 
as suggested for rabbit kidney cytochrome P4504A6 gene (Muerhoff et al., 1992), 
a concept that is not inconsistent with molecular modelling studies involving the 
PPAR (Lewis and Lake, 1993; and below).
The mouse PPAR consists of two domains: a DNA-binding domain of 
approximately 70 amino acids in length that interacts with responsive genes, and a 
ligand-binding domain of approximately 200-250 amino acid residues in length 
that binds the inducer and may additionally be involved in transcriptional gene 
activation (Issemann and Green, 1990, 1991; and Green, 1992). Since the PPAR 
has been cloned, sequenced, and its amino acid sequence predicted, it is possible 
to employ molecular graphic techniques to construct a three-dimensional model of
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a portion of the putative PPAR ligand-binding domain (Lewis and Lake, 1993). 
This model generation is based on a prediction of secondary and tertiary 
configuration by employing standard protein folding packages such as the Sybyl 
software package (Tripos Associates, St Louis, MO, USA). Based on the common 
key groups of several known peroxisome proliferators (such as carboxyl group), a 
likely binding site containing amino acid residues (i.e. one isoleucine, one lysine, 
and two phenylalanine moieties) in the appropriate orientation has been identified 
(Lewis and Lake, 1993). The basic e-amino group of a lysine residue in the 
ligand-binding domain may play a significant role in ligand binding to the key 
acidic functions of peroxisome proliferators. The more potent cytochrome 
P4504A1 inducers and peroxisome proliferators such as methylclofenapate (Lock 
et al., 1989) appear to have two phenyl rings in their structures, which apparently 
provide better binding with the putative binding site (Gibson et a l, 1993).
As demonstrated above, bifonazole, but not clotrimazole, was capable 
of both induction of P4504A1 and peroxisome proliferation. Examination of the 
structures of bifonazole and clotrimazole reveals that they are very similar, the 
difference being spatial differences in the disposition of the phenyl rings and 
mono-chlorine substitution (Figure 1.6.). It is striking that neither of these two 
azole antifungals have a carboxyl group in the parent compounds. However, the 
imidazole moiety in bifonazole may be sufficiently bioisosteric to the carboxyl 
group (Figure 7.2.) for facile interaction with the PPAR. In view of this, 
clotrimazole interaction with the receptor may not be favoured because of steric 
hindrance imparted by orientation of the phenyl rings.
Alternatively, the imidazole ring may be vulnerable to oxidation as 
reported in the metabolism of nafimidone hydrochloride, an imidazole-substituted 
anticonvulsant (Rush et al, 1990). This oxidation appears to be a frequent feature
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in the metabolism of mono-substituted imidazole compounds such as 
ketoconazole (Heel, 1982) and econazole (Midgley etal., 1981). Such oxidations 
can lead to opening of the imidazole ring, as happens in the metabolism of 
ketoconazole (Heel, 1982). Consequently, this may also be the case with the in 
vivo and in vitro metabolism of bifonazole in which oxidation of the imidazole 
ring may be followed by scission and degradation of the ring and production of 
mono- or di-carboxyl groups (Figure 7.3.), which can subsequently interact with 
basic amino acid residues in the PPAR. However, it must be emphasised that no 
reports for the ring-opening of bifonazole was found in my literature survey, but 
the possibility still remains. The postulated metabolism of the imidazole ring to a 
carboxyl group, however, may not occur with clotrimazole, due to the steric 
arrangement of the molecule which may not fit the relevant P450, or if the 
carboxyl group is formed, the carboxyl metabolite may be too bulky to interact 
with the PPAR. Although, this induction mechanism remains speculative at 
present, it would be an interesting avenue for further explanation.
Modelling of the interactions of bifonazole, clotrimazole, and 
clofibric acid with the putative ligand binding site of the PPAR further supports 
the finding that bifonazole, but not clotrimazole, induces P4504A1 and 
peroxisome proliferation. The results of these computer modelling studies reveals 
a more facile docking of bifonazole and clofibric acid with the PPAR than 
clotrimazole (Figures 7.4., 7.5. & 7.6.), as reflected in the more favourable AG 
values of -37.1 kcal mol"^, -28.4 kcal mol'^ and -14.6 kcal mol"^ respectively. 
The less favourable interaction of clotrimazole with the PPAR may largely be 
dictated by the steric hindrance imparted by the spatial orientation of the phenyl 
rings and chlorination of the molecule.
177
c  N — COOH + NH 3
H I
CHgCOOH
0  NHCHpCOOH + C O 2
H ^
Figure 7.3. A proposed scheme for the oxidation of the imidazole 
ring of bifonazole to mono- and di-carboxylic acids.
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Figures 7.4. Interaction of bifonazole with a putative binding site in a 
portion of the Peroxisome Proliferator Activated Receptor, PPAR, ligand-binding 
domain, AG value = -37.1 kcal moM.
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Figures 7.5. Possible interaction of clofibric acid and the peroxisome 
proliferator activated receptor (PPAR), AG value = -28.4 kcal mol"^.
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\Figure 7.6. Postulated interaction of clotrimazole and the Peroxisome 
Proliferator Activated Receptor (PPAR), AG value = -14.6 kcal mol'l.
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In Chapter 5 using the primary cultures of rat hepatocytes, I 
demonstrated that of the six imidazole and triazole antifungai drugs studied, 
bifonazole is the only one that induces the P4504A subfamily. This finding was 
consistent with the computer modelling of their respective interactions with the 
putative ligand binding site of the PPAR, with poor interactions for miconazole 
(Figure 7.7.), geniconazole (Figure 7.8.), itraconazole (Figure 7.9.), and UK- 
47265 (Figure 7.10.). The calculated free energy of interaction with the PPAR 
(AG) was estimated to be -14.4 kcal mol"^, -12.7 kcal mol"^, -16.7 kcal mol"^, and 
-8.2 kcal mol’ ,^ for miconazole, geniconazole, itraconazole, and UK-47265, 
respectively. The less favourable interaction of these latter azoles is apparently 
due to their spatial orientations, largely bulk.
Therefore, the correlation of the molecular modelling work with the in 
vivo and in vitro results on the induction of P4504A subfamily and peroxisome 
proliferation, further supports the suggestion that the PPAR may play a role in the 
P4504A1 induction and peroxisome proliferation processes. However, 
identification of the putative regulatory element(s) of the 5' flanking region of 
P4504A1 gene, and comparison with the equivalent regions in the better 
characterised acyl-CoA oxidase gene, may determine the role of PPAR in the 
regulation of the P4504A1 gene. However, preliminary results from this 
laboratory suggests that no peroxisome proliferator responsive element to the 
PPAR is present in the first 1 kb of 5' flanking sequence of the rat P4504A1,4A2, 
and 4A3 genes (J. Richardson, personal communication), and the -6kb of human 
cytochrome P4504A gene (S. Hood, personal communication). Whether this 
means the total absence of these response elements, or that this receptor binding 
site is present further upstream than the 5’ flanking regions isolated to date, 
remains to be determined.
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Figure 7.7. Interaction of miconazole with a putative binding site in 
the PPAR ligand-binding domain, AG value = -14.4 kcal mol’l .
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Figure 7.8. Postulated interaction of geniconazole and the 
peroxisome proliferator activated receptor (PPAR), AG value = -12.7 kcal mol"^.
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Figure 7.9. Possible interaction of itraconazole and the peroxisome 
proliferator activated receptor (PPAR), AG value = -16.7 kcal mol’^.
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Figure 7.10. Interaction of UK-47,265 with a putative binding site in 
the PPAR ligand-binding domain, AG value = -8.2 kcal mol'l.
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7.2.2. Perturbation of Lipid Metabolism as an Alternative 
Mechanism for Co-Induction of the P4504A1 and 
Peroxisome Proliferation.
The induction of P4504A1 and peroxisome proliferation by bifonazole 
is similar in nature to that induced by other peroxisome proliferators, such as 
clofibrate and nafenopin (Chapters 3 & 5, and Horie et al., 1991). Accordingly, 
like other peroxisome proliferators bifonazole may cause perturbation of lipid 
metabolism, which requires further investigation. Inhibition of fatty acid oxidation 
following administration of peroxisome proliferators is a very early event, as 
mediated by the dual mechanism of inhibition of mitochondrial medium chain 
fatty acid oxidation (Lock et al., 1989), or sequestration of essential CoA by the 
peroxisome proliferator itself (Bronfman et al., 1986), with the possibility of 
resultant accumulation of medium and long chain fatty acids in the hepatocyte.
In this context, a number of workers have reported that the PPAR can 
be activated by fatty acids and induce peroxisomal 6-oxidation (Gottlicher et al., 
1992; Schmidt et al., 1992; Dreyer et al., 1993; and Keller et al., 1993). However, 
whereas it has been shown that natural fatty acids, particularly polyunsaturated 
fatty acids, activate PPARs as potently as does Wy-14643, which is the most 
effective activator known so far (Keller et al., 1993), other reports indicate low 
relative potency of fatty acids compared to activation by xenobiotic peroxisome 
proliferators (Gottlicher et a l, 1992; Schmidt et al., 1992; and Dreyer et al.,
1993). Therefore, it is not clear at present wheather fatty acids are directly 
involved in peroxisome proliferation induced by xenobiotics, although, they may 
activate the receptor in nutritionally elevated peroxisome proliferation and be the 
endogenous ligands.
187
Alternatively, the accumulation of medium and long chain fatty acids 
in the hepatocyte may possibly induce P4504A1 synthesis and fatty acid 6- 
oxidation in order to maintain cellular lipid homeostasis. The latter event may 
result in generation of the true ligand for PPAR, which has not yet been identified. 
In support of this theory is the early induction of cytochrome P4504A subfamily 
and increase in fatty acid co-hydroxylation, prior to induction of peroxisomal 6- 
oxidation, in response to the administration of peroxisome proliferators (Milton et 
al., 1990). In addition, induction of peroxisomal 6-xoidation appears to be 
dependent on an earlier phase of protein synthesis (Milton et al., 1990; and 
Gibson, 1992). However, activation of the PPAR by fatty acids in PPAR- 
transfected hepatocytes was not inhibited by an inhibitor of cytochrome P4504A1, 
1-aminobenzotriazole (Gottlicher et al., 1993). A scheme for the role of lipid 
perturbation and the PPAR in peroxisome proliferation is outlined in Figure 7.11.
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Retinoic Acid 
(RA)
Retinoid X Receptor 
(RXR)
RXR-RA
Peroxisome Proliferator Ï
Inhibition of fatty acid oxidation 
and iipid perturbation
Accumulation of medium and 
long chain fatty acids
PPAR
...........
Ligand-PPAR/RXR-RA
Early induction of 
P4504A1
t
Formation of the endogenous 
ligand for PPAR?
5'
Peroxisome proliferation response element(s)
of responsive genes inciuding,
acyi CoA-oxidase,
trifunctional protein,
cytochrome P4504A6,
cytochrome P4504A1 ?
Figure 7.11. Postulated scheme for the common regulation of the 
cytochrome P4504A1 and peroxisomal acyl-CoA oxidase genes.
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7.3. Conclusion.
The results from the present study further confirm the ability of azole 
antifungal drugs to induce mammalian cytochromes P450. However, of the six 
azole antifungals studied, only bifonazole (in a similar manner to clofibrate) was 
able to induce the cytochrome P4504A subfamily, in vivo and in vitro. Bifonazole 
induction of P4504A1 was associated with relatively potent induction of 
peroxisome proliferation which further supports the close relationship between 
these two phenomena. The induction potency of bifonazole may be due to a facile 
interaction with the putative ligand-binding site of the PPAR, and probably 
implicates the involvement of this steroid hormone receptor in the process of 
P4504A1 induction and peroxisome proliferation, a hypothesis that remains to be 
further addressed.
Furthermore, such structure-activity relationship studies at the 
molecular level may be important in the design or selection of new antifungal 
agents with minimal or no toxicity to man. Additionally, replacement of the 
imidazole ring with the triazole ring may have the advantage of increased 
specificity for fungal enzyme systems and improved antifungal activity.
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7.4. Suggestions for the Future Work.
1. To further investigate the metabolism of bifonazole in rat and man, in order to 
study the possibility of the ring-opening of the imidazole ring. The oxidation and 
opening of the imidazole ring have been previously reported for ketoconazole.
2. To study the in vivo and in vitro enantioselectivity of bifonazole in the 
induction of cytochrome P4504A1 and peroxisome proliferation, as the three- 
dimensional structural studies have shown better structural overlap of the S(+)- 
enantiomer of bifonazole with clofibric acid than the R(-)-antipode.
3. To further examine the peroxisomal effect of the azole antifungals employed in 
this study (only bifonazole and clotrimazole were studied by me), particularly in 
view of the fact that none of them were able to induce the P4504A subfamily.
4. To investigate the possible activation of the PPAR by bifonazole. The 
molecular modelling of the putative binding site of the PPAR with bifonazole 
have shown facile docking.
5. To study the effect of bifonazole on lipid metabolism. Many peroxisome 
proliferators cause perturbation of lipid metabolism, which could be a possible 
explanation for the mechanism of action of bifonazole.
6. To isolate and identify the further upstream 5’ flanking regions of rat and 
human P4504A1 in order to determine the presence or total absence of the 
response elements to the PPAR.
7. To investigate multiplicity of the PPAR in rat, in order to explain the structural 
diversity of the peroxisome proliferators in this species.
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8. To study the molecular multiplicity of PPAR between species, particularly 
man, to rationalise the biochemical responses.
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